20405238	116	Hammack SE	Roles for pituitary adenylate cyclase-activating peptide (PACAP) expression and signaling in the bed nucleus of the stria terminalis (BNST) in mediating the behavioral consequences of chronic stress.	Journal of molecular neuroscience 	2010	43
20664079	116	Golombek DA	Physiology of circadian entrainment.	Physiological reviews	2010	138
21350482	116	Ressler KJ	Post-traumatic stress disorder is associated with PACAP and the PAC1 receptor.	Nature	2011	192
22530815	116	Andero R	Fear extinction and BDNF: translating animal models of PTSD to the clinic.	Genes, brain, and behavior	2012	45
22584867	116	Ayalew M	Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction.	Molecular psychiatry	2012	99
12062094	207	Humbert S	The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt.	Developmental cell	2002	112
12376533	207	Beffert U	Reelin-mediated signaling locally regulates protein kinase B/Akt and glycogen synthase kinase 3beta.	The Journal of biological chemistry	2002	84
15800333	207	Lefranc F	Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis.	Journal of clinical oncology 	2005	153
17627510	207	Maiese K	Mechanistic insights into diabetes mellitus and oxidative stress.	Current medicinal chemistry	2007	64
18281460	207	Hambardzumyan D	PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo.	Genes and development	2008	145
19265662	207	Bleau AM	PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells.	Cell stem cell	2009	219
19357263	207	Arai K	An oligovascular niche: cerebral endothelial cells promote the survival and proliferation of oligodendrocyte precursor cells.	The Journal of neuroscience 	2009	60
19778506	207	Kim JY	DISC1 regulates new neuron development in the adult brain via modulation of AKT-mTOR signaling through KIAA1212.	Neuron	2009	121
19996208	207	Davies MA	Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma.	Clinical cancer research 	2009	62
20563248	207	Molina JR	Invasive glioblastoma cells acquire stemness and increased Akt activation.	Neoplasia	2010	59
21212100	207	Ricciardi S	Reduced AKT/mTOR signaling and protein synthesis dysregulation in a Rett syndrome animal model.	Human molecular genetics	2011	61
21793738	207	Lindhurst MJ	A mosaic activating mutation in AKT1 associated with the Proteus syndrome.	The New England journal of medicine	2011	154
21975935	207	Yoo YA	Sonic hedgehog pathway promotes metastasis and lymphangiogenesis via activation of Akt, EMT, and MMP-9 pathway in gastric cancer.	Cancer research	2011	80
22057914	207	Cheng Y	MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis.	Molecular cancer therapeutics	2012	38
22067563	207	Wakimoto H	Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells.	Neuro-oncology	2012	59
22196333	207	Mazei-Robison MS	Role for mTOR signaling and neuronal activity in morphine-induced adaptations in ventral tegmental area dopamine neurons.	Neuron	2011	36
22402744	207	Weeraratne SD	Pleiotropic effects of miR-183~96~182 converge to regulate cell survival, proliferation and migration in medulloblastoma.	Acta neuropathologica	2012	53
22817723	207	O'Neill C	Insulin and IGF-1 signalling: longevity, protein homoeostasis and Alzheimer's disease.	Biochemical Society transactions	2012	33
23470275	207	O' Neill C	PI3-kinase/Akt/mTOR signaling: impaired on/off switches in aging, cognitive decline and Alzheimer's disease.	Experimental gerontology	2013	30
23543703	207	Snyder MA	NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia.	Frontiers in cellular neuroscience	2013	42
23589885	207	Kucharzewska P	Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development.	Proceedings of the National Academy of Sciences of the United States of America	2013	132
24336570	207	Johnson BE	Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.	Science	2014	192
24861879	207	Shi Z	MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-Ras.	Neuro-oncology	2014	27
24896186	207	Wang L	Novel somatic and germline mutations in intracranial germ cell tumours.	Nature	2014	26
24980823	207	Wang L	MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in glioma.	Oncotarget	2014	36
24998913	207	Lee JV	Akt-dependent metabolic reprogramming regulates tumor cell histone acetylation.	Cell metabolism	2014	64
25599672	207	D'Gama AM	Mammalian target of rapamycin pathway mutations cause hemimegalencephaly and focal cortical dysplasia.	Annals of neurology	2015	31
25796440	207	Paw I	Mechanisms regulating glioma invasion.	Cancer letters	2015	31
26947078	207	Chen F	Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma.	Cell reports	2016	24
27524440	207	Liang Q	Zika Virus NS4A and NS4B Proteins Deregulate Akt-mTOR Signaling in Human Fetal Neural Stem Cells to Inhibit Neurogenesis and Induce Autophagy.	Cell stem cell	2016	19
8103819	348	Poirier J	Apolipoprotein E polymorphism and Alzheimer's disease.	Lancet	1993	159
8398148	348	Rebeck GW	Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions.	Neuron	1993	161
8415756	348	Schmechel DE	Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease.	Proceedings of the National Academy of Sciences of the United States of America	1993	251
8446617	348	Strittmatter WJ	Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.	Proceedings of the National Academy of Sciences of the United States of America	1993	629
8592548	348	Reiman EM	Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E.	The New England journal of medicine	1996	313
9343467	348	Farrer LA	Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium.	JAMA	1997	654
10227624	348	Jack CR Jr	Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment.	Neurology	1999	309
10487842	348	Lue LF	Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease.	The American journal of pathology	1999	378
10681270	348	Christen Y	Oxidative stress and Alzheimer disease.	The American journal of clinical nutrition	2000	102
10762153	348	Killiany RJ	Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease.	Annals of neurology	2000	150
10811879	348	Small GW	Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease.	Proceedings of the National Academy of Sciences of the United States of America	2000	152
10944562	348	Bookheimer SY	Patterns of brain activation in people at risk for Alzheimer's disease.	The New England journal of medicine	2000	281
11248079	348	Reiman EM	Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease.	Proceedings of the National Academy of Sciences of the United States of America	2001	137
11264981	348	Dietschy JM	Cholesterol metabolism in the brain.	Current opinion in lipidology	2001	159
11445259	348	Jernigan TL	Effects of age on tissues and regions of the cerebrum and cerebellum.	Neurobiology of aging	2001	186
11487050	348	Nunomura A	Oxidative damage is the earliest event in Alzheimer disease.	Journal of neuropathology and experimental neurology	2001	328
11526211	348	de Leon MJ	Prediction of cognitive decline in normal elderly subjects with 2-(18)Ffluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET).	Proceedings of the National Academy of Sciences of the United States of America	2001	148
12164721	348	Luchsinger JA	Caloric intake and the risk of Alzheimer disease.	Archives of neurology	2002	97
12566949	348	Kuller LH	Risk factors for dementia in the cardiovascular health cognition study.	Neuroepidemiology	2003	86
12580704	348	Luchsinger JA	Antioxidant vitamin intake and risk of Alzheimer disease.	Archives of neurology	2003	82
14568809	348	Lopez OL	Risk factors for mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 2.	Archives of neurology	2003	89
14688411	348	Reiman EM	Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia.	Proceedings of the National Academy of Sciences of the United States of America	2004	267
14729357	348	Anderson DH	Characterization of beta amyloid assemblies in drusen: the deposits associated with aging and age-related macular degeneration.	Experimental eye research	2004	85
14991811	348	Gorno-Tempini ML	Cognition and anatomy in three variants of primary progressive aphasia.	Annals of neurology	2004	291
15477533	348	Tang-Wai DF	Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy.	Neurology	2004	110
15623696	348	Mosconi L	MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET.	Neurology	2004	85
15699382	348	Bondi MW	fMRI evidence of compensatory mechanisms in older adults at genetic risk for Alzheimer disease.	Neurology	2005	114
15911795	348	Enzinger C	Risk factors for progression of brain atrophy in aging: six-year follow-up of normal subjects.	Neurology	2005	71
15932949	348	Reiman EM	Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism.	Proceedings of the National Academy of Sciences of the United States of America	2005	120
15987548	348	Omalu BI	Chronic traumatic encephalopathy in a National Football League player.	Neurosurgery	2005	124
16087905	348	Dickerson BC	Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD.	Neurology	2005	186
16108925	348	Newman AB	Dementia and Alzheimer's disease incidence in relationship to cardiovascular disease in the Cardiovascular Health Study cohort.	Journal of the American Geriatrics Society	2005	81
16289476	348	Scheff SW	Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment.	Neurobiology of aging	2006	162
16682537	348	Jicha GA	Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia.	Archives of neurology	2006	131
16738250	348	Johnson SC	The influence of Alzheimer disease family history and apolipoprotein E epsilon4 on mesial temporal lobe activation.	The Journal of neuroscience 	2006	71
16782234	348	Zipser BD	Microvascular injury and blood-brain barrier leakage in Alzheimer's disease.	Neurobiology of aging	2007	84
16807921	348	Honig LS	Shorter telomeres are associated with mortality in those with APOE epsilon4 and dementia.	Annals of neurology	2006	60
17030648	348	Scarmeas N	Mediterranean diet, Alzheimer disease, and vascular mediation.	Archives of neurology	2006	74
17030756	348	Wishart HA	Regional brain atrophy in cognitively intact adults with a single APOE epsilon4 allele.	Neurology	2006	61
17077159	348	Mondadori CR	Better memory and neural efficiency in young apolipoprotein E epsilon4 carriers.	Cerebral cortex	2007	74
17101822	348	Schaefer EJ	Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study.	Archives of neurology	2006	111
17353383	348	Luchsinger JA	Measures of adiposity and dementia risk in elderly persons.	Archives of neurology	2007	57
17420320	348	Luchsinger JA	Relation of diabetes to mild cognitive impairment.	Archives of neurology	2007	128
17470753	348	Scheff SW	Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment.	Neurology	2007	157
17474819	348	Coon KD	A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease.	The Journal of clinical psychiatry	2007	148
17485647	348	Kemppainen NM	PET amyloid ligand 11CPIB uptake is increased in mild cognitive impairment.	Neurology	2007	86
17509484	348	Shaw P	Cortical morphology in children and adolescents with different apolipoprotein E gene polymorphisms: an observational study.	The Lancet. Neurology	2007	89
17515542	348	Bowman GL	Blood-brain barrier impairment in Alzheimer disease: stability and functional significance.	Neurology	2007	55
17698496	348	Lockhart A	PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis.	Brain 	2007	90
17879383	348	Sonnen JA	Pathological correlates of dementia in a longitudinal, population-based sample of aging.	Annals of neurology	2007	154
18003925	348	Mosconi L	Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism.	Proceedings of the National Academy of Sciences of the United States of America	2007	85
18054253	348	Vemuri P	Alzheimer's disease diagnosis in individual subjects using structural MR images: validation studies.	NeuroImage	2008	142
18349428	348	Calderón-Garcidueñas L	Long-term air pollution exposure is associated with neuroinflammation, an altered innate immune response, disruption of the blood-brain barrier, ultrafine particulate deposition, and accumulation of amyloid beta-42 and alpha-synuclein in children and young adults.	Toxicologic pathology	2008	103
18369648	348	Thal DR	Cerebral amyloid angiopathy and its relationship to Alzheimer's disease.	Acta neuropathologica	2008	57
18378884	348	Vernooij MW	Prevalence and risk factors of cerebral microbleeds: the Rotterdam Scan Study.	Neurology	2008	117
18412267	348	Mesulam M	Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia.	Annals of neurology	2008	135
18608129	348	Brouwers N	Molecular genetics of Alzheimer's disease: an update.	Annals of medicine	2008	54
18663180	348	Cramer C	Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study.	Neurology	2008	56
18691658	348	Hua X	Tensor-based morphometry as a neuroimaging biomarker for Alzheimer's disease: an MRI study of 676 AD, MCI, and normal subjects.	NeuroImage	2008	135
18723162	348	Devanand DP	Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimer's disease.	Biological psychiatry	2008	68
18801597	348	Smith CD	White matter diffusion alterations in normal women at risk of Alzheimer's disease.	Neurobiology of aging	2010	42
19076441	348	Mosconi L	Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease.	Annals of the New York Academy of Sciences	2008	90
19204149	348	Palop JJ	Epilepsy and cognitive impairments in Alzheimer disease.	Archives of neurology	2009	145
19251758	348	Schuff N	MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers.	Brain 	2009	166
19255410	348	Berlau DJ	APOE epsilon2 is associated with intact cognition but increased Alzheimer pathology in the oldest old.	Neurology	2009	55
19319544	348	Bell RD	Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease.	Acta neuropathologica	2009	186
19339712	348	Drzezga A	Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease.	Neurology	2009	66
19346482	348	Reiman EM	Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease.	Proceedings of the National Academy of Sciences of the United States of America	2009	243
19349228	348	Langbaum JB	Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI).	NeuroImage	2009	97
19362884	348	Knopman DS	Fourteen-year longitudinal study of vascular risk factors, APOE genotype, and cognition: the ARIC MRI Study.	Alzheimer's and dementia 	2009	67
19584447	348	Honea RA	Impact of APOE on the healthy aging brain: a voxel-based MRI and DTI study.	Journal of Alzheimer's disease 	2009	57
19587325	348	Okello A	Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study.	Neurology	2009	106
19671904	348	Scarmeas N	Physical activity, diet, and risk of Alzheimer disease.	JAMA	2009	157
19812458	348	Honea RA	Cardiorespiratory fitness and preserved medial temporal lobe volume in Alzheimer disease.	Alzheimer disease and associated disorders	2009	73
19901249	348	Migliaccio R	Clinical syndromes associated with posterior atrophy: early age at onset AD spectrum.	Neurology	2009	57
19918254	348	Fotuhi M	Changing perspectives regarding late-life dementia.	Nature reviews. Neurology	2009	77
19923550	348	Salloway S	A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.	Neurology	2009	173
19966301	348	Finch CE	Evolution in health and medicine Sackler colloquium: Evolution of the human lifespan and diseases of aging: roles of infection, inflammation, and nutrition.	Proceedings of the National Academy of Sciences of the United States of America	2010	80
20031276	348	Rasgon NL	Insulin resistance and hippocampal volume in women at risk for Alzheimer's disease.	Neurobiology of aging	2011	41
20065246	348	Honea RA	Reduced gray matter volume in normal adults with a maternal family history of Alzheimer disease.	Neurology	2010	47
20155424	348	Grinberg LT	Vascular pathology in the aged human brain.	Acta neuropathologica	2010	61
20231448	348	Mosconi L	Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer's.	Proceedings of the National Academy of Sciences of the United States of America	2010	59
20373342	348	Vemuri P	Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease.	Annals of neurology	2010	61
20463288	348	O'Brien JL	Longitudinal fMRI in elderly reveals loss of hippocampal activation with clinical decline.	Neurology	2010	69
20538373	348	Caroli A	The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort.	Neurobiology of aging	2010	46
20541837	348	Koch W	Diagnostic power of default mode network resting state fMRI in the detection of Alzheimer's disease.	Neurobiology of aging	2012	48
20547867	348	Chen Y	ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling.	Proceedings of the National Academy of Sciences of the United States of America	2010	77
20592257	348	Landau SM	Comparing predictors of conversion and decline in mild cognitive impairment.	Neurology	2010	153
20739645	348	Ahtiluoto S	Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study.	Neurology	2010	90
20837822	348	Baker LD	Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes.	Archives of neurology	2011	125
20847408	348	Valla J	Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the APOE ε4 allele, the major late-onset Alzheimer's susceptibility gene.	Journal of Alzheimer's disease 	2010	52
20864661	348	Zhu YC	Severity of dilated Virchow-Robin spaces is associated with age, blood pressure, and MRI markers of small vessel disease: a population-based study.	Stroke	2010	48
20876479	348	Poels MM	Prevalence and risk factors of cerebral microbleeds: an update of the Rotterdam scan study.	Stroke	2010	76
21035308	348	Cunnane S	Brain fuel metabolism, aging, and Alzheimer's disease.	Nutrition	2011	78
21060014	348	Carmichael O	Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative.	Archives of neurology	2010	72
21158978	348	Morgan D	Immunotherapy for Alzheimer's disease.	Journal of internal medicine	2011	55
21159973	348	Sheline YI	APOE4 allele disrupts resting state fMRI connectivity in the absence of amyloid plaques or decreased CSF Aβ42.	The Journal of neuroscience 	2010	123
21283692	348	Twine NA	Whole transcriptome sequencing reveals gene expression and splicing differences in brain regions affected by Alzheimer's disease.	PloS one	2011	79
21307170	348	Poels MM	Incidence of cerebral microbleeds in the general population: the Rotterdam Scan Study.	Stroke	2011	44
21422459	348	Gupta VB	Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging.	Neurology	2011	44
21481640	348	Barthel H	Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study.	The Lancet. Neurology	2011	75
21529702	348	Pike KE	Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study.	Neuropsychologia	2011	45
21596774	348	Nelson PT	Hippocampal sclerosis in advanced age: clinical and pathological features.	Brain 	2011	69
21706175	348	Schmidt R	Heterogeneity in age-related white matter changes.	Acta neuropathologica	2011	47
21779331	348	Han X	Metabolomics in early Alzheimer's disease: identification of altered plasma sphingolipidome using shotgun lipidomics.	PloS one	2011	67
21802369	348	Murray ME	Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study.	The Lancet. Neurology	2011	118
21851856	348	Trachtenberg AJ	The effects of APOE on the functional architecture of the resting brain.	NeuroImage	2012	33
21873229	348	Chen J	Topology of human apolipoprotein E3 uniquely regulates its diverse biological functions.	Proceedings of the National Academy of Sciences of the United States of America	2011	52
21955814	348	Calderón-Garcidueñas L	Neuroinflammation, hyperphosphorylated tau, diffuse amyloid plaques, and down-regulation of the cellular prion protein in air pollution exposed children and young adults.	Journal of Alzheimer's disease 	2012	45
21971471	348	Reiman EM	Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments.	Journal of Alzheimer's disease 	2011	103
21975202	348	Jones DT	Age-related changes in the default mode network are more advanced in Alzheimer disease.	Neurology	2011	74
22169231	348	Sabuncu MR	The association between a polygenic Alzheimer score and cortical thickness in clinically normal subjects.	Cerebral cortex	2012	32
22228589	348	Zhu Y	APOE genotype alters glial activation and loss of synaptic markers in mice.	Glia	2012	38
22232206	348	Head D	Exercise Engagement as a Moderator of the Effects of APOE Genotype on Amyloid Deposition.	Archives of neurology	2012	56
22302550	348	Rodrigue KM	β-Amyloid burden in healthy aging: regional distribution and cognitive consequences.	Neurology	2012	97
22305802	348	Sperling R	Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis.	The Lancet. Neurology	2012	67
22339463	348	Panza F	Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.	Immunotherapy	2012	39
22371413	348	Tan ZS	Red blood cell ω-3 fatty acid levels and markers of accelerated brain aging.	Neurology	2012	39
22409939	348	Jack CR Jr	Shapes of the trajectories of 5 major biomarkers of Alzheimer disease.	Archives of neurology	2012	42
22457774	348	Zhao X	Disrupted small-world brain networks in moderate Alzheimer's disease: a resting-state FMRI study.	PloS one	2012	37
22517093	348	Seppälä TT	CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings.	Neurology	2012	37
22529823	348	Fornito A	Connectomic intermediate phenotypes for psychiatric disorders.	Frontiers in psychiatry	2012	34
22581847	348	Tremblay S	Sports concussions and aging: a neuroimaging investigation.	Cerebral cortex	2013	30
22613170	348	McDonald BC	Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: a replication and extension study.	Brain, behavior, and immunity	2013	33
22633529	348	Fleisher AS	Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease.	Neurobiology of aging	2013	40
22637583	348	Koffie RM	Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-β.	Brain 	2012	62
22670023	348	Lal C	Neurocognitive impairment in obstructive sleep apnea.	Chest	2012	50
22699906	348	Damoiseaux JS	Gender modulates the APOE ε4 effect in healthy older adults: convergent evidence from functional brain connectivity and spinal fluid tau levels.	The Journal of neuroscience 	2012	47
22825311	348	Honig LS	Association of shorter leukocyte telomere repeat length with dementia and mortality.	Archives of neurology	2012	37
22828738	348	Kim SM	Regional cerebral perfusion in patients with Alzheimer's disease and mild cognitive impairment: effect of APOE epsilon4 allele.	Neuroradiology	2013	25
22961445	348	Nordberg A	A European multicentre PET study of fibrillar amyloid in Alzheimer's disease.	European journal of nuclear medicine and molecular imaging	2013	30
22972644	348	Mielke MM	Indicators of amyloid burden in a population-based study of cognitively normal elderly.	Neurology	2012	33
22972646	348	Lo RY	Vascular burden and Alzheimer disease pathologic progression.	Neurology	2012	47
23018443	348	Soontornniyomkij V	Cerebral β-amyloid deposition predicts HIV-associated neurocognitive disorders in APOE ε4 carriers.	AIDS	2012	32
23037886	348	Irwin DJ	Neuropathologic substrates of Parkinson disease dementia.	Annals of neurology	2012	81
23100439	348	Hashimoto T	Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid β peptide.	The Journal of neuroscience 	2012	39
23153970	348	Hua X	Unbiased tensor-based morphometry: improved robustness and sample size estimates for Alzheimer's disease clinical trials.	NeuroImage	2013	51
23238736	348	Jagust WJ	Apolipoprotein E, not fibrillar β-amyloid, reduces cerebral glucose metabolism in normal aging.	The Journal of neuroscience 	2012	49
23240599	348	Jahanshad N	Disrupted brain networks in the aging HIV+ population.	Brain connectivity	2012	32
23243071	348	Gomperts SN	Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia.	Neurology	2013	35
23280791	348	Vemuri P	Effect of lifestyle activities on Alzheimer disease biomarkers and cognition.	Annals of neurology	2012	35
23407718	348	Tsuang D	APOE ε4 increases risk for dementia in pure synucleinopathies.	JAMA neurology	2013	45
23424032	348	Knopman DS	Brain injury biomarkers are not dependent on β-amyloid in normal elderly.	Annals of neurology	2013	45
23424091	348	Gurol ME	Cerebral amyloid angiopathy burden associated with leukoaraiosis: a positron emission tomography/magnetic resonance imaging study.	Annals of neurology	2013	37
23446680	348	Jack CR Jr	Brain β-amyloid load approaches a plateau.	Neurology	2013	58
23515006	348	Stonehouse W	DHA supplementation improved both memory and reaction time in healthy young adults: a randomized controlled trial.	The American journal of clinical nutrition	2013	27
23553344	348	Rodrigue KM	Risk factors for β-amyloid deposition in healthy aging: vascular and genetic effects.	JAMA neurology	2013	41
23599929	348	Protas HD	Posterior cingulate glucose metabolism, hippocampal glucose metabolism, and hippocampal volume in cognitively normal, late-middle-aged persons at 3 levels of genetic risk for Alzheimer disease.	JAMA neurology	2013	28
23883936	348	Rhinn H	Integrative genomics identifies APOE ε4 effectors in Alzheimer's disease.	Nature	2013	51
24132374	348	Hughes TM	Pulse wave velocity is associated with β-amyloid deposition in the brains of very elderly adults.	Neurology	2013	31
24259049	348	Hudry E	Gene transfer of human Apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain.	Science translational medicine	2013	26
24269021	348	Johnson SC	Amyloid burden and neural function in people at risk for Alzheimer's Disease.	Neurobiology of aging	2014	29
24276092	348	Dean DC 3rd	Brain differences in infants at differential genetic risk for late-onset Alzheimer disease: a cross-sectional imaging study.	JAMA neurology	2014	46
24378418	348	Reed B	Associations between serum cholesterol levels and cerebral amyloidosis.	JAMA neurology	2014	30
24401693	348	Duan L	Stem cell derived basal forebrain cholinergic neurons from Alzheimer's disease patients are more susceptible to cell death.	Molecular neurodegeneration	2014	26
24450891	348	Salloway S	Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.	The New England journal of medicine	2014	245
24559670	348	Kanekiyo T	ApoE and Aβ in Alzheimer's disease: accidental encounters or partners?	Neuron	2014	66
24623839	348	Yates PA	Incidence of cerebral microbleeds in preclinical Alzheimer disease.	Neurology	2014	20
24713533	348	Romero JR	Risk factors, stroke prevention treatments, and prevalence of cerebral microbleeds in the Framingham Heart Study.	Stroke	2014	29
24748674	348	Mormino EC	Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease.	Neurology	2014	60
25155658	348	Palmqvist S	Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography.	JAMA neurology	2014	44
25217293	348	Michaelson DM	APOE ε4: the most prevalent yet understudied risk factor for Alzheimer's disease.	Alzheimer's and dementia 	2014	21
25253756	348	Kryscio RJ	Self-reported memory complaints: implications from a longitudinal cohort with autopsies.	Neurology	2014	31
25633388	348	Marioni RE	DNA methylation age of blood predicts all-cause mortality in later life.	Genome biology	2015	114
25672924	348	Wang R	Effects of vascular risk factors and APOE ε4 on white matter integrity and cognitive decline.	Neurology	2015	18
25775353	348	Jack CR Jr	Age, Sex, and APOE ε4 Effects on Memory, Brain Structure, and β-Amyloid Across the Adult Life Span.	JAMA neurology	2015	49
25805643	348	Murray ME	Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum.	Brain 	2015	39
25988462	348	Jansen WJ	Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.	JAMA	2015	73
25988463	348	Ossenkoppele R	Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis.	JAMA	2015	36
26208959	348	Liu E	Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials.	Neurology	2015	20
26214150	348	Willette AA	Association of Insulin Resistance With Cerebral Glucose Uptake in Late Middle-Aged Adults at Risk for Alzheimer Disease.	JAMA neurology	2015	23
26354483	348	Jaunmuktane Z	Evidence for human transmission of amyloid-β pathology and cerebral amyloid angiopathy.	Nature	2015	41
26518018	348	Bieniek KF	Chronic traumatic encephalopathy pathology in a neurodegenerative disorders brain bank.	Acta neuropathologica	2015	26
26754172	348	Heslegrave A	Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease.	Molecular neurodegeneration	2016	16
26791201	348	Theendakara V	Direct Transcriptional Effects of Apolipoprotein E.	The Journal of neuroscience 	2016	13
27016693	348	Cacace R	Molecular genetics of early-onset Alzheimer's disease revisited.	Alzheimer's and dementia 	2016	12
27025652	348	Selkoe DJ	The amyloid hypothesis of Alzheimer's disease at 25 years.	EMBO molecular medicine	2016	126
27312738	348	Arvanitakis Z	Relation of cerebral vessel disease to Alzheimer's disease dementia and cognitive function in elderly people: a cross-sectional study.	The Lancet. Neurology	2016	16
27979356	348	Irwin DJ	Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis.	The Lancet. Neurology	2017	7
2649245	351	Weidemann A	Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein.	Cell	1989	191
7857653	351	Saido TC	Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques.	Neuron	1995	118
8073293	351	Bush AI	Rapid induction of Alzheimer A beta amyloid formation by zinc.	Science	1994	176
8626743	351	Kuo YM	Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains.	The Journal of biological chemistry	1996	141
8810256	351	Hsiao K	Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice.	Science	1996	937
9126051	351	Ferguson B	Axonal damage in acute multiple sclerosis lesions.	Brain 	1997	190
10681545	351	Wang HY	beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology.	The Journal of biological chemistry	2000	144
10735393	351	Näslund J	Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline.	JAMA	2000	252
10833057	351	Roof RL	Gender differences in acute CNS trauma and stroke: neuroprotective effects of estrogen and progesterone.	Journal of neurotrauma	2000	105
10978169	351	Walsh DM	The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain.	Biochemistry	2000	115
11145990	351	Dovey HF	Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain.	Journal of neurochemistry	2001	177
11409420	351	Grabowski TJ	Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy.	Annals of neurology	2001	113
11683988	351	Selkoe DJ	Clearing the brain's amyloid cobwebs.	Neuron	2001	124
11733217	351	Butterfield DA	Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide.	Trends in molecular medicine	2001	172
11910111	351	DeMattos RB	Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease.	Science	2002	105
11932745	351	Walsh DM	Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo.	Nature	2002	991
11959919	351	Rapoport M	Tau is essential to beta -amyloid-induced neurotoxicity.	Proceedings of the National Academy of Sciences of the United States of America	2002	178
12031889	351	Butterfield DA	Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress.	Free radical biology and medicine	2002	136
12084879	351	Thal DR	Phases of A beta-deposition in the human brain and its relevance for the development of AD.	Neurology	2002	398
12244078	351	Kuhlmann T	Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time.	Brain 	2002	99
12702875	351	Kayed R	Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis.	Science	2003	950
14643377	351	Oddo S	Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease.	Neurobiology of aging	2003	215
14970312	351	Cutler RG	Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease.	Proceedings of the National Academy of Sciences of the United States of America	2004	208
15073156	351	Caillé I	Soluble form of amyloid precursor protein regulates proliferation of progenitors in the adult subventricular zone.	Development	2004	85
15474976	351	Tuppo EE	The role of inflammation in Alzheimer's disease.	The international journal of biochemistry and cell biology	2005	127
15731448	351	Stokin GB	Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease.	Science	2005	295
15834427	351	Klyubin I	Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo.	Nature medicine	2005	138
15864339	351	Gandy S	The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease.	The Journal of clinical investigation	2005	101
16362629	351	Laske C	Stage-dependent BDNF serum concentrations in Alzheimer's disease.	Journal of neural transmission	2006	67
16401735	351	Markesbery WR	Neuropathologic substrate of mild cognitive impairment.	Archives of neurology	2006	155
16541076	351	Lesné S	A specific amyloid-beta protein assembly in the brain impairs memory.	Nature	2006	803
16645451	351	Xie Z	The common inhalation anesthetic isoflurane induces apoptosis and increases amyloid beta protein levels.	Anesthesiology	2006	73
16738244	351	Deshpande A	Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons.	The Journal of neuroscience 	2006	115
16799555	351	Bateman RJ	Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo.	Nature medicine	2006	135
16837572	351	Rajendran L	Alzheimer's disease beta-amyloid peptides are released in association with exosomes.	Proceedings of the National Academy of Sciences of the United States of America	2006	227
16921174	351	Sleegers K	APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy.	Brain 	2006	99
16959815	351	Cabrejo L	Phenotype associated with APP duplication in five families.	Brain 	2006	62
17086100	351	Nicoll JA	Abeta species removal after abeta42 immunization.	Journal of neuropathology and experimental neurology	2006	108
17286590	351	Walsh DM	A beta oligomers - a decade of discovery.	Journal of neurochemistry	2007	518
17430239	351	Craft S	Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment.	Current Alzheimer research	2007	126
17664130	351	Butterfield DA	Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment.	Free radical biology and medicine	2007	101
17785178	351	Palop JJ	Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease.	Neuron	2007	321
17855343	351	Townsend M	Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway.	The Journal of biological chemistry	2007	90
17942819	351	Reger MA	Intranasal insulin improves cognition and modulates beta-amyloid in early AD.	Neurology	2008	161
17950572	351	Lockstone HE	Gene expression profiling in the adult Down syndrome brain.	Genomics	2007	58
18201969	351	Kienlen-Campard P	Amyloidogenic processing but not amyloid precursor protein (APP) intracellular C-terminal domain production requires a precisely oriented APP dimer assembled by transmembrane GXXXG motifs.	The Journal of biological chemistry	2008	53
18359102	351	Selkoe DJ	Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior.	Behavioural brain research	2008	303
18417702	351	Klyubin I	Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization.	The Journal of neuroscience 	2008	105
18458217	351	Bian H	CSF biomarkers in frontotemporal lobar degeneration with known pathology.	Neurology	2008	54
18757748	351	Hansson Petersen CA	The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae.	Proceedings of the National Academy of Sciences of the United States of America	2008	140
18953056	351	Boche D	Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain.	Brain 	2008	80
19118806	351	Roher AE	Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease.	Alzheimer's and dementia 	2009	58
19228952	351	Meilandt WJ	Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Abeta oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice.	The Journal of neuroscience 	2009	54
19355849	351	Vellas B	Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders.	Current Alzheimer research	2009	48
19433662	351	Dong Y	The common inhalational anesthetic sevoflurane induces apoptosis and increases beta-amyloid protein levels.	Archives of neurology	2009	53
19862561	351	Hung YH	Copper in the brain and Alzheimer's disease.	Journal of biological inorganic chemistry 	2010	46
19940172	351	Cohen AD	Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve.	The Journal of neuroscience 	2009	73
19951690	351	Sun B	Imbalance between GABAergic and Glutamatergic Transmission Impairs Adult Neurogenesis in an Animal Model of Alzheimer's Disease.	Cell stem cell	2009	49
20008651	351	Storandt M	Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition.	Archives of neurology	2009	128
20061647	351	Murphy MP	Alzheimer's disease and the amyloid-beta peptide.	Journal of Alzheimer's disease 	2010	63
20101004	351	Hartz AM	Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer's disease.	Molecular pharmacology	2010	63
20209079	351	Soscia SJ	The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide.	PloS one	2010	147
20237263	351	Kaneko M	Loss of HRD1-mediated protein degradation causes amyloid precursor protein accumulation and amyloid-beta generation.	The Journal of neuroscience 	2010	43
20552018	351	Schonrock N	Neuronal microRNA deregulation in response to Alzheimer's disease amyloid-beta.	PloS one	2010	56
20851519	351	Haanpää M	NeuPSIG guidelines on neuropathic pain assessment.	Pain	2011	102
21262831	351	Watts JC	Bioluminescence imaging of Abeta deposition in bigenic mouse models of Alzheimer's disease.	Proceedings of the National Academy of Sciences of the United States of America	2011	42
22017494	351	Rosen RF	Exogenous seeding of cerebral β-amyloid deposition in βAPP-transgenic rats.	Journal of neurochemistry	2012	36
22116809	351	Hartz AM	Amyloid-β contributes to blood-brain barrier leakage in transgenic human amyloid precursor protein mice and in humans with cerebral amyloid angiopathy.	Stroke	2012	36
22635102	351	Bush AI	The metal theory of Alzheimer's disease.	Journal of Alzheimer's disease 	2013	28
22869752	351	Sanchez PE	Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model.	Proceedings of the National Academy of Sciences of the United States of America	2012	102
23525040	351	Suberbielle E	Physiologic brain activity causes DNA double-strand breaks in neurons, with exacerbation by amyloid-β.	Nature neuroscience	2013	77
23575824	351	Cohen RM	A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric aβ, and frank neuronal loss.	The Journal of neuroscience 	2013	40
25253695	351	Benilova I	The Alzheimer disease protective mutation A2T modulates kinetic and thermodynamic properties of amyloid-β (Aβ) aggregation.	The Journal of biological chemistry	2014	27
25382023	351	Vardarajan BN	Coding mutations in SORL1 and Alzheimer disease.	Annals of neurology	2015	22
25620700	351	Matarin M	A genome-wide gene-expression analysis and database in transgenic mice during development of amyloid or tau pathology.	Cell reports	2015	20
26243569	351	Wiseman FK	A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome.	Nature reviews. Neuroscience	2015	29
26651341	351	Head E	Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology.	Current Alzheimer research	2016	13
26931567	351	Maeda S	Expression of A152T human tau causes age-dependent neuronal dysfunction and loss in transgenic mice.	EMBO reports	2016	12
27114849	351	Plummer S	The Neuroprotective Properties of the Amyloid Precursor Protein Following Traumatic Brain Injury.	Aging and disease	2016	13
27120160	351	Paquet D	Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9.	Nature	2016	39
15561405	361	Simard M	The neurobiology of glia in the context of water and ion homeostasis.	Neuroscience	2004	107
16325200	361	Hiroaki Y	Implications of the aquaporin-4 structure on array formation and cell adhesion.	Journal of molecular biology	2006	102
16831965	361	Pittock SJ	Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression.	Archives of neurology	2006	103
17282996	361	Roemer SF	Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis.	Brain 	2007	143
17449477	361	Takahashi T	Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre.	Brain 	2007	109
18945724	361	Jarius S	Antibody to aquaporin-4 in the long-term course of neuromyelitis optica.	Brain 	2008	84
19096776	361	Zador Z	Role of aquaporin-4 in cerebral edema and stroke.	Handbook of experimental pharmacology	2009	58
19383790	361	Ho JD	Crystal structure of human aquaporin 4 at 1.8 A and its mechanism of conductance.	Proceedings of the National Academy of Sciences of the United States of America	2009	85
19938104	361	Bennett JL	Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica.	Annals of neurology	2009	157
20047900	361	Saadoun S	Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice.	Brain 	2010	140
20639914	361	Jarius S	AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance.	Nature reviews. Neurology	2010	100
20825655	361	Jarius S	Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance.	Journal of neuroinflammation	2010	44
21368286	361	Popescu BF	Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications.	Neurology	2011	57
21536639	361	Asgari N	A population-based study of neuromyelitis optica in Caucasians.	Neurology	2011	38
21550068	361	Jarius S	Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures.	Journal of the neurological sciences	2011	41
22146605	361	Min JH	Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder.	Multiple sclerosis	2012	40
22260418	361	Jarius S	Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients.	Journal of neuroinflammation	2012	91
22387049	361	Wolburg H	The disturbed blood-brain barrier in human glioblastoma.	Molecular aspects of medicine	2012	35
22577216	361	Kitley J	Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan.	Brain 	2012	34
23142960	361	Jacob A	Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders.	Journal of neurology, neurosurgery, and psychiatry	2013	30
23486868	361	Matthews L	Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution.	Neurology	2013	25
24118483	361	Jarius S	Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature.	Brain pathology	2013	36
24272588	361	Trebst C	Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).	Journal of neurology	2014	44
24425068	361	Kitley J	Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.	JAMA neurology	2014	54
24700511	361	Titulaer MJ	Overlapping demyelinating syndromes and anti–N-methyl-D-aspartate receptor encephalitis.	Annals of neurology	2014	43
25112508	361	Papadopoulos MC	Treatment of neuromyelitis optica: state-of-the-art and emerging therapies.	Nature reviews. Neurology	2014	40
25695963	361	Kim HJ	MRI characteristics of neuromyelitis optica spectrum disorder: an international update.	Neurology	2015	32
16209725	551	Depue RA	A neurobehavioral model of affiliative bonding: implications for conceptualizing a human trait of affiliation.	The Behavioral and brain sciences	2005	98
16303870	551	Wismer Fries AB	Early experience in humans is associated with changes in neuropeptides critical for regulating social behavior.	Proceedings of the National Academy of Sciences of the United States of America	2005	96
18053631	551	Caldwell HK	Vasopressin: behavioral roles of an "original" neuropeptide.	Progress in neurobiology	2008	111
19084465	551	Skuse DH	Dopaminergic-neuropeptide interactions in the social brain.	Trends in cognitive sciences	2009	59
19341763	551	Veenema AH	Early life stress, the development of aggression and neuroendocrine and neurobiological correlates: what can we learn from animal models?	Frontiers in neuroendocrinology	2009	48
20346754	551	Insel TR	The challenge of translation in social neuroscience: a review of oxytocin, vasopressin, and affiliative behavior.	Neuron	2010	207
21840129	551	Rilling JK	Effects of intranasal oxytocin and vasopressin on cooperative behavior and associated brain activity in men.	Psychoneuroendocrinology	2012	70
22079778	551	Albers HE	The regulation of social recognition, social communication and aggression: vasopressin in the social behavior neural network.	Hormones and behavior	2012	40
22326707	551	Zink CF	Human neuroimaging of oxytocin and vasopressin in social cognition.	Hormones and behavior	2012	42
22504348	551	McCall C	The animal and human neuroendocrinology of social cognition, motivation and behavior.	Nature neuroscience	2012	53
22840551	551	Atzil S	Synchrony and specificity in the maternal and the paternal brain: relations to oxytocin and vasopressin.	Journal of the American Academy of Child and Adolescent Psychiatry	2012	31
24157401	551	Rilling JK	Sex differences in the neural and behavioral response to intranasal oxytocin and vasopressin during human social interaction.	Psychoneuroendocrinology	2014	51
25951955	551	Dumais KM	Vasopressin and oxytocin receptor systems in the brain: Sex differences and sex-specific regulation of social behavior.	Frontiers in neuroendocrinology	2016	17
14693108	590	McKeith I	Dementia with Lewy bodies.	The Lancet. Neurology	2004	104
16854944	590	Engler H	Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.	Brain 	2006	150
18199998	590	Brimijoin S	A cocaine hydrolase engineered from human butyrylcholinesterase selectively blocks cocaine toxicity and reinstatement of drug seeking in rats.	Neuropsychopharmacology 	2008	68
21056464	590	van Eijk MM	Effect of rivastigmine as an adjunct to usual care with haloperidol on duration of delirium and mortality in critically ill patients: a multicentre, double-blind, placebo-controlled randomised trial.	Lancet	2010	46
23658161	590	Moran RJ	Free energy, precision and learning: the role of cholinergic neuromodulation.	The Journal of neuroscience 	2013	50
11927139	627	Karege F	Decreased serum brain-derived neurotrophic factor levels in major depressed patients.	Psychiatry research	2002	183
12008958	627	Fujimura H	Brain-derived neurotrophic factor is stored in human platelets and released by agonist stimulation.	Thrombosis and haemostasis	2002	84
12052919	627	Simerly RB	Wired for reproduction: organization and development of sexually dimorphic circuits in the mammalian forebrain.	Annual review of neuroscience	2002	177
12086747	627	Cotman CW	Exercise: a behavioral intervention to enhance brain health and plasticity.	Trends in neurosciences	2002	402
12140781	627	Sklar P	Family-based association study of 76 candidate genes in bipolar disorder: BDNF is a potential risk locus. Brain-derived neutrophic factor.	Molecular psychiatry	2002	108
12553913	627	Egan MF	The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function.	Cell	2003	721
12842310	627	Shimizu E	Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants.	Biological psychiatry	2003	168
12851636	627	Weickert CS	Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia.	Molecular psychiatry	2003	106
12890761	627	Hariri AR	Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance.	The Journal of neuroscience 	2003	248
15001809	627	Duman RS	Role of neurotrophic factors in the etiology and treatment of mood disorders.	Neuromolecular medicine	2004	88
15128854	627	Chen ZY	Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons.	The Journal of neuroscience 	2004	174
15145621	627	Hashimoto K	Critical role of brain-derived neurotrophic factor in mood disorders.	Brain research. Brain research reviews	2004	76
15537879	627	Pezawas L	The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology.	The Journal of neuroscience 	2004	240
15585351	627	Lommatzsch M	The impact of age, weight and gender on BDNF levels in human platelets and plasma.	Neurobiology of aging	2005	111
15644983	627	Campbell S	The role of the hippocampus in the pathophysiology of major depression.	Journal of psychiatry and neuroscience 	2004	123
15741046	627	Mattson MP	Beneficial effects of intermittent fasting and caloric restriction on the cardiovascular and cerebrovascular systems.	The Journal of nutritional biochemistry	2005	93
15768049	627	Szeszko PR	Brain-derived neurotrophic factor val66met polymorphism and volume of the hippocampal formation.	Molecular psychiatry	2005	99
16005437	627	Schumacher J	Evidence for a relationship between genetic variants at the brain-derived neurotrophic factor (BDNF) locus and major depression.	Biological psychiatry	2005	65
16458264	627	Kaufman J	Brain-derived neurotrophic factor-5-HTTLPR gene interactions and environmental modifiers of depression in children.	Biological psychiatry	2006	164
16680163	627	Kleim JA	BDNF val66met polymorphism is associated with modified experience-dependent plasticity in human motor cortex.	Nature neuroscience	2006	114
16818862	627	Ho BC	Cognitive and magnetic resonance imaging brain morphometric correlates of brain-derived neurotrophic factor Val66Met gene polymorphism in patients with schizophrenia and healthy volunteers.	Archives of general psychiatry	2006	62
17130481	627	Gray J	Hyperphagia, severe obesity, impaired cognitive function, and hyperactivity associated with functional loss of one copy of the brain-derived neurotrophic factor (BDNF) gene.	Diabetes	2006	105
17151862	627	Krabbe KS	Brain-derived neurotrophic factor (BDNF) and type 2 diabetes.	Diabetologia	2007	88
17291990	627	Johnson JB	Alternate day calorie restriction improves clinical findings and reduces markers of oxidative stress and inflammation in overweight adults with moderate asthma.	Free radical biology and medicine	2007	104
17404118	627	Frodl T	Association of the brain-derived neurotrophic factor Val66Met polymorphism with reduced hippocampal volumes in major depression.	Archives of general psychiatry	2007	87
17414812	627	Ferris LT	The effect of acute exercise on serum brain-derived neurotrophic factor levels and cognitive function.	Medicine and science in sports and exercise	2007	98
17482146	627	Kim JM	Interactions between life stressors and susceptibility genes (5-HTTLPR and BDNF) on depression in Korean elders.	Biological psychiatry	2007	73
17522015	627	Bredy TW	Histone modifications around individual BDNF gene promoters in prefrontal cortex are associated with extinction of conditioned fear.	Learning and memory	2007	164
17700574	627	Groves JO	Is it time to reassess the BDNF hypothesis of depression?	Molecular psychiatry	2007	81
17762509	627	Schmidt HD	The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior.	Behavioural pharmacology	2007	172
18347599	627	Pezawas L	Evidence of biologic epistasis between BDNF and SLC6A4 and implications for depression.	Molecular psychiatry	2008	68
18504424	627	Hamilton JP	Amygdala volume in major depressive disorder: a meta-analysis of magnetic resonance imaging studies.	Molecular psychiatry	2008	75
18571629	627	Sen S	Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications.	Biological psychiatry	2008	209
18632683	627	Mellios N	A set of differentially expressed miRNAs, including miR-30a-5p, act as post-transcriptional inhibitors of BDNF in prefrontal cortex.	Human molecular genetics	2008	81
18707012	627	Komulainen P	BDNF is a novel marker of cognitive function in ageing women: the DR's EXTRA Study.	Neurobiology of learning and memory	2008	61
18752720	627	Brunoni AR	A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression.	The international journal of neuropsychopharmacology	2008	118
18753648	627	Han JC	Brain-derived neurotrophic factor and obesity in the WAGR syndrome.	The New England journal of medicine	2008	72
18817811	627	Cirulli F	Early life stress as a risk factor for mental health: role of neurotrophins from rodents to non-human primates.	Neuroscience and biobehavioral reviews	2009	50
18845611	627	Cheeran B	A common polymorphism in the brain-derived neurotrophic factor gene (BDNF) modulates human cortical plasticity and the response to rTMS.	The Journal of physiology	2008	149
18852698	627	Verhagen M	Meta-analysis of the BDNF Val66Met polymorphism in major depressive disorder: effects of gender and ethnicity.	Molecular psychiatry	2010	99
19153574	627	Gatt JM	Interactions between BDNF Val66Met polymorphism and early life stress predict brain and arousal pathways to syndromal depression and anxiety.	Molecular psychiatry	2009	129
19255578	627	Petryshen TL	Population genetic study of the brain-derived neurotrophic factor (BDNF) gene.	Molecular psychiatry	2010	50
19335934	627	Montag C	The BDNF Val66Met polymorphism impacts parahippocampal and amygdala volume in healthy humans: incremental support for a genetic risk factor for depression.	Psychological medicine	2009	47
19358879	627	Casey BJ	Brain-derived neurotrophic factor as a model system for examining gene by environment interactions across development.	Neuroscience	2009	46
19368899	627	Vinogradov S	Is serum brain-derived neurotrophic factor a biomarker for cognitive enhancement in schizophrenia?	Biological psychiatry	2009	51
19498435	627	Zuccato C	Brain-derived neurotrophic factor in neurodegenerative diseases.	Nature reviews. Neurology	2009	167
19621014	627	Taliaz D	Knockdown of brain-derived neurotrophic factor in specific brain sites precipitates behaviors associated with depression and reduces neurogenesis.	Molecular psychiatry	2010	88
19745020	627	McHughen SA	BDNF val66met polymorphism influences motor system function in the human brain.	Cerebral cortex	2010	48
19923361	627	Seifert T	Endurance training enhances BDNF release from the human brain.	American journal of physiology. Regulatory, integrative and comparative physiology	2010	67
19940189	627	Sasaki M	BDNF-hypersecreting human mesenchymal stem cells promote functional recovery, axonal sprouting, and protection of corticospinal neurons after spinal cord injury.	The Journal of neuroscience 	2009	50
20162032	627	Cunha C	A simple role for BDNF in learning and memory?	Frontiers in molecular neuroscience	2010	85
20194826	627	Keller S	Increased BDNF promoter methylation in the Wernicke area of suicide subjects.	Archives of general psychiatry	2010	63
20334574	627	Bocchio-Chiavetto L	Serum and plasma BDNF levels in major depression: a replication study and meta-analyses.	The world journal of biological psychiatry 	2010	68
20392958	627	Erickson KI	Brain-derived neurotrophic factor is associated with age-related decline in hippocampal volume.	The Journal of neuroscience 	2010	79
20653908	627	Hashimoto K	Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions.	Psychiatry and clinical neurosciences	2010	69
20702043	627	Bus BA	Determinants of serum brain-derived neurotrophic factor.	Psychoneuroendocrinology	2011	41
20705090	627	Chiu CT	Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders.	Pharmacology and therapeutics	2010	54
20726622	627	Knaepen K	Neuroplasticity - exercise-induced response of peripheral brain-derived neurotrophic factor: a systematic review of experimental studies in human subjects.	Sports medicine	2010	78
20726844	627	Johansson BB	Current trends in stroke rehabilitation. A review with focus on brain plasticity.	Acta neurologica Scandinavica	2011	36
20733577	627	Green MJ	Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis.	Molecular psychiatry	2011	68
20856249	627	Molendijk ML	Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment.	Molecular psychiatry	2011	56
20965453	627	Antal A	Brain-derived neurotrophic factor (BDNF) gene polymorphisms shape cortical plasticity in humans.	Brain stimulation	2010	48
21081796	627	Zoladz JA	The effect of physical activity on the brain derived neurotrophic factor: from animal to human studies.	Journal of physiology and pharmacology 	2010	44
21195196	627	Chiang MC	BDNF gene effects on brain circuitry replicated in 455 twins.	NeuroImage	2011	39
21253405	627	Lee BH	The roles of BDNF in the pathophysiology of major depression and in antidepressant treatment.	Psychiatry investigation	2010	43
21368041	627	Pruunsild P	Identification of cis-elements and transcription factors regulating neuronal activity-dependent transcription of human BDNF gene.	The Journal of neuroscience 	2011	60
21531985	627	Erickson KI	The aging hippocampus: interactions between exercise, depression, and BDNF.	The Neuroscientist 	2012	56
21550050	627	Fernandes BS	Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis.	Journal of psychiatric research	2011	52
21672499	627	Mondelli V	Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: a pathway to smaller hippocampal volume.	The Journal of clinical psychiatry	2011	38
21912609	627	Fuchikami M	DNA methylation profiles of the brain-derived neurotrophic factor (BDNF) gene as a potent diagnostic biomarker in major depression.	PloS one	2011	66
22029953	627	Heyman E	Intense exercise increases circulating endocannabinoid and BDNF levels in humans--possible implications for reward and depression.	Psychoneuroendocrinology	2012	32
22218094	627	Bath KG	BDNF Val66Met impairs fluoxetine-induced enhancement of adult hippocampus plasticity.	Neuropsychopharmacology 	2012	38
22261206	627	Anderson-Hanley C	Exergaming and older adult cognition: a cluster randomized clinical trial.	American journal of preventive medicine	2012	46
22750524	627	Intlekofer KA	Exercise counteracts declining hippocampal function in aging and Alzheimer's disease.	Neurobiology of disease	2013	51
22771240	627	Laje G	Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients.	Biological psychiatry	2012	36
22847651	627	Vivar C	All about running: synaptic plasticity, growth factors and adult hippocampal neurogenesis.	Current topics in behavioral neurosciences	2013	55
22880079	627	Yoshida T	Decreased serum levels of mature brain-derived neurotrophic factor (BDNF), but not its precursor proBDNF, in patients with major depressive disorder.	PloS one	2012	40
23312562	627	Felmingham KL	The brain-derived neurotrophic factor Val66Met polymorphism predicts response to exposure therapy in posttraumatic stress disorder.	Biological psychiatry	2013	37
23422958	627	Perroud N	Response to psychotherapy in borderline personality disorder and methylation status of the BDNF gene.	Translational psychiatry	2013	40
23481688	627	Hjorth E	Omega-3 fatty acids enhance phagocytosis of Alzheimer's disease-related amyloid-β42 by human microglia and decrease inflammatory markers.	Journal of Alzheimer's disease 	2013	27
23600729	627	Huang T	The effects of physical activity and exercise on brain-derived neurotrophic factor in healthy humans: A review.	Scandinavian journal of medicine and science in sports	2014	35
23674053	627	Lu B	BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases.	Nature reviews. Neuroscience	2013	95
23720292	627	Gomez-Pinilla F	The influence of exercise on cognitive abilities.	Comprehensive Physiology	2013	37
23739121	627	Ikegame T	DNA methylation of the BDNF gene and its relevance to psychiatric disorders.	Journal of human genetics	2013	31
23958957	627	Molendijk ML	Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N=9484).	Molecular psychiatry	2014	64
24048383	627	Anastasia A	Val66Met polymorphism of BDNF alters prodomain structure to induce neuronal growth cone retraction.	Nature communications	2013	29
24103211	627	Haile CN	Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression.	The international journal of neuropsychopharmacology	2014	27
24276217	627	Weinstein G	Serum brain-derived neurotrophic factor and the risk for dementia: the Framingham Heart Study.	JAMA neurology	2014	22
24374101	627	Fitzgerald PJ	Can fear extinction be enhanced? A review of pharmacological and behavioral findings.	Brain research bulletin	2014	35
24433458	627	Hosang GM	Interaction between stress and the BDNF Val66Met polymorphism in depression: a systematic review and meta-analysis.	BMC medicine	2014	39
24733968	627	Duman RS	Pathophysiology of depression and innovative treatments: remodeling glutamatergic synaptic connections.	Dialogues in clinical neuroscience	2014	35
24912158	627	Gideons ES	Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses.	Proceedings of the National Academy of Sciences of the United States of America	2014	38
25266124	627	Fernandes BS	Peripheral brain-derived neurotrophic factor in schizophrenia and the role of antipsychotics: meta-analysis and implications.	Molecular psychiatry	2015	18
25330738	627	Darcq E	MicroRNA-30a-5p in the prefrontal cortex controls the transition from moderate to excessive alcohol consumption.	Molecular psychiatry	2015	18
25451089	627	Leal G	Regulation of hippocampal synaptic plasticity by BDNF.	Brain research	2015	34
25455510	627	Szuhany KL	A meta-analytic review of the effects of exercise on brain-derived neurotrophic factor.	Journal of psychiatric research	2015	27
25553404	627	Polyakova M	BDNF as a biomarker for successful treatment of mood disorders: a systematic &amp;amp; quantitative meta-analysis.	Journal of affective disorders	2015	31
25582786	627	Duman CH	Spine synapse remodeling in the pathophysiology and treatment of depression.	Neuroscience letters	2015	21
25772071	627	Young JE	Elucidating molecular phenotypes caused by the SORL1 Alzheimer's disease genetic risk factor using human induced pluripotent stem cells.	Cell stem cell	2015	18
25805886	627	Kimhy D	The Impact of Aerobic Exercise on Brain-Derived Neurotrophic Factor and Neurocognition in Individuals With Schizophrenia: A Single-Blind, Randomized Clinical Trial.	Schizophrenia bulletin	2015	21
27113997	627	Qin XY	Decreased peripheral brain-derived neurotrophic factor levels in Alzheimer's disease: a meta-analysis study (N=7277).	Molecular psychiatry	2017	6
28199828	627	Marsh SE	HuCNS-SC Human NSCs Fail to Differentiate, Form Ectopic Clusters, and Provide No Cognitive Benefits in a Transgenic Model of Alzheimer's Disease.	Stem cell reports	2017	6
17156911	706	Venneti S	The peripheral benzodiazepine receptor (Translocator protein 18kDa) in microglia: from pathology to imaging.	Progress in neurobiology	2006	72
18093844	706	Fujita M	Kinetic analysis in healthy humans of a novel positron emission tomography radioligand to image the peripheral benzodiazepine receptor, a potential biomarker for inflammation.	NeuroImage	2008	61
18374421	706	Chen MK	Translocator protein 18 kDa (TSPO): molecular sensor of brain injury and repair.	Pharmacology and therapeutics	2008	101
19077109	706	Cosenza-Nashat M	Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain.	Neuropathology and applied neurobiology	2009	60
19948230	706	Kreisl WC	Comparison of (11)C-(R)-PK 11195 and (11)CPBR28, two radioligands for translocator protein (18 kDa) in human and monkey: Implications for positron emission tomographic imaging of this inflammation biomarker.	NeuroImage	2010	48
21149489	706	Owen DR	Mixed-affinity binding in humans with 18-kDa translocator protein ligands.	Journal of nuclear medicine 	2011	62
22968319	706	Kreisl WC	A genetic polymorphism for translocator protein 18 kDa affects both in vitro and in vivo radioligand binding in human brain to this putative biomarker of neuroinflammation.	Journal of cerebral blood flow and metabolism 	2013	46
23775979	706	Kreisl WC	In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease.	Brain 	2013	54
24397957	706	Karlstetter M	Translocator protein (18 kDa) (TSPO) is expressed in reactive retinal microglia and modulates microglial inflammation and phagocytosis.	Journal of neuroinflammation	2014	25
25385788	706	Kenk M	Imaging neuroinflammation in gray and white matter in schizophrenia: an in-vivo PET study with 18F-FEPPA.	Schizophrenia bulletin	2015	35
25629589	706	Setiawan E	Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes.	JAMA psychiatry	2015	55
25766898	706	Lyoo CH	Cerebellum Can Serve As a Pseudo-Reference Region in Alzheimer Disease to Detect Neuroinflammation Measured with PET Radioligand Binding to Translocator Protein.	Journal of nuclear medicine 	2015	18
26384512	706	Stefaniak J	Imaging of neuroinflammation in dementia: a review.	Journal of neurology, neurosurgery, and psychiatry	2016	11
27117856	706	Yokokura M	Depiction of microglial activation in aging and dementia: Positron emission tomography with &lt;sup&gt;11&lt;/sup&gt;CDPA713 versus &lt;sup&gt;11&lt;/sup&gt;C( R)PK11195.	Journal of cerebral blood flow and metabolism 	2017	8
27609240	706	Hafizi S	Imaging Microglial Activation in Untreated First-Episode Psychosis: A PET Study With &lt;sup&gt;18&lt;/sup&gt;FFEPPA.	The American journal of psychiatry	2017	7
12218410	717	Cohen ER	Effect of basal conditions on the magnitude and dynamics of the blood oxygenation level-dependent fMRI response.	Journal of cerebral blood flow and metabolism 	2002	110
19211719	717	Ainslie PN	Integration of cerebrovascular CO2 reactivity and chemoreflex control of breathing: mechanisms of regulation, measurement, and interpretation.	American journal of physiology. Regulatory, integrative and comparative physiology	2009	88
20133432	717	Hodges MR	The role of medullary serotonin (5-HT) neurons in respiratory control: contributions to eupneic ventilation, CO2 chemoreception, and thermoregulation.	Journal of applied physiology	2010	45
21486813	717	Sato K	The distribution of blood flow in the carotid and vertebral arteries during dynamic exercise in humans.	The Journal of physiology	2011	40
22495584	717	Willie CK	Regional brain blood flow in man during acute changes in arterial blood gases.	The Journal of physiology	2012	84
23719379	717	DeGennaro M	orco mutant mosquitoes lose strong preference for humans and are not repelled by volatile DEET.	Nature	2013	62
1549228	759	Arriagada PV	Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease.	Neurology	1992	441
1822725	759	Arnold SE	The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease.	Cerebral cortex	1991	232
2358525	759	West MJ	Unbiased stereological estimation of the number of neurons in the human hippocampus.	The Journal of comparative neurology	1990	180
3760943	759	Zola-Morgan S	Human amnesia and the medial temporal region: enduring memory impairment following a bilateral lesion limited to field CA1 of the hippocampus.	The Journal of neuroscience 	1986	169
8756452	759	Rempel-Clower NL	Three cases of enduring memory impairment after bilateral damage limited to the hippocampal formation.	The Journal of neuroscience 	1996	123
9626555	759	De Kloet ER	Brain corticosteroid receptor balance in health and disease.	Endocrine reviews	1998	344
9861045	759	Yrjänheikki J	Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia.	Proceedings of the National Academy of Sciences of the United States of America	1998	205
9952257	759	Bragin A	Hippocampal and entorhinal cortex high-frequency oscillations (100--500 Hz) in human epileptic brain and in kainic acid--treated rats with chronic seizures.	Epilepsia	1999	128
12434059	759	Cohen I	On the origin of interictal activity in human temporal lobe epilepsy in vitro.	Science	2002	196
12450487	759	Avoli M	Network and pharmacological mechanisms leading to epileptiform synchronization in the limbic system in vitro.	Progress in neurobiology	2002	102
12495631	759	Lee AK	Memory of sequential experience in the hippocampus during slow wave sleep.	Neuron	2002	257
16682538	759	Apostolova LG	Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps.	Archives of neurology	2006	122
16872686	759	Izquierdo I	Different molecular cascades in different sites of the brain control memory consolidation.	Trends in neurosciences	2006	71
17018552	759	Apostolova LG	3D comparison of hippocampal atrophy in amnestic mild cognitive impairment and Alzheimer's disease.	Brain 	2006	92
17986679	759	Ballmaier M	Hippocampal morphology and distinguishing late-onset from early-onset elderly depression.	The American journal of psychiatry	2008	55
18356518	759	Bakker A	Pattern separation in the human hippocampal CA3 and dentate gyrus.	Science	2008	232
18375977	759	Sicotte NL	Regional hippocampal atrophy in multiple sclerosis.	Brain 	2008	71
18840532	759	Yushkevich PA	A high-resolution computational atlas of the human hippocampus from postmortem magnetic resonance imaging at 9.4 T.	NeuroImage	2009	51
18988639	759	Frisoni GB	Mapping local hippocampal changes in Alzheimer's disease and normal ageing with MRI at 3 Tesla.	Brain 	2008	51
19736350	759	Schobel SA	Differential targeting of the CA1 subfield of the hippocampal formation by schizophrenia and related psychotic disorders.	Archives of general psychiatry	2009	112
20143386	759	Apostolova LG	3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI.	Human brain mapping	2010	42
20194830	759	Wang Z	Magnetic resonance imaging of hippocampal subfields in posttraumatic stress disorder.	Archives of general psychiatry	2010	58
20938031	759	Kerchner GA	Hippocampal CA1 apical neuropil atrophy in mild Alzheimer disease visualized with 7-T MRI.	Neurology	2010	50
21123571	759	Ibarz JM	Emergent dynamics of fast ripples in the epileptic hippocampus.	The Journal of neuroscience 	2010	49
21164173	759	Lacy JW	Distinct pattern separation related transfer functions in human CA3/dentate and CA1 revealed using high-resolution fMRI and variable mnemonic similarity.	Learning and memory	2011	77
21484934	759	Duncan K	Evidence for area CA1 as a match/mismatch detector: a high-resolution fMRI study of the human hippocampus.	Hippocampus	2012	50
21775513	759	Chen J	Associative retrieval processes in the human medial temporal lobe: hippocampal retrieval success and CA1 mismatch detection.	Learning and memory	2011	35
21907247	759	Schmidt B	Disambiguating the similar: the dentate gyrus and pattern separation.	Behavioural brain research	2012	42
22307057	759	Foster TC	Dissecting the age-related decline on spatial learning and memory tasks in rodent models: N-methyl-D-aspartate receptors and voltage-dependent Ca2+ channels in senescent synaptic plasticity.	Progress in neurobiology	2012	44
22312444	759	Liu L	Trans-synaptic spread of tau pathology in vivo.	PloS one	2012	258
22331913	759	Teicher MH	Childhood maltreatment is associated with reduced volume in the hippocampal subfields CA3, dentate gyrus, and subiculum.	Proceedings of the National Academy of Sciences of the United States of America	2012	104
22440643	759	Wisse LE	Subfields of the hippocampal formation at 7 T MRI: in vivo volumetric assessment.	NeuroImage	2012	39
22573677	759	Libby LA	Differential connectivity of perirhinal and parahippocampal cortices within human hippocampal subregions revealed by high-resolution functional imaging.	The Journal of neuroscience 	2012	56
22652019	759	Boldrini M	Hippocampal angiogenesis and progenitor cell proliferation are increased with antidepressant use in major depression.	Biological psychiatry	2012	57
22885059	759	Schapiro AC	Shaping of object representations in the human medial temporal lobe based on temporal regularities.	Current biology 	2012	66
23415948	759	Winterburn JL	A novel in vivo atlas of human hippocampal subfields using high-resolution 3 T magnetic resonance imaging.	NeuroImage	2013	44
23428745	759	Lavenex P	Building hippocampal circuits to learn and remember: insights into the development of human memory.	Behavioural brain research	2013	32
23583108	759	Schobel SA	Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver.	Neuron	2013	84
23692496	759	Blümcke I	International consensus classification of hippocampal sclerosis in temporal lobe epilepsy: a Task Force report from the ILAE Commission on Diagnostic Methods.	Epilepsia	2013	40
24443091	759	Tang X	Shape abnormalities of subcortical and ventricular structures in mild cognitive impairment and Alzheimer's disease: detecting, quantifying, and predicting.	Human brain mapping	2014	24
24888442	759	Schlichting ML	CA1 subfield contributions to memory integration and inference.	Hippocampus	2014	25
25127742	759	Haukvik UK	In vivo hippocampal subfield volumes in schizophrenia and bipolar disorder.	Biological psychiatry	2015	16
25596463	759	Yushkevich PA	Quantitative comparison of 21 protocols for labeling hippocampal subfields and parahippocampal subregions in in vivo MRI: towards a harmonized segmentation protocol.	NeuroImage	2015	31
25611508	759	Montagne A	Blood-brain barrier breakdown in the aging human hippocampus.	Neuron	2015	122
26135716	759	Buzsáki G	Hippocampal sharp wave-ripple: A cognitive biomarker for episodic memory and planning.	Hippocampus	2015	56
27602521	759	Takeuchi T	Locus coeruleus and dopaminergic consolidation of everyday memory.	Nature	2016	12
8090221	1020	Tsai LH	p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5.	Nature	1994	184
11163260	1020	Niethammer M	NUDEL is a novel Cdk5 substrate that associates with LIS1 and cytoplasmic dynein.	Neuron	2000	129
12796778	1020	Toyo-oka K	14-3-3epsilon is important for neuronal migration by binding to NUDEL: a molecular explanation for Miller-Dieker syndrome.	Nature genetics	2003	95
15056716	1020	Wang Q	Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5.	The Journal of neuroscience 	2004	116
17241267	1020	Wang JZ	Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration.	The European journal of neuroscience	2007	107
17610816	1020	Qu D	Role of Cdk5-mediated phosphorylation of Prx2 in MPTP toxicity and Parkinson's disease.	Neuron	2007	63
18194444	1020	Iqbal K	Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention.	Journal of cellular and molecular medicine	2008	50
20473298	1020	Huang E	The role of Cdk5-mediated apurinic/apyrimidinic endonuclease 1 phosphorylation in neuronal death.	Nature cell biology	2010	42
21844361	1020	Qu J	S-Nitrosylation activates Cdk5 and contributes to synaptic spine loss induced by beta-amyloid peptide.	Proceedings of the National Academy of Sciences of the United States of America	2011	41
23142263	1020	Shukla V	Deregulated Cdk5 activity is involved in inducing Alzheimer's disease.	Archives of medical research	2012	33
24361499	1020	Lai TW	Excitotoxicity and stroke: identifying novel targets for neuroprotection.	Progress in neurobiology	2014	87
7585152	1029	Merlo A	5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers.	Nature medicine	1995	274
8153634	1029	Kamb A	A cell cycle regulator potentially involved in genesis of many tumor types.	Science	1994	337
9776413	1029	Cairncross JG	Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.	Journal of the National Cancer Institute	1998	181
10416987	1029	Ishii N	Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines.	Brain pathology	1999	155
15466178	1029	Ohgaki H	Genetic pathways to glioblastoma: a population-based study.	Cancer research	2004	282
15822191	1029	Esteller M	Aberrant DNA methylation as a cancer-inducing mechanism.	Annual review of pharmacology and toxicology	2005	96
15899794	1029	Rich JN	Gene expression profiling and genetic markers in glioblastoma survival.	Cancer research	2005	78
15977639	1029	Ohgaki H	Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas.	Journal of neuropathology and experimental neurology	2005	237
17456751	1029	Ohgaki H	Genetic pathways to primary and secondary glioblastoma.	The American journal of pathology	2007	299
20068183	1029	Schiffman JD	Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas.	Cancer research	2010	86
20347935	1029	Pogue AI	Micro RNA-125b (miRNA-125b) function in astrogliosis and glial cell proliferation.	Neuroscience letters	2010	50
21145824	1029	Um TH	Aberrant CpG island hypermethylation in dysplastic nodules and early HCC of hepatitis B virus-related human multistep hepatocarcinogenesis.	Journal of hepatology	2011	41
21636552	1029	Raabe EH	BRAF activation induces transformation and then senescence in human neural stem cells: a pilocytic astrocytoma model.	Clinical cancer research 	2011	42
22984612	1029	Bhat R	Astrocyte senescence as a component of Alzheimer's disease.	PloS one	2012	43
23412337	1029	Sottoriva A	Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics.	Proceedings of the National Academy of Sciences of the United States of America	2013	266
24910096	1029	Johmura Y	Necessary and sufficient role for a mitosis skip in senescence induction.	Molecular cell	2014	32
25117714	1029	Ozawa T	Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor glioma.	Cancer cell	2014	54
11255443	1038	Morris JC	Mild cognitive impairment represents early-stage Alzheimer disease.	Archives of neurology	2001	319
14732621	1038	Grundman M	Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials.	Archives of neurology	2004	168
17210801	1038	Fagan AM	Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.	Archives of neurology	2007	293
18378167	1038	Hua X	3D characterization of brain atrophy in Alzheimer's disease and mild cognitive impairment using tensor-based morphometry.	NeuroImage	2008	85
18450517	1038	Wilcock GK	Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.	The Lancet. Neurology	2008	54
18829698	1038	Knopman DS	Development of methodology for conducting clinical trials in frontotemporal lobar degeneration.	Brain 	2008	57
20147537	1038	Fjell AM	CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease.	The Journal of neuroscience 	2010	71
21035623	1038	Craig-Schapiro R	YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease.	Biological psychiatry	2010	75
22745490	1038	Brier MR	Loss of intranetwork and internetwork resting state functional connections with Alzheimer's disease progression.	The Journal of neuroscience 	2012	114
10759066	1137	Paterson D	Neuronal nicotinic receptors in the human brain.	Progress in neurobiology	2000	111
11245666	1137	Buisson B	Chronic exposure to nicotine upregulates the human (alpha)4((beta)2 nicotinic acetylcholine receptor function.	The Journal of neuroscience 	2001	102
12151749	1137	Picciotto MR	Effect of nicotine and nicotinic receptors on anxiety and depression.	Neuroreport	2002	95
15858066	1137	Hurst RS	A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization.	The Journal of neuroscience 	2005	138
17597586	1137	Gotti C	Heterogeneity and complexity of native brain nicotinic receptors.	Biochemical pharmacology	2007	85
17825262	1137	Grady SR	The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum.	Biochemical pharmacology	2007	105
19023041	1137	Buccafusco JJ	Desensitization of nicotinic acetylcholine receptors as a strategy for drug development.	The Journal of pharmacology and experimental therapeutics	2009	50
19126755	1137	Albuquerque EX	Mammalian nicotinic acetylcholine receptors: from structure to function.	Physiological reviews	2009	366
20109142	1137	Thomsen MS	Cognitive improvement by activation of alpha7 nicotinic acetylcholine receptors: from animal models to human pathophysiology.	Current pharmaceutical design	2010	47
20331614	1137	Rollema H	Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence.	British journal of pharmacology	2010	54
20400469	1137	Jackson KJ	Role of alpha5 nicotinic acetylcholine receptors in pharmacological and behavioral effects of nicotine in mice.	The Journal of pharmacology and experimental therapeutics	2010	57
21741954	1137	Wallace TL	Targeting the nicotinic alpha7 acetylcholine receptor to enhance cognition in disease.	Biochemical pharmacology	2011	44
21795541	1137	McGranahan TM	α4β2 nicotinic acetylcholine receptors on dopaminergic neurons mediate nicotine reward and anxiety relief.	The Journal of neuroscience 	2011	40
23143843	1137	Picciotto MR	Molecular mechanisms underlying behaviors related to nicotine addiction.	Cold Spring Harbor perspectives in medicine	2013	45
23201359	1137	Young JW	Nicotinic agonist-induced improvement of vigilance in mice in the 5-choice continuous performance test.	Behavioural brain research	2013	29
23641218	1137	Hendrickson LM	Neuronal nicotinic acetylcholine receptors: common molecular substrates of nicotine and alcohol dependence.	Frontiers in psychiatry	2013	29
25460185	1137	Zoli M	Diversity of native nicotinic receptor subtypes in mammalian brain.	Neuropharmacology	2015	27
25639674	1137	Dineley KT	Nicotinic ACh receptors as therapeutic targets in CNS disorders.	Trends in pharmacological sciences	2015	39
7556170	1268	Galiègue S	Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations.	European journal of biochemistry	1995	256
8819477	1268	Showalter VM	Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands.	The Journal of pharmacology and experimental therapeutics	1996	127
9204917	1268	Glass M	Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor.	The Journal of neuroscience 	1997	116
9454810	1268	Rinaldi-Carmona M	SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.	The Journal of pharmacology and experimental therapeutics	1998	128
11164622	1268	Pertwee RG	Cannabinoid receptors and pain.	Progress in neurobiology	2001	104
12461523	1268	Kathuria S	Modulation of anxiety through blockade of anandamide hydrolysis.	Nature medicine	2003	386
12960289	1268	Klein TW	The cannabinoid system and immune modulation.	Journal of leukocyte biology	2003	130
15354183	1268	Giuffrida A	Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms.	Neuropsychopharmacology 	2004	76
15728830	1268	Ramírez BG	Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.	The Journal of neuroscience 	2005	127
15927244	1268	Viveros MP	Endocannabinoid system and stress and anxiety responses.	Pharmacology, biochemistry, and behavior	2005	83
16467563	1268	Eggan SM	Immunocytochemical distribution of the cannabinoid CB1 receptor in the primate neocortex: a regional and laminar analysis.	Cerebral cortex	2007	80
16596770	1268	Pertwee RG	Pharmacological actions of cannabinoids.	Handbook of experimental pharmacology	2005	114
17115043	1268	Robbe D	Cannabinoids reveal importance of spike timing coordination in hippocampal function.	Nature neuroscience	2006	110
17245363	1268	Thomas A	Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro.	British journal of pharmacology	2007	83
18482430	1268	Pertwee RG	Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond.	Addiction biology	2008	52
18606950	1268	Eggan SM	Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia.	Archives of general psychiatry	2008	60
20098669	1268	Cencioni MT	Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors.	PloS one	2010	55
21747398	1268	Hirvonen J	Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers.	Molecular psychiatry	2012	87
22669173	1268	Schacht JP	Associations between cannabinoid receptor-1 (CNR1) variation and hippocampus and amygdala volumes in heavy cannabis users.	Neuropsychopharmacology 	2012	30
22688188	1268	Gunduz-Cinar O	Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity.	Molecular psychiatry	2013	80
23670490	1268	Neumeister A	Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study.	Molecular psychiatry	2013	49
24076098	1268	Galve-Roperh I	Cannabinoid receptor signaling in progenitor/stem cell proliferation and differentiation.	Progress in lipid research	2013	31
24633558	1268	Battistella G	Long-term effects of cannabis on brain structure.	Neuropsychopharmacology 	2014	31
25981172	1268	Jenniches I	Anxiety, Stress, and Fear Response in Mice With Reduced Endocannabinoid Levels.	Biological psychiatry	2016	18
26068727	1268	Morena M	Neurobiological Interactions Between Stress and the Endocannabinoid System.	Neuropsychopharmacology 	2016	31
11381111	1312	Egan MF	Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia.	Proceedings of the National Academy of Sciences of the United States of America	2001	543
11743939	1312	Weinberger DR	Prefrontal neurons and the genetics of schizophrenia.	Biological psychiatry	2001	111
11925305	1312	Malhotra AK	A functional polymorphism in the COMT gene and performance on a test of prefrontal cognition.	The American journal of psychiatry	2002	125
12595695	1312	Zubieta JK	COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor.	Science	2003	214
12716966	1312	Mattay VS	Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine.	Proceedings of the National Academy of Sciences of the United States of America	2003	248
12963670	1312	Goldberg TE	Executive subprocesses in working memory: relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia.	Archives of general psychiatry	2003	148
14702260	1312	Diamond A	Genetic and neurochemical modulation of prefrontal cognitive functions in children.	The American journal of psychiatry	2004	78
15190105	1312	Tunbridge EM	Catechol-o-methyltransferase inhibition improves set-shifting performance and elevates stimulated dopamine release in the rat prefrontal cortex.	The Journal of neuroscience 	2004	121
15242692	1312	Goldberg TE	Genes and the parsing of cognitive processes.	Trends in cognitive sciences	2004	85
15457404	1312	Chen J	Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain.	American journal of human genetics	2004	348
15821730	1312	Meyer-Lindenberg A	Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype.	Nature neuroscience	2005	115
16611807	1312	Bertolino A	Additive effects of genetic variation in dopamine regulating genes on working memory cortical activity in human brain.	The Journal of neuroscience 	2006	76
16786032	1312	Meyer-Lindenberg A	Impact of complex genetic variation in COMT on human brain function.	Molecular psychiatry	2006	101
16818870	1312	Brody AL	Gene variants of brain dopamine pathways and smoking-induced dopamine release in the ventral caudate/nucleus accumbens.	Archives of general psychiatry	2006	72
16950222	1312	Bertolino A	Prefrontal-hippocampal coupling during memory processing is modulated by COMT val158met genotype.	Biological psychiatry	2006	61
16984965	1312	Abdolmaleky HM	Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder.	Human molecular genetics	2006	108
17015232	1312	Ross CA	Neurobiology of schizophrenia.	Neuron	2006	162
17063156	1312	Apud JA	Tolcapone improves cognition and cortical information processing in normal human subjects.	Neuropsychopharmacology 	2007	71
17146014	1312	Drabant EM	Catechol O-methyltransferase val158met genotype and neural mechanisms related to affective arousal and regulation.	Archives of general psychiatry	2006	82
17636131	1312	Tan HY	Epistasis between catechol-O-methyltransferase and type II metabotropic glutamate receptor 3 genes on working memory brain function.	Proceedings of the National Academy of Sciences of the United States of America	2007	60
17726000	1312	Tan HY	Dysfunctional and compensatory prefrontal cortical systems, genes and the pathogenesis of schizophrenia.	Cerebral cortex	2007	67
17913879	1312	Frank MJ	Genetic triple dissociation reveals multiple roles for dopamine in reinforcement learning.	Proceedings of the National Academy of Sciences of the United States of America	2007	163
18057197	1312	Tan HY	Catechol-O-methyltransferase Val158Met modulation of prefrontal-parietal-striatal brain systems during arithmetic and temporal transformations in working memory.	The Journal of neuroscience 	2007	56
18160646	1312	Boettiger CA	Immediate reward bias in humans: fronto-parietal networks and a role for the catechol-O-methyltransferase 158(Val/Val) genotype.	The Journal of neuroscience 	2007	101
18317466	1312	Slifstein M	COMT genotype predicts cortical-limbic D1 receptor availability measured with 11CNNC112 and PET.	Molecular psychiatry	2008	57
18474208	1312	Bassett AS	Schizophrenia and 22q11.2 deletion syndrome.	Current psychiatry reports	2008	54
18497887	1312	Tan HY	Genetic variation in AKT1 is linked to dopamine-associated prefrontal cortical structure and function in humans.	The Journal of clinical investigation	2008	55
18620336	1312	Durstewitz D	The dual-state theory of prefrontal cortex dopamine function with relevance to catechol-o-methyltransferase genotypes and schizophrenia.	Biological psychiatry	2008	103
18958202	1312	Nagel IE	Human aging magnifies genetic effects on executive functioning and working memory.	Frontiers in human neuroscience	2008	52
19104049	1312	Dreher JC	Variation in dopamine genes influences responsivity of the human reward system.	Proceedings of the National Academy of Sciences of the United States of America	2009	108
19175757	1312	Lonsdorf TB	Genetic gating of human fear learning and extinction: possible implications for gene-environment interaction in anxiety disorder.	Psychological science	2009	65
19210038	1312	Raz N	Genetic and vascular modifiers of age-sensitive cognitive skills: effects of COMT, BDNF, ApoE, and hypertension.	Neuropsychology	2009	48
19812213	1312	Williams-Gray CH	The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort.	Brain 	2009	133
21471363	1312	Jacobs E	Estrogen shapes dopamine-dependent cognitive processes: implications for women's health.	The Journal of neuroscience 	2011	69
21508242	1312	Doll BB	Dopaminergic genes predict individual differences in susceptibility to confirmation bias.	The Journal of neuroscience 	2011	52
21543598	1312	Ursini G	Stress-related methylation of the catechol-O-methyltransferase Val 158 allele predicts human prefrontal cognition and activity.	The Journal of neuroscience 	2011	51
22364739	1312	Farrell SM	COMT Val(158)Met genotype determines the direction of cognitive effects produced by catechol-O-methyltransferase inhibition.	Biological psychiatry	2012	33
22487033	1312	Collins AG	How much of reinforcement learning is working memory, not reinforcement learning? A behavioral, computational, and neurogenetic analysis.	The European journal of neuroscience	2012	39
22815523	1312	Stice E	Multilocus genetic composite reflecting dopamine signaling capacity predicts reward circuitry responsivity.	The Journal of neuroscience 	2012	44
24363137	1312	Yarnall AJ	Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study.	Neurology	2014	47
25080285	1312	Nombela C	Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD study.	Brain 	2014	24
8673487	1351	Starr A	Auditory neuropathy.	Brain 	1996	135
9414327	1351	Annegers JF	A population-based study of seizures after traumatic brain injuries.	The New England journal of medicine	1998	122
12782577	1351	Choe G	Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo.	Cancer research	2003	105
16376315	1351	Liu QR	Rodent BDNF genes, novel promoters, novel splice variants, and regulation by cocaine.	Brain research	2006	101
18835452	1351	Stoodley CJ	Functional topography in the human cerebellum: a meta-analysis of neuroimaging studies.	NeuroImage	2009	319
20152963	1351	Stoodley CJ	Evidence for topographic organization in the cerebellum of motor control versus cognitive and affective processing.	Cortex; a journal devoted to the study of the nervous system and behavior	2010	187
20219352	1351	Zhi F	The use of hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma.	European journal of cancer	2010	56
20603482	1351	Dotson VM	Recurrent depressive symptoms and the incidence of dementia and mild cognitive impairment.	Neurology	2010	53
20660554	1351	Barlow KM	Epidemiology of postconcussion syndrome in pediatric mild traumatic brain injury.	Pediatrics	2010	43
21907811	1351	Stoodley CJ	Functional topography of the cerebellum for motor and cognitive tasks: an fMRI study.	NeuroImage	2012	144
21924367	1351	Skidmore FM	Reliability analysis of the resting state can sensitively and specifically identify the presence of Parkinson disease.	NeuroImage	2013	27
21975446	1351	Donchin O	Cerebellar regions involved in adaptation to force field and visuomotor perturbation.	Journal of neurophysiology	2012	41
24192549	1351	Maegele M	An update on the coagulopathy of trauma.	Shock	2014	20
24290159	1351	Greving JP	Development of the PHASES score for prediction of risk of rupture of intracranial aneurysms: a pooled analysis of six prospective cohort studies.	The Lancet. Neurology	2014	28
24927536	1351	Park CY	Targeted inversion and reversion of the blood coagulation factor 8 gene in human iPS cells using TALENs.	Proceedings of the National Academy of Sciences of the United States of America	2014	23
25406224	1351	Grimaldi G	Cerebellar Transcranial Direct Current Stimulation (ctDCS): A Novel Approach to Understanding Cerebellar Function in Health and Disease.	The Neuroscientist 	2016	19
25485684	1351	Johansson JU	Prostaglandin signaling suppresses beneficial microglial function in Alzheimer's disease models.	The Journal of clinical investigation	2015	29
25609685	1351	Marko MK	Behavioural and neural basis of anomalous motor learning in children with autism.	Brain 	2015	15
25683123	1351	Zhu Z	Dominance genetic variation contributes little to the missing heritability for human complex traits.	American journal of human genetics	2015	18
26212079	1351	Park CY	Functional Correction of Large Factor VIII Gene Chromosomal Inversions in Hemophilia A Patient-Derived iPSCs Using CRISPR-Cas9.	Cell stem cell	2015	25
26315980	1351	Sarpal DK	Baseline Striatal Functional Connectivity as a Predictor of Response to Antipsychotic Drug Treatment.	The American journal of psychiatry	2016	14
26384521	1351	Kovesdy CP	Association of Race With Mortality and Cardiovascular Events in a Large Cohort of US Veterans.	Circulation	2015	22
11931738	1385	Nestler EJ	Neurobiology of depression.	Neuron	2002	499
12559841	1385	Nestler EJ	Common molecular and cellular substrates of addiction and memory.	Neurobiology of learning and memory	2002	86
15013227	1385	Nguyen PV	Regulation of hippocampal synaptic plasticity by cyclic AMP-dependent protein kinases.	Progress in neurobiology	2003	88
17553428	1385	Cheng HY	microRNA modulation of circadian-clock period and entrainment.	Neuron	2007	197
18457678	1385	Williams CM	Blueberry-induced changes in spatial working memory correlate with changes in hippocampal CREB phosphorylation and brain-derived neurotrophic factor (BDNF) levels.	Free radical biology and medicine	2008	61
18550328	1385	Lutgendorf SK	Depression, social support, and beta-adrenergic transcription control in human ovarian cancer.	Brain, behavior, and immunity	2009	47
18940959	1385	Crews FT	Mechanisms of neurodegeneration and regeneration in alcoholism.	Alcohol and alcoholism	2009	147
19428444	1385	Lebesgue D	Estradiol rescues neurons from global ischemia-induced cell death: multiple cellular pathways of neuroprotection.	Steroids	2009	55
20168088	1385	Carloni S	Activation of autophagy and Akt/CREB signaling play an equivalent role in the neuroprotective effect of rapamycin in neonatal hypoxia-ischemia.	Autophagy	2010	46
22960213	1385	Lipovich L	Activity-dependent human brain coding/noncoding gene regulatory networks.	Genetics	2012	36
24636259	1385	Cheng TL	MeCP2 suppresses nuclear microRNA processing and dendritic growth by regulating the DGCR8/Drosha complex.	Developmental cell	2014	49
1538563	1392	Chrousos GP	The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis.	JAMA	1992	380
8840086	1392	Meaney MJ	Early environmental regulation of forebrain glucocorticoid receptor gene expression: implications for adrenocortical responses to stress.	Developmental neuroscience	1996	114
9854171	1392	Arborelius L	The role of corticotropin-releasing factor in depression and anxiety disorders.	The Journal of endocrinology	1999	215
10918705	1392	Heim C	Pituitary-adrenal and autonomic responses to stress in women after sexual and physical abuse in childhood.	JAMA	2000	316
11027914	1392	Holsboer F	The corticosteroid receptor hypothesis of depression.	Neuropsychopharmacology 	2000	306
11041447	1392	Challis JRG	Endocrine and paracrine regulation of birth at term and preterm.	Endocrine reviews	2000	153
11282691	1392	Heim C	Altered pituitary-adrenal axis responses to provocative challenge tests in adult survivors of childhood abuse.	The American journal of psychiatry	2001	131
11356984	1392	Sarnyai Z	The role of corticotropin-releasing factor in drug addiction.	Pharmacological reviews	2001	103
11430844	1392	Heim C	The role of childhood trauma in the neurobiology of mood and anxiety disorders: preclinical and clinical studies.	Biological psychiatry	2001	456
11689280	1392	Weinstock M	Alterations induced by gestational stress in brain morphology and behaviour of the offspring.	Progress in neurobiology	2001	102
11920153	1392	Gold PW	Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states.	Molecular psychiatry	2002	225
12047726	1392	Viau V	Functional cross-talk between the hypothalamic-pituitary-gonadal and -adrenal axes.	Journal of neuroendocrinology	2002	89
12079865	1392	Jéquier E	Leptin signaling, adiposity, and energy balance.	Annals of the New York Academy of Sciences	2002	119
12220880	1392	Avishai-Eliner S	Stressed-out, or in (utero)?	Trends in neurosciences	2002	104
12377295	1392	Tsigos C	Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress.	Journal of psychosomatic research	2002	278
12597862	1392	Cowley MA	The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis.	Neuron	2003	282
12605072	1392	Koob GF	Alcoholism: allostasis and beyond.	Alcoholism, clinical and experimental research	2003	236
12832253	1392	Capuron L	Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy.	The American journal of psychiatry	2003	76
12975524	1392	Dallman MF	Chronic stress and obesity: a new view of "comfort food".	Proceedings of the National Academy of Sciences of the United States of America	2003	251
14728093	1392	Nemeroff CB	Neurobiological consequences of childhood trauma.	The Journal of clinical psychiatry	2004	90
15944068	1392	Weinstock M	The potential influence of maternal stress hormones on development and mental health of the offspring.	Brain, behavior, and immunity	2005	109
15946990	1392	Ito N	Human hair follicles display a functional equivalent of the hypothalamic-pituitary-adrenal axis and synthesize cortisol.	FASEB journal 	2005	91
15996533	1392	Swaab DF	The stress system in the human brain in depression and neurodegeneration.	Ageing research reviews	2005	133
16162953	1392	Mawdsley JE	Psychological stress in IBD: new insights into pathogenic and therapeutic implications.	Gut	2005	77
16166805	1392	Elenkov IJ	Cytokine dysregulation, inflammation and well-being.	Neuroimmunomodulation	2005	86
16472586	1392	Dinan TG	Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker?	Gastroenterology	2006	111
16918397	1392	Hauger RL	Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets.	CNS and neurological disorders drug targets	2006	100
16930158	1392	Koob GF	The neurobiology of addiction: a neuroadaptational view relevant for diagnosis.	Addiction	2006	106
17115806	1392	Davis M	Neural systems involved in fear and anxiety measured with fear-potentiated startle.	The American psychologist	2006	147
17197073	1392	Slominski A	Differential expression of HPA axis homolog in the skin.	Molecular and cellular endocrinology	2007	57
17524488	1392	Bao AM	The stress system in depression and neurodegeneration: focus on the human hypothalamus.	Brain research reviews	2008	84
17825799	1392	Heim C	The dexamethasone/corticotropin-releasing factor test in men with major depression: role of childhood trauma.	Biological psychiatry	2008	64
18275977	1392	Nieuwenhuizen AG	The hypothalamic-pituitary-adrenal-axis in the regulation of energy balance.	Physiology and behavior	2008	59
18339361	1392	Tyrka AR	Childhood parental loss and adult hypothalamic-pituitary-adrenal function.	Biological psychiatry	2008	62
18602762	1392	Heim C	The link between childhood trauma and depression: insights from HPA axis studies in humans.	Psychoneuroendocrinology	2008	258
18991954	1392	Sinha R	Chronic stress, drug use, and vulnerability to addiction.	Annals of the New York Academy of Sciences	2008	288
19406581	1392	Lopez-Duran NL	Hypothalamic-pituitary-adrenal axis dysregulation in depressed children and adolescents: a meta-analysis.	Psychoneuroendocrinology	2009	75
19571587	1392	Papadimitriou A	Regulation of the hypothalamic-pituitary-adrenal axis.	Neuroimmunomodulation	2009	47
19575614	1392	Holsboer F	Stress hormone regulation: biological role and translation into therapy.	Annual review of psychology	2010	55
19631614	1392	Shalev U	Role of CRF and other neuropeptides in stress-induced reinstatement of drug seeking.	Brain research	2010	56
19693004	1392	Davis M	Phasic vs sustained fear in rats and humans: role of the extended amygdala in fear vs anxiety.	Neuropsychopharmacology 	2010	321
19906236	1392	Hauger RL	Role of CRF receptor signaling in stress vulnerability, anxiety, and depression.	Annals of the New York Academy of Sciences	2009	70
20160137	1392	Wood SK	Individual differences in reactivity to social stress predict susceptibility and resilience to a depressive phenotype: role of corticotropin-releasing factor.	Endocrinology	2010	68
21257974	1392	Stetler C	Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research.	Psychosomatic medicine	2011	116
21272009	1392	Crabbe JC	Preclinical studies of alcohol binge drinking.	Annals of the New York Academy of Sciences	2011	54
22488525	1392	Bangasser DA	Sex differences in molecular and cellular substrates of stress.	Cellular and molecular neurobiology	2012	33
22885871	1392	Burkett JP	The behavioral, anatomical and pharmacological parallels between social attachment, love and addiction.	Psychopharmacology	2012	43
23508240	1392	Macdonald K	Helping oxytocin deliver: considerations in the development of oxytocin-based therapeutics for brain disorders.	Frontiers in neuroscience	2013	30
24456850	1392	Zorrilla EP	Corticotropin releasing factor: a key role in the neurobiology of addiction.	Frontiers in neuroendocrinology	2014	40
24495607	1392	Belvederi Murri M	HPA axis and aging in depression: systematic review and meta-analysis.	Psychoneuroendocrinology	2014	23
24627581	1392	Mulak A	Sex hormones in the modulation of irritable bowel syndrome.	World journal of gastroenterology	2014	26
25402857	1392	Grieder TE	VTA CRF neurons mediate the aversive effects of nicotine withdrawal and promote intake escalation.	Nature neuroscience	2014	23
25409596	1392	Kwako LE	The corticotropin releasing hormone-1 (CRH1) receptor antagonist pexacerfont in alcohol dependence: a randomized controlled experimental medicine study.	Neuropsychopharmacology 	2015	21
25486982	1392	Gold PW	The organization of the stress system and its dysregulation in depressive illness.	Molecular psychiatry	2015	44
25976297	1392	Mantsch JR	Stress-Induced Reinstatement of Drug Seeking: 20 Years of Progress.	Neuropsychopharmacology 	2016	40
27109623	1392	Schwandt ML	The CRF1 Antagonist Verucerfont in Anxious Alcohol-Dependent Women: Translation of Neuroendocrine, But not of Anti-Craving Effects.	Neuropsychopharmacology 	2016	14
9077376	1401	Ridker PM	Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.	The New England journal of medicine	1997	538
11692019	1401	Rost NS	Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study.	Stroke	2001	105
11744348	1401	Das UN	Is obesity an inflammatory condition?	Nutrition	2001	122
14725719	1401	Smith CJ	Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome.	BMC neurology	2004	84
15477419	1401	Latini R	Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction.	Circulation	2004	80
16170078	1401	Emsley HC	A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients.	Journal of neurology, neurosurgery, and psychiatry	2005	109
16330181	1401	Alley DE	Socioeconomic status and C-reactive protein levels in the US population: NHANES IV.	Brain, behavior, and immunity	2006	62
17011077	1401	Ravaglia G	Blood inflammatory markers and risk of dementia: The Conselice Study of Brain Aging.	Neurobiology of aging	2007	57
17389308	1401	Jefferson AL	Inflammatory biomarkers are associated with total brain volume: the Framingham Heart Study.	Neurology	2007	64
17524614	1401	Frey DJ	The effects of 40 hours of total sleep deprivation on inflammatory markers in healthy young adults.	Brain, behavior, and immunity	2007	71
18480203	1401	Zethelius B	Use of multiple biomarkers to improve the prediction of death from cardiovascular causes.	The New England journal of medicine	2008	179
19171901	1401	Witte AV	Caloric restriction improves memory in elderly humans.	Proceedings of the National Academy of Sciences of the United States of America	2009	108
19240794	1401	van Leeuwen WM	Sleep restriction increases the risk of developing cardiovascular diseases by augmenting proinflammatory responses through IL-17 and CRP.	PloS one	2009	82
19245965	1401	Frankel DS	Resistin, adiponectin, and risk of heart failure the Framingham offspring study.	Journal of the American College of Cardiology	2009	59
19416750	1401	Stewart JC	A prospective evaluation of the directionality of the depression-inflammation relationship.	Brain, behavior, and immunity	2009	65
19433690	1401	Rohleder N	Biologic cost of caring for a cancer patient: dysregulation of pro- and anti-inflammatory signaling pathways.	Journal of clinical oncology 	2009	50
19567439	1401	Melander O	Novel and conventional biomarkers for prediction of incident cardiovascular events in the community.	JAMA	2009	114
20048208	1401	Schnabel RB	Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community.	Circulation	2010	65
20203163	1401	Matias PJ	Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters.	Clinical journal of the American Society of Nephrology 	2010	43
20497981	1401	Blankenberg S	Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project.	Circulation	2010	60
20695006	1401	Debette S	Visceral fat is associated with lower brain volume in healthy middle-aged adults.	Annals of neurology	2010	50
20921964	1401	Harvie MN	The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women.	International journal of obesity	2011	75
21616287	1401	Fallah-Rad N	The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy.	Journal of the American College of Cardiology	2011	62
21680719	1401	Tan ZS	Association of metabolic dysregulation with volumetric brain magnetic resonance imaging and cognitive markers of subclinical brain aging in middle-aged adults: the Framingham Offspring Study.	Diabetes care	2011	42
21835901	1401	Colish J	Obstructive sleep apnea: effects of continuous positive airway pressure on cardiac remodeling as assessed by cardiac biomarkers, echocardiography, and cardiac MRI.	Chest	2012	32
22055018	1401	Wikgren M	Short telomeres in depression and the general population are associated with a hypocortisolemic state.	Biological psychiatry	2012	41
22184371	1401	Tarhini AA	Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma.	Journal of clinical oncology 	2012	33
22357713	1401	Satizabal CL	Circulating IL-6 and CRP are associated with MRI findings in the elderly: the 3C-Dijon Study.	Neurology	2012	39
22406004	1401	Liu L	Fatigue and sleep quality are associated with changes in inflammatory markers in breast cancer patients undergoing chemotherapy.	Brain, behavior, and immunity	2012	38
22431676	1401	Kavousi M	Evaluation of newer risk markers for coronary heart disease risk classification: a cohort study.	Annals of internal medicine	2012	57
22494534	1401	Miller GE	Clustering of depression and inflammation in adolescents previously exposed to childhood adversity.	Biological psychiatry	2012	51
22907935	1401	Wang TJ	Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study.	Circulation	2012	66
23089630	1401	Lamers F	Evidence for a differential role of HPA-axis function, inflammation and metabolic syndrome in melancholic versus atypical depression.	Molecular psychiatry	2013	65
23870425	1401	Valkanova V	CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies.	Journal of affective disorders	2013	68
24699939	1401	Smolen JS	Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy.	Annals of the rheumatic diseases	2014	21
25017001	1401	Uher R	An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline.	The American journal of psychiatry	2014	34
25128861	1401	Young JJ	A review of the relationship between proinflammatory cytokines and major depressive disorder.	Journal of affective disorders	2014	34
25640603	1401	Wright KP Jr	Influence of sleep deprivation and circadian misalignment on cortisol, inflammatory markers, and cytokine balance.	Brain, behavior, and immunity	2015	15
25734736	1401	Chey WD	Irritable bowel syndrome: a clinical review.	JAMA	2015	69
26065825	1401	Haapakoski R	Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder.	Brain, behavior, and immunity	2015	28
26552591	1401	Felger JC	Inflammation is associated with decreased functional connectivity within corticostriatal reward circuitry in depression.	Molecular psychiatry	2016	26
26754953	1401	Haroon E	Conceptual convergence: increased inflammation is associated with increased basal ganglia glutamate in patients with major depression.	Molecular psychiatry	2016	11
8931596	1437	Reiss AL	Brain development, gender and IQ in children. A volumetric imaging study.	Brain 	1996	165
10234034	1437	Gur RC	Sex differences in brain gray and white matter in healthy young adults: correlations with cognitive performance.	The Journal of neuroscience 	1999	134
11811649	1437	Sowell ER	Development of cortical and subcortical brain structures in childhood and adolescence: a structural MRI study.	Developmental medicine and child neurology	2002	170
12952922	1437	Doran KS	Group B streptococcal beta-hemolysin/cytolysin activates neutrophil signaling pathways in brain endothelium and contributes to development of meningitis.	The Journal of clinical investigation	2003	76
14702257	1437	Ballmaier M	Anterior cingulate, gyrus rectus, and orbitofrontal abnormalities in elderly depressed patients: an MRI-based parcellation of the prefrontal cortex.	The American journal of psychiatry	2004	96
16774798	1437	Smith CD	Age and gender effects on human brain anatomy: a voxel-based morphometric study in healthy elderly.	Neurobiology of aging	2007	76
17827035	1437	Teipel SJ	Multivariate deformation-based analysis of brain atrophy to predict Alzheimer's disease in mild cognitive impairment.	NeuroImage	2007	59
18761410	1437	Altaye M	Infant brain probability templates for MRI segmentation and normalization.	NeuroImage	2008	51
19157572	1437	Li X	Elevated immune response in the brain of autistic patients.	Journal of neuroimmunology	2009	132
19487648	1437	Driscoll I	Longitudinal pattern of regional brain volume change differentiates normal aging from MCI.	Neurology	2009	118
19666104	1437	Enstrom AM	Differential monocyte responses to TLR ligands in children with autism spectrum disorders.	Brain, behavior, and immunity	2010	73
20030565	1437	Frugier T	In situ detection of inflammatory mediators in post mortem human brain tissue after traumatic injury.	Journal of neurotrauma	2010	55
20075088	1437	Walhovd KB	Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease.	AJNR. American journal of neuroradiology	2010	90
20350607	1437	Sadleir RJ	Transcranial direct current stimulation (tDCS) in a realistic head model.	NeuroImage	2010	48
20484626	1437	Emmanouilidou E	Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival.	The Journal of neuroscience 	2010	237
20833247	1437	Ashwood P	Altered T cell responses in children with autism.	Brain, behavior, and immunity	2011	60
22302554	1437	Mattsson N	Age and diagnostic performance of Alzheimer disease CSF biomarkers.	Neurology	2012	34
23365250	1437	Douaud G	Brain microstructure reveals early abnormalities more than two years prior to clinical progression from mild cognitive impairment to Alzheimer's disease.	The Journal of neuroscience 	2013	35
24667615	1437	Walko TD 3rd	Cerebrospinal fluid mitochondrial DNA: a novel DAMP in pediatric traumatic brain injury.	Shock	2014	20
24691121	1437	Choi SS	Human astrocytes: secretome profiles of cytokines and chemokines.	PloS one	2014	31
25236348	1437	Thrane AS	Drowning stars: reassessing the role of astrocytes in brain edema.	Trends in neurosciences	2014	33
26554728	1437	De Mattos-Arruda L	Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma.	Nature communications	2015	20
16258095	1499	Ellison DW	beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee.	Journal of clinical oncology 	2005	68
17287208	1499	Fang D	Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity.	The Journal of biological chemistry	2007	220
17295177	1499	Villanueva A	Genomics and signaling pathways in hepatocellular carcinoma.	Seminars in liver disease	2007	150
17979879	1499	Mimeault M	Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers.	Journal of cellular and molecular medicine	2007	59
18769486	1499	Kool M	Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features.	PloS one	2008	203
19197950	1499	Fattet S	Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics.	The Journal of pathology	2009	50
19418460	1499	Wexler EM	Endogenous Wnt signaling maintains neural progenitor cell potency.	Stem cells	2009	53
19703993	1499	Saydam O	Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway.	Molecular and cellular biology	2009	83
20716670	1499	Mimeault M	Frequent deregulations in the hedgehog signaling network and cross-talks with the epidermal growth factor receptor pathway involved in cancer progression and targeted therapies.	Pharmacological reviews	2010	42
21636786	1499	Gaston-Massuet C	Increased Wingless (Wnt) signaling in pituitary progenitor/stem cells gives rise to pituitary tumors in mice and humans.	Proceedings of the National Academy of Sciences of the United States of America	2011	41
22056988	1499	Yang W	Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation.	Nature	2011	210
22729031	1499	Lippmann ES	Derivation of blood-brain barrier endothelial cells from human pluripotent stem cells.	Nature biotechnology	2012	68
22820256	1499	Pugh TJ	Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations.	Nature	2012	203
23139209	1499	Gong A	FoxM1 and Wnt/β-catenin signaling in glioma stem cells.	Cancer research	2012	34
23303705	1499	Shehzad A	Curcumin in various cancers.	BioFactors	2013	32
24209998	1499	Dey N	Wnt signaling in triple negative breast cancer is associated with metastasis.	BMC cancer	2013	29
24413733	1499	Brastianos PK	Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas.	Nature genetics	2014	36
24614104	1499	Tucci V	Dominant β-catenin mutations cause intellectual disability with recognizable syndromic features.	The Journal of clinical investigation	2014	26
24936790	1499	Cecchelli R	A stable and reproducible human blood-brain barrier model derived from hematopoietic stem cells.	PloS one	2014	22
25444902	1499	Zhang J	EZH2 is a negative prognostic factor and exhibits pro-oncogenic activity in glioblastoma.	Cancer letters	2015	18
27378147	1499	Marchetto MC	Altered proliferation and networks in neural cells derived from idiopathic autistic individuals.	Molecular psychiatry	2017	12
9489700	1641	Gleeson JG	Doublecortin, a brain-specific gene mutated in human X-linked lissencephaly and double cortex syndrome, encodes a putative signaling protein.	Cell	1998	177
10399933	1641	Gleeson JG	Doublecortin is a microtubule-associated protein and is expressed widely by migrating neurons.	Neuron	1999	280
14660786	1641	Jin K	Increased hippocampal neurogenesis in Alzheimer's disease.	Proceedings of the National Academy of Sciences of the United States of America	2004	197
15654838	1641	Couillard-Despres S	Doublecortin expression levels in adult brain reflect neurogenesis.	The European journal of neuroscience	2005	210
16387639	1641	Koizumi H	Doublecortin-like kinase functions with doublecortin to mediate fiber tract decussation and neuronal migration.	Neuron	2006	80
16713637	1641	LoTurco JJ	The multipolar stage and disruptions in neuronal migration.	Trends in neurosciences	2006	66
23303060	1641	Anacker C	Glucocorticoid-related molecular signaling pathways regulating hippocampal neurogenesis.	Neuropsychopharmacology 	2013	29
25140959	1641	Jamuar SS	Somatic mutations in cerebral cortical malformations.	The New England journal of medicine	2014	43
15509549	1742	Gylys KH	Synaptic changes in Alzheimer's disease: increased amyloid-beta and gliosis in surviving terminals is accompanied by decreased PSD-95 fluorescence.	The American journal of pathology	2004	72
15603740	1742	Huang K	Huntingtin-interacting protein HIP14 is a palmitoyl transferase involved in palmitoylation and trafficking of multiple neuronal proteins.	Neuron	2004	100
15603741	1742	Fukata M	Identification of PSD-95 palmitoylating enzymes.	Neuron	2004	177
16767099	1742	Hahn CG	Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia.	Nature medicine	2006	180
17916412	1742	Glantz LA	Synaptophysin and postsynaptic density protein 95 in the human prefrontal cortex from mid-gestation into early adulthood.	Neuroscience	2007	56
20921115	1742	Nicodemus KK	Biological validation of increased schizophrenia risk with NRG1, ERBB4, and AKT1 epistasis via functional neuroimaging in healthy controls.	Archives of general psychiatry	2010	40
21490598	1742	Brennand KJ	Modelling schizophrenia using human induced pluripotent stem cells.	Nature	2011	340
21741804	1742	Zohar J	High dose hydrocortisone immediately after trauma may alter the trajectory of PTSD: interplay between clinical and animal studies.	European neuropsychopharmacology 	2011	43
22388811	1742	Cook DJ	Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain.	Nature	2012	70
25152434	1742	Hall J	Genetic risk for schizophrenia: convergence on synaptic pathways involved in plasticity.	Biological psychiatry	2015	52
25392198	1742	Planagumà J	Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice.	Brain 	2015	46
15118803	1812	Goldman-Rakic PS	Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction.	Psychopharmacology	2004	105
15916700	1812	Arnsten AF	Methylphenidate improves prefrontal cortical cognitive function through alpha2 adrenoceptor and dopamine D1 receptor actions: Relevance to therapeutic effects in Attention Deficit Hyperactivity Disorder.	Behavioral and brain functions 	2005	89
17277774	1812	Vijayraghavan S	Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory.	Nature neuroscience	2007	240
17679637	1812	Shaw P	Polymorphisms of the dopamine D4 receptor, clinical outcome, and cortical structure in attention-deficit/hyperactivity disorder.	Archives of general psychiatry	2007	61
19179847	1812	Le Foll B	Genetics of dopamine receptors and drug addiction: a comprehensive review.	Behavioural pharmacology	2009	73
19197069	1812	McNab F	Changes in cortical dopamine D1 receptor binding associated with cognitive training.	Science	2009	107
8799184	1813	Laruelle M	Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects.	Proceedings of the National Academy of Sciences of the United States of America	1996	204
9429233	1813	Thompson J	D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele.	Pharmacogenetics	1997	111
9619147	1813	Abi-Dargham A	Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort.	The American journal of psychiatry	1998	130
9672901	1813	Pohjalainen T	The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers.	Molecular psychiatry	1998	140
10395223	1813	Jönsson EG	Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers.	Molecular psychiatry	1999	149
11873706	1813	Seeman P	Atypical antipsychotics: mechanism of action.	Canadian journal of psychiatry. Revue canadienne de psychiatrie	2002	96
14642968	1813	Kapur S	Half a century of antipsychotics and still a central role for dopamine D2 receptors.	Progress in neuro-psychopharmacology and biological psychiatry	2003	99
15992780	1813	Frank GK	Increased dopamine D2/D3 receptor binding after recovery from anorexia nervosa measured by positron emission tomography and 11craclopride.	Biological psychiatry	2005	79
16769933	1813	Pavese N	Microglial activation correlates with severity in Huntington disease: a clinical and PET study.	Neurology	2006	79
18063800	1813	Klein TA	Genetically determined differences in learning from errors.	Science	2007	129
18077373	1813	Zhang Y	Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory.	Proceedings of the National Academy of Sciences of the United States of America	2007	123
18097655	1813	Schlagenhauf F	Reward system activation in schizophrenic patients switched from typical neuroleptics to olanzapine.	Psychopharmacology	2008	59
18316420	1813	Fehr C	Association of low striatal dopamine d2 receptor availability with nicotine dependence similar to that seen with other drugs of abuse.	The American journal of psychiatry	2008	60
18354387	1813	Huang W	Significant association of ANKK1 and detection of a functional polymorphism with nicotine dependence in an African-American sample.	Neuropsychopharmacology 	2009	49
18829695	1813	Bertolino A	Functional variants of the dopamine receptor D2 gene modulate prefronto-striatal phenotypes in schizophrenia.	Brain 	2009	48
19282821	1813	Davis CA	Dopamine for "wanting" and opioids for "liking": a comparison of obese adults with and without binge eating.	Obesity	2009	71
19321766	1813	Jocham G	Dopamine DRD2 polymorphism alters reversal learning and associated neural activity.	The Journal of neuroscience 	2009	56
19620978	1813	Frank MJ	Prefrontal and striatal dopaminergic genes predict individual differences in exploration and exploitation.	Nature neuroscience	2009	118
19902317	1813	Steele KE	Alterations of central dopamine receptors before and after gastric bypass surgery.	Obesity surgery	2010	58
19933774	1813	Marek GJ	Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?	Molecular pharmacology	2010	43
20116437	1813	Stice E	Reward circuitry responsivity to food predicts future increases in body mass: moderating effects of DRD2 and DRD4.	NeuroImage	2010	94
20194823	1813	Kegeles LS	Increased synaptic dopamine function in associative regions of the striatum in schizophrenia.	Archives of general psychiatry	2010	114
20560996	1813	Seeman P	All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2(high) receptors.	CNS neuroscience and therapeutics	2011	49
20631684	1813	Frank MJ	Neurogenetics and pharmacology of learning, motivation, and cognition.	Neuropsychopharmacology 	2011	58
20643630	1813	Seeman P	Dopamine D2 receptors as treatment targets in schizophrenia.	Clinical schizophrenia and related psychoses	2010	41
20856250	1813	Volkow ND	Motivation deficit in ADHD is associated with dysfunction of the dopamine reward pathway.	Molecular psychiatry	2011	59
21150907	1813	Moyer RA	Intronic polymorphisms affecting alternative splicing of human dopamine D2 receptor are associated with cocaine abuse.	Neuropsychopharmacology 	2011	45
21289169	1813	Jocham G	Dopamine-mediated reinforcement learning signals in the striatum and ventromedial prefrontal cortex underlie value-based choices.	The Journal of neuroscience 	2011	56
21349901	1813	O'Sullivan SS	Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours.	Brain 	2011	40
21499141	1813	Kim SH	Reduced striatal dopamine D2 receptors in people with Internet addiction.	Neuroreport	2011	41
22474070	1813	Howes OD	The nature of dopamine dysfunction in schizophrenia and what this means for treatment.	Archives of general psychiatry	2012	149
23167711	1813	Boileau I	The D2/3 dopamine receptor in pathological gambling: a positron emission tomography study with 11C-(+)-propyl-hexahydro-naphtho-oxazin and 11Craclopride.	Addiction	2013	30
23636255	1813	Fisher BE	Treadmill exercise elevates striatal dopamine D2 receptor binding potential in patients with early Parkinson's disease.	Neuroreport	2013	25
23650017	1813	Eisenstein SA	A comparison of D2 receptor specific binding in obese and normal-weight individuals using PET with (N-(11)Cmethyl)benperidol.	Synapse	2013	26
25740524	1813	Karlsson HK	Obesity is associated with decreased μ-opioid but unaltered dopamine D2 receptor availability in the brain.	The Journal of neuroscience 	2015	21
17601741	1861	Grundmann K	Overexpression of human wildtype torsinA and human DeltaGAG torsinA in a transgenic mouse model causes phenotypic abnormalities.	Neurobiology of disease	2007	55
19641103	1861	Martella G	Impairment of bidirectional synaptic plasticity in the striatum of a mouse model of DYT1 dystonia: role of endogenous acetylcholine.	Brain 	2009	48
19826400	1861	Tanabe LM	Primary dystonia: molecules and mechanisms.	Nature reviews. Neurology	2009	51
20482602	1861	Albanese A	EFNS guidelines on diagnosis and treatment of primary dystonias.	European journal of neurology	2011	49
20965251	1861	Niethammer M	Hereditary dystonia as a neurodevelopmental circuit disorder: Evidence from neuroimaging.	Neurobiology of disease	2011	48
24937429	1861	Liang CC	TorsinA hypofunction causes abnormal twisting movements and sensorimotor circuit neurodegeneration.	The Journal of clinical investigation	2014	38
16844713	1917	Asanuma K	Network modulation in the treatment of Parkinson's disease.	Brain 	2006	89
19081516	1917	Benabid AL	Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease.	The Lancet. Neurology	2009	159
21825213	1917	Castrioto A	Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation.	Archives of neurology	2011	51
25297382	1917	Jahanshahi M	Parkinson's disease, the subthalamic nucleus, inhibition, and impulsivity.	Movement disorders 	2015	19
2981413	1956	Libermann TA	Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin.	Nature	1985	263
7585629	1956	Moscatello DK	Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors.	Cancer research	1995	118
9006938	1956	Huang HS	The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling.	The Journal of biological chemistry	1997	162
10202547	1956	Hatten ME	Central nervous system neuronal migration.	Annual review of neuroscience	1999	158
10728703	1956	Frederick L	Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.	Cancer research	2000	153
11283316	1956	Wechsler-Reya R	The developmental biology of brain tumors.	Annual review of neuroscience	2001	101
11431323	1956	Sonoda Y	Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma.	Cancer research	2001	86
11504770	1956	Smith JS	PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme.	Journal of the National Cancer Institute	2001	100
14638850	1956	Rich JN	Phase II trial of gefitinib in recurrent glioblastoma.	Journal of clinical oncology 	2004	122
15956649	1956	Haas-Kogan DA	Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.	Journal of the National Cancer Institute	2005	132
16624948	1956	Almeida CG	Beta-amyloid accumulation impairs multivesicular body sorting by inhibiting the ubiquitin-proteasome system.	The Journal of neuroscience 	2006	75
16912159	1956	Wang MY	Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells.	Cancer research	2006	96
16931954	1956	Hicks DG	Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR.	The American journal of surgical pathology	2006	68
17085664	1956	Balak MN	Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.	Clinical cancer research 	2006	195
17483330	1956	Palmieri D	Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain.	Cancer research	2007	101
17785346	1956	Krex D	Long-term survival with glioblastoma multiforme.	Brain 	2007	171
18362333	1956	Diehn M	Identification of noninvasive imaging surrogates for brain tumor gene-expression modules.	Proceedings of the National Academy of Sciences of the United States of America	2008	85
18403491	1956	Sampson JH	Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors.	Neuro-oncology	2008	54
18421051	1956	Lin NU	Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.	Journal of clinical oncology 	2008	97
18425114	1956	Al-Nedawi K	Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells.	Nature cell biology	2008	350
18565887	1956	Murat A	Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma.	Journal of clinical oncology 	2008	213
18829483	1956	Lo HW	Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators.	Clinical cancer research 	2008	65
18936474	1956	Heymach JV	Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.	Journal of clinical oncology 	2008	56
19075262	1956	Prados MD	Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.	Journal of clinical oncology 	2009	88
19109410	1956	Graner MW	Proteomic and immunologic analyses of brain tumor exosomes.	FASEB journal 	2009	101
19176518	1956	Fan QW	EGFR signals to mTOR through PKC and independently of Akt in glioma.	Science signaling	2009	60
19204207	1956	van den Bent MJ	Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.	Journal of clinical oncology 	2009	110
19228746	1956	Lin NU	Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.	Clinical cancer research 	2009	105
19252415	1956	Golding SE	Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells.	Cancer biology and therapy	2009	49
19412429	1956	Pillay V	The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.	Neoplasia	2009	48
19421193	1956	Bos PD	Genes that mediate breast cancer metastasis to the brain.	Nature	2009	433
19433789	1956	O'Keeffe GC	Dopamine-induced proliferation of adult neural precursor cells in the mammalian subventricular zone is mediated through EGF.	Proceedings of the National Academy of Sciences of the United States of America	2009	47
19544433	1956	Kelly JJ	Proliferation of human glioblastoma stem cells occurs independently of exogenous mitogens.	Stem cells	2009	62
19920198	1956	Gravendeel LA	Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology.	Cancer research	2009	128
19960228	1956	Peereboom DM	Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme.	Journal of neuro-oncology	2010	57
20113523	1956	Ren Y	MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol.	BMC cancer	2010	47
20146086	1956	Clarke JL	High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer.	Journal of neuro-oncology	2010	50
20150372	1956	Raizer JJ	A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.	Neuro-oncology	2010	56
20515495	1956	Krakstad C	Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics.	Molecular cancer	2010	65
20595147	1956	Porta R	Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation.	The European respiratory journal	2011	60
20627894	1956	Eichler AF	EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer.	Neuro-oncology	2010	48
20647323	1956	Hadjipanayis CG	EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma.	Cancer research	2010	82
20679611	1956	Yap TA	Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors.	Journal of clinical oncology 	2010	77
20716591	1956	Sathornsumetee S	Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.	Neuro-oncology	2010	48
20921459	1956	Sampson JH	Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.	Journal of clinical oncology 	2010	184
21030498	1956	Heon S	Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.	Clinical cancer research 	2010	44
21189092	1956	de Boer RA	Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction.	Annals of medicine	2011	74
21471286	1956	Hegi ME	Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib--a phase II trial.	Molecular cancer therapeutics	2011	35
21610077	1956	Kinney SM	Tissue-specific distribution and dynamic changes of 5-hydroxymethylcytosine in mammalian genomes.	The Journal of biological chemistry	2011	46
21865399	1956	Grommes C	"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer.	Neuro-oncology	2011	57
21914172	1956	Sihto H	Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study.	Breast cancer research 	2011	40
22025148	1956	Lai A	Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.	Journal of clinical oncology 	2011	91
22065080	1956	Koul D	Antitumor activity of NVP-BKM120--a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells.	Clinical cancer research 	2012	44
22127113	1956	Brand TM	The nuclear epidermal growth factor receptor signaling network and its role in cancer.	Discovery medicine	2011	51
22137795	1956	Snuderl M	Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma.	Cancer cell	2011	184
22282022	1956	Doebele RC	Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer.	Cancer	2012	48
22454081	1956	Gallardo A	Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas.	British journal of cancer	2012	55
22588883	1956	Vivanco I	Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.	Cancer discovery	2012	73
22677429	1956	Park SJ	Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.	Lung cancer	2012	50
22780919	1956	Morgan RA	Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma.	Human gene therapy	2012	71
22801742	1956	Doecke JD	Blood-based protein biomarkers for diagnosis of Alzheimer disease.	Archives of neurology	2012	65
22847020	1956	Phuphanich S	Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma.	Cancer immunology, immunotherapy 	2013	68
22891331	1956	Fenton TR	Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240.	Proceedings of the National Academy of Sciences of the United States of America	2012	32
22964225	1956	Johnson H	Molecular characterization of EGFR and EGFRvIII signaling networks in human glioblastoma tumor xenografts.	Molecular and cellular proteomics 	2012	30
23070115	1956	Uchida H	Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus.	Molecular therapy 	2013	26
23123196	1956	Yang W	EGFR-induced and PKCε monoubiquitylation-dependent NF-κB activation upregulates PKM2 expression and promotes tumorigenesis.	Molecular cell	2012	55
23129122	1956	Wu YL	Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803).	Annals of oncology 	2013	36
23154552	1956	Weickhardt AJ	Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.	Journal of thoracic oncology 	2012	80
23341526	1956	Welsh JW	Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.	Journal of clinical oncology 	2013	71
23401448	1956	Mok T	Treating patients with EGFR-sensitizing mutations: first line or second line--is there a difference?	Journal of clinical oncology 	2013	27
23407558	1956	Yu HA	Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors.	Journal of thoracic oncology 	2013	48
23707073	1956	Babic I	EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer.	Cell metabolism	2013	30
23964022	1956	Giachino C	Molecular diversity subdivides the adult forebrain neural stem cell population.	Stem cells	2014	24
24021541	1956	Iuchi T	Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma.	Lung cancer	2013	31
24135280	1956	Fan QW	EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma.	Cancer cell	2013	50
24269963	1956	Roskoski R Jr	The ErbB/HER family of protein-tyrosine kinases and cancer.	Pharmacological research	2014	122
24390343	1956	Scafidi J	Intranasal epidermal growth factor treatment rescues neonatal brain injury.	Nature	2014	43
24425048	1956	Kim J	microRNA-148a is a prognostic oncomiR that targets MIG6 and BIM to regulate EGFR and apoptosis in glioblastoma.	Cancer research	2014	25
24470557	1956	Wen PY	Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.	Neuro-oncology	2014	23
24513263	1956	Vanderlaan PA	Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer.	Lung cancer	2014	20
24553385	1956	Bettegowda C	Detection of circulating tumor DNA in early- and late-stage human malignancies.	Science translational medicine	2014	385
25031274	1956	Lee SM	Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases.	Journal of the National Cancer Institute	2014	22
25080476	1956	Müller C	Hematogenous dissemination of glioblastoma multiforme.	Science translational medicine	2014	27
25150284	1956	Labussière M	Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.	Neurology	2014	29
25247337	1956	Hoffknecht P	Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease.	Journal of thoracic oncology 	2015	25
25468223	1956	Cohen AL	Glioma biology and molecular markers.	Cancer treatment and research	2015	26
25586468	1956	Schuster J	A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.	Neuro-oncology	2015	54
25943888	1956	Aldape K	Glioblastoma: pathology, molecular mechanisms and markers.	Acta neuropathologica	2015	25
26308162	1956	Russo A	A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives.	Oncotarget	2015	30
26354927	1956	Dubbink HJ	Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.	Neuro-oncology	2016	14
26410082	1956	Brastianos PK	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets.	Cancer discovery	2015	51
26724471	1956	Lin JJ	Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.	Journal of thoracic oncology 	2016	12
26823294	1956	Schuler M	First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases.	Journal of thoracic oncology 	2016	12
26874901	1956	Chan A	Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.	The Lancet. Oncology	2016	13
26898616	1956	Tan CS	Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.	Lung cancer	2016	17
26942675	1956	Li X	Mitochondria-Translocated PGK1 Functions as a Protein Kinase to Coordinate Glycolysis and the TCA Cycle in Tumorigenesis.	Molecular cell	2016	14
27083334	1956	Park K	Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.	The Lancet. Oncology	2016	46
10936180	2026	Encinas M	Sequential treatment of SH-SY5Y cells with retinoic acid and brain-derived neurotrophic factor gives rise to fully differentiated, neurotrophic factor-dependent, human neuron-like cells.	Journal of neurochemistry	2000	122
12686268	2026	Nitsche MA	Level of action of cathodal DC polarisation induced inhibition of the human motor cortex.	Clinical neurophysiology 	2003	105
16401847	2026	Zandbergen EG	Prediction of poor outcome within the first 3 days of postanoxic coma.	Neurology	2006	68
16864809	2026	Wijdicks EF	Practice parameter: prediction of outcome in comatose survivors after cardiopulmonary resuscitation (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.	Neurology	2006	151
24627036	2026	Shahim P	Blood biomarkers for brain injury in concussed professional ice hockey players.	JAMA neurology	2014	45
1464675	2033	Picton TW	The P300 wave of the human event-related potential.	Journal of clinical neurophysiology 	1992	171
2461285	2033	Farwell LA	Talking off the top of your head: toward a mental prosthesis utilizing event-related brain potentials.	Electroencephalography and clinical neurophysiology	1988	249
12829797	2033	Dehaene S	A neuronal network model linking subjective reports and objective physiological data during conscious perception.	Proceedings of the National Academy of Sciences of the United States of America	2003	109
14696723	2033	Jeon YW	Meta-analysis of P300 and schizophrenia: patients, paradigms, and practical implications.	Psychophysiology	2003	76
15254080	2033	Yeung N	Independent coding of reward magnitude and valence in the human brain.	The Journal of neuroscience 	2004	159
15329307	2033	Bramon E	Meta-analysis of the P300 and P50 waveforms in schizophrenia.	Schizophrenia research	2004	105
19170946	2033	Furdea A	An auditory oddball (P300) spelling system for brain-computer interfaces.	Psychophysiology	2009	53
20478875	2033	Leitman DI	Sensory deficits and distributed hierarchical dysfunction in schizophrenia.	The American journal of psychiatry	2010	41
20858924	2033	Brunner P	Does the 'P300' speller depend on eye gaze?	Journal of neural engineering	2010	52
20869593	2033	Min SW	Acetylation of tau inhibits its degradation and contributes to tauopathy.	Neuron	2010	162
21307242	2033	Jin H	α-Synuclein negatively regulates protein kinase Cδ expression to suppress apoptosis in dopaminergic neurons by reducing p300 histone acetyltransferase activity.	The Journal of neuroscience 	2011	38
23325432	2033	Varley KE	Dynamic DNA methylation across diverse human cell lines and tissues.	Genome research	2013	189
23994208	2033	De Vos M	Towards a truly mobile auditory brain-computer interface: exploring the P300 to take away.	International journal of psychophysiology 	2014	21
25925534	2033	Twomey DM	The classic P300 encodes a build-to-threshold decision variable.	The European journal of neuroscience	2015	22
12435860	2056	Ehrenreich H	Erythropoietin therapy for acute stroke is both safe and beneficial.	Molecular medicine	2002	162
12663857	2056	Calvillo L	Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling.	Proceedings of the National Academy of Sciences of the United States of America	2003	85
12975460	2056	Villa P	Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis.	The Journal of experimental medicine	2003	103
15178821	2056	Wang L	Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats.	Stroke	2004	196
16634041	2056	Carmichael ST	Cellular and molecular mechanisms of neural repair after stroke: making waves.	Annals of neurology	2006	143
18279854	2056	Theus MH	In vitro hypoxic preconditioning of embryonic stem cells as a strategy of promoting cell survival and functional benefits after transplantation into the ischemic rat brain.	Experimental neurology	2008	55
18324962	2056	Arcasoy MO	The non-haematopoietic biological effects of erythropoietin.	British journal of haematology	2008	78
19091002	2056	Hanson LR	Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease.	BMC neuroscience	2008	68
19651565	2056	Zhu C	Erythropoietin improved neurologic outcomes in newborns with hypoxic-ischemic encephalopathy.	Pediatrics	2009	61
19834012	2056	Ehrenreich H	Recombinant human erythropoietin in the treatment of acute ischemic stroke.	Stroke	2009	145
22449939	2056	Hruska M	Ephrin regulation of synapse formation, function and plasticity.	Molecular and cellular neurosciences	2012	44
23008465	2056	Wu YW	Erythropoietin for neuroprotection in neonatal encephalopathy: safety and pharmacokinetics.	Pediatrics	2012	46
23281216	2056	Min K	Umbilical cord blood therapy potentiated with erythropoietin for children with cerebral palsy: a double-blind, randomized, placebo-controlled trial.	Stem cells	2013	26
25058216	2056	Robertson CS	Effect of erythropoietin and transfusion threshold on neurological recovery after traumatic brain injury: a randomized clinical trial.	JAMA	2014	44
25157725	2056	Leuchter RH	Association between early administration of high-dose erythropoietin in preterm infants and brain MRI abnormality at term-equivalent age.	JAMA	2014	24
12784331	2064	Bendell JC	Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.	Cancer	2003	119
15256471	2064	Yu JS	Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma.	Cancer research	2004	132
16192626	2064	Weil RJ	Breast cancer metastasis to the central nervous system.	The American journal of pathology	2005	94
16868082	2064	Kinoshita M	Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption.	Proceedings of the National Academy of Sciences of the United States of America	2006	143
17159499	2064	Stemmler HJ	Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier.	Anti-cancer drugs	2007	57
17363517	2064	Lin NU	Brain metastases: the HER2 paradigm.	Clinical cancer research 	2007	81
17686164	2064	Viani GA	Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials.	BMC cancer	2007	74
18772890	2064	Cancer Genome Atlas Research Network.	Comprehensive genomic characterization defines human glioblastoma genes and core pathways.	Nature	2008	2168
18973228	2064	Ferretti E	MicroRNA profiling in human medulloblastoma.	International journal of cancer	2009	85
18981013	2064	Luu TH	A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study.	Clinical cancer research 	2008	59
20357763	2064	Dijkers EC	Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer.	Clinical pharmacology and therapeutics	2010	145
20498394	2064	Kennecke H	Metastatic behavior of breast cancer subtypes.	Journal of clinical oncology 	2010	290
20863372	2064	Hoefnagel LD	Receptor conversion in distant breast cancer metastases.	Breast cancer research 	2010	49
21050424	2064	Chacón RD	Triple-negative breast cancer.	Breast cancer research 	2010	57
21497451	2064	Sperduto PW	Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases.	International journal of radiation oncology, biology, physics	2012	37
21509760	2064	Musolino A	Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study.	Cancer	2011	35
21642515	2064	Pierga JY	High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients.	Annals of oncology 	2012	59
21671017	2064	Harrell JC	Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse.	Breast cancer research and treatment	2012	73
21959118	2064	Elsadek B	Impact of albumin on drug delivery--new applications on the horizon.	Journal of controlled release 	2012	64
22124109	2064	Niikura N	Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors.	Journal of clinical oncology 	2012	67
22544643	2064	Lin NU	Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network.	Cancer	2012	50
22744937	2064	Sawaya H	Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab.	Circulation. Cardiovascular imaging	2012	66
23000189	2064	Park EJ	Ultrasound-mediated blood-brain/blood-tumor barrier disruption improves outcomes with trastuzumab in a breast cancer brain metastasis model.	Journal of controlled release 	2012	37
23122784	2064	Bachelot T	Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.	The Lancet. Oncology	2013	72
23302230	2064	Alkins R	Focused ultrasound delivers targeted immune cells to metastatic brain tumors.	Cancer research	2013	32
23764181	2064	Pivot X	6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.	The Lancet. Oncology	2013	37
24029656	2064	Tamura K	64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer.	Journal of nuclear medicine 	2013	32
24298071	2064	Lin NU	CNS metastases in breast cancer: old challenge, new frontiers.	Clinical cancer research 	2013	33
25025958	2064	Singh JC	HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development.	British journal of cancer	2014	22
26530965	2064	Murtaza M	Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer.	Nature communications	2015	33
1710175	2332	Verkerk AJ	Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome.	Cell	1991	692
1878973	2332	Pieretti M	Absence of expression of the FMR-1 gene in fragile X syndrome.	Cell	1991	297
11007554	2332	Irwin SA	Dendritic spine structural anomalies in fragile-X mental retardation syndrome.	Cerebral cortex	2000	191
11223852	2332	Irwin SA	Abnormal dendritic spine characteristics in the temporal and visual cortices of patients with fragile-X syndrome: a quantitative examination.	American journal of medical genetics	2001	206
11445641	2332	Hagerman RJ	Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X.	Neurology	2001	227
12427636	2332	Brunberg JA	Fragile X premutation carriers: characteristic MR imaging findings of adult male patients with progressive cerebellar and cognitive dysfunction.	AJNR. American journal of neuroradiology	2002	83
14570712	2332	Ceman S	Phosphorylation influences the translation state of FMRP-associated polyribosomes.	Human molecular genetics	2003	108
15065016	2332	Hagerman RJ	Fragile-X-associated tremor/ataxia syndrome (FXTAS) in females with the FMR1 premutation.	American journal of human genetics	2004	85
15219735	2332	Bear MF	The mGluR theory of fragile X mental retardation.	Trends in neurosciences	2004	507
15805463	2332	Darnell JC	Kissing complex RNAs mediate interaction between the Fragile-X mental retardation protein KH2 domain and brain polyribosomes.	Genes and development	2005	97
16055059	2332	Koekkoek SK	Deletion of FMR1 in Purkinje cells enhances parallel fiber LTD, enlarges spines, and attenuates cerebellar eyelid conditioning in Fragile X syndrome.	Neuron	2005	141
16184602	2332	Hessl D	Abnormal elevation of FMR1 mRNA is associated with psychological symptoms in individuals with the fragile X premutation.	American journal of medical genetics. Part B, Neuropsychiatric genetics 	2005	99
16246864	2332	Iwahashi CK	Protein composition of the intranuclear inclusions of FXTAS.	Brain 	2006	114
17166860	2332	Hessl D	Amygdala dysfunction in men with the fragile X premutation.	Brain 	2007	58
17618523	2332	Berry-Kravis E	Fragile X-associated tremor/ataxia syndrome: clinical features, genetics, and testing guidelines.	Movement disorders 	2007	92
17932962	2332	Gothelf D	Neuroanatomy of fragile X syndrome is associated with aberrant behavior and the fragile X mental retardation protein (FMRP).	Annals of neurology	2008	73
18160642	2332	Narayanan U	FMRP phosphorylation reveals an immediate-early signaling pathway triggered by group I mGluR and mediated by PP2A.	The Journal of neuroscience 	2007	92
19193898	2332	Christie SB	The FXG: a presynaptic fragile X granule expressed in a subset of developing brain circuits.	The Journal of neuroscience 	2009	68
19422761	2332	Bourgeois JA	A review of fragile X premutation disorders: expanding the psychiatric perspective.	The Journal of clinical psychiatry	2009	79
21651511	2332	Willemsen R	CGG repeat in the FMR1 gene: size matters.	Clinical genetics	2011	41
21783174	2332	Hessl D	Decreased fragile X mental retardation protein expression underlies amygdala dysfunction in carriers of the fragile X premutation.	Biological psychiatry	2011	44
22463693	2332	Tassone F	Neuropathological, clinical and molecular pathology in female fragile X premutation carriers with and without FXTAS.	Genes, brain, and behavior	2012	41
22887750	2332	Lokanga RA	Somatic expansion in mouse and human carriers of fragile X premutation alleles.	Human mutation	2013	26
23042784	2332	Wang T	Genome-wide DNA hydroxymethylation changes are associated with neurodevelopmental genes in the developing human cerebellum.	Human molecular genetics	2012	40
23202739	2332	Bagni C	Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics.	The Journal of clinical investigation	2012	56
23478018	2332	Sellier C	Sequestration of DROSHA and DGCR8 by expanded CGG RNA repeats alters microRNA processing in fragile X-associated tremor/ataxia syndrome.	Cell reports	2013	70
23793382	2332	Hagerman P	Fragile X-associated tremor/ataxia syndrome (FXTAS): pathology and mechanisms.	Acta neuropathologica	2013	46
24005575	2332	Pastori C	Comprehensive analysis of the transcriptional landscape of the human FMR1 gene reveals two new long noncoding RNAs differentially expressed in Fragile X syndrome and Fragile X-associated tremor/ataxia syndrome.	Human genetics	2014	27
24108107	2332	Yao B	Genome-wide alteration of 5-hydroxymethylcytosine in a mouse model of fragile X-associated tremor/ataxia syndrome.	Human molecular genetics	2014	23
24167470	2332	Fernández E	The FMRP regulon: from targets to disease convergence.	Frontiers in neuroscience	2013	27
24654675	2332	Doers ME	iPSC-derived forebrain neurons from FXS individuals show defects in initial neurite outgrowth.	Stem cells and development	2014	23
7822316	2475	Sabers CJ	Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells.	The Journal of biological chemistry	1995	171
14729330	2475	Li Y	TSC2: filling the GAP in the mTOR signaling pathway.	Trends in biochemical sciences	2004	110
16012795	2475	Chang SM	Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.	Investigational new drugs	2005	89
16341243	2475	Thomas GV	Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.	Nature medicine	2006	163
17827463	2475	Stupp R	Chemoradiotherapy in malignant glioma: standard of care and future directions.	Journal of clinical oncology 	2007	108
17913600	2475	Swiech L	Role of mTOR in physiology and pathology of the nervous system.	Biochimica et biophysica acta	2008	96
18184959	2475	Bissler JJ	Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.	The New England journal of medicine	2008	278
18215105	2475	Cloughesy TF	Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma.	PLoS medicine	2008	194
18722871	2475	Curatolo P	Tuberous sclerosis.	Lancet	2008	152
19234517	2475	Hartman TR	The role of the Birt-Hogg-Dubé protein in mTOR activation and renal tumorigenesis.	Oncogene	2009	59
19817806	2475	Wong M	Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies.	Epilepsia	2010	59
19963289	2475	Hoeffer CA	mTOR signaling: at the crossroads of plasticity, memory and disease.	Trends in neurosciences	2010	270
20472883	2475	Akhavan D	mTOR signaling in glioblastoma: lessons learned from bench to bedside.	Neuro-oncology	2010	46
21047224	2475	Krueger DA	Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.	The New England journal of medicine	2010	206
21228155	2475	Rieker C	Nucleolar disruption in dopaminergic neurons leads to oxidative damage and parkinsonism through repression of mammalian target of rapamycin signaling.	The Journal of neuroscience 	2011	39
21269838	2475	Howell JJ	mTOR couples cellular nutrient sensing to organismal metabolic homeostasis.	Trends in endocrinology and metabolism	2011	107
21317208	2475	Prasad G	Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide.	Neuro-oncology	2011	44
21336308	2475	Zheng M	Inactivation of Rheb by PRAK-mediated phosphorylation is essential for energy-depletion-induced suppression of mTORC1.	Nature cell biology	2011	56
21460795	2475	Galan-Moya EM	Secreted factors from brain endothelial cells maintain glioblastoma stem-like cell expansion through the mTOR pathway.	EMBO reports	2011	38
21890410	2475	Crino PB	mTOR: A pathogenic signaling pathway in developmental brain malformations.	Trends in molecular medicine	2011	51
22268788	2475	Hoeffer CA	Altered mTOR signaling and enhanced CYFIP2 expression levels in subjects with fragile X syndrome.	Genes, brain, and behavior	2012	46
22340590	2475	Pei Y	An animal model of MYC-driven medulloblastoma.	Cancer cell	2012	81
22349822	2475	Wen ZH	Critical role of arachidonic acid-activated mTOR signaling in breast carcinogenesis and angiogenesis.	Oncogene	2013	25
22612226	2475	van Vliet EA	Inhibition of mammalian target of rapamycin reduces epileptogenesis and blood-brain barrier leakage but not microglia activation.	Epilepsia	2012	33
23158522	2475	Franz DN	Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.	Lancet	2013	113
23644232	2475	Wong M	Mammalian target of rapamycin (mTOR) pathways in neurological diseases.	Biomedical journal	2013	29
23739003	2475	Wong M	A critical review of mTOR inhibitors and epilepsy: from basic science to clinical trials.	Expert review of neurotherapeutics	2013	27
24390152	2475	Freret T	Mechanisms underlying the neuroprotective effect of brain reserve against late life depression.	Journal of neural transmission	2015	22
24474794	2475	Liu X	Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK.	Proceedings of the National Academy of Sciences of the United States of America	2014	56
24585383	2475	Scheffer IE	Mutations in mammalian target of rapamycin regulator DEPDC5 cause focal epilepsy with brain malformations.	Annals of neurology	2014	27
24666346	2475	Neasta J	mTOR complex 1: a key player in neuroadaptations induced by drugs of abuse.	Journal of neurochemistry	2014	21
24899720	2475	Caccamo A	Genetic reduction of mammalian target of rapamycin ameliorates Alzheimer's disease-like cognitive and pathological deficits by restoring hippocampal gene expression signature.	The Journal of neuroscience 	2014	30
25282103	2475	Wood AR	Defining the role of common variation in the genomic and biological architecture of adult human height.	Nature genetics	2014	268
25554914	2475	Albert V	mTOR signaling in cellular and organismal energetics.	Current opinion in cell biology	2015	49
25813405	2475	Wang Y	CRNDE, a long-noncoding RNA, promotes glioma cell growth and invasion through mTOR signaling.	Cancer letters	2015	33
25867026	2475	Sesen J	Metformin inhibits growth of human glioblastoma cells and enhances therapeutic response.	PloS one	2015	18
25913192	2475	Venkatesh HS	Neuronal Activity Promotes Glioma Growth through Neuroligin-3 Secretion.	Cell	2015	38
26018084	2475	Nakashima M	Somatic Mutations in the MTOR gene cause focal cortical dysplasia type IIb.	Annals of neurology	2015	19
26947070	2475	Cárdenas C	Selective Vulnerability of Cancer Cells by Inhibition of Ca(2+) Transfer from Endoplasmic Reticulum to Mitochondria.	Cell reports	2016	16
27889578	2475	Switon K	Molecular neurobiology of mTOR.	Neuroscience	2017	10
14684836	2571	Veldic M	DNA-methyltransferase 1 mRNA is selectively overexpressed in telencephalic GABAergic interneurons of schizophrenia brains.	Proceedings of the National Academy of Sciences of the United States of America	2004	80
15237077	2571	Woo TU	Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder.	Archives of general psychiatry	2004	109
15700048	2571	Rapoport JL	The neurodevelopmental model of schizophrenia: update 2005.	Molecular psychiatry	2005	201
17586305	2571	Kaplitt MG	Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial.	Lancet	2007	266
17726539	2571	Huang HS	GAD1 mRNA expression and DNA methylation in prefrontal cortex of subjects with schizophrenia.	PloS one	2007	70
19188247	2571	Huang ZJ	Activity-dependent development of inhibitory synapses and innervation pattern: role of GABA signalling and beyond.	The Journal of physiology	2009	50
19321177	2571	Thompson M	Decreased glutamic acid decarboxylase(67) mRNA expression in multiple brain areas of patients with schizophrenia and mood disorders.	Journal of psychiatric research	2009	47
20437582	2571	Malter MP	Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis.	Annals of neurology	2010	62
21223646	2571	Thompson Ray M	Decreased BDNF, trkB-TK+ and GAD67 mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders.	Journal of psychiatry and neuroscience 	2011	72
21419704	2571	LeWitt PA	AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial.	The Lancet. Neurology	2011	128
21795557	2571	Hyde TM	Expression of GABA signaling molecules KCC2, NKCC1, and GAD1 in cortical development and schizophrenia.	The Journal of neuroscience 	2011	77
22159125	2571	Volman V	Downregulation of parvalbumin at cortical GABA synapses reduces network gamma oscillatory activity.	The Journal of neuroscience 	2011	47
22948975	2571	Grayson DR	The dynamics of DNA methylation in schizophrenia and related psychiatric disorders.	Neuropsychopharmacology 	2013	60
22983435	2571	Volk DW	Deficits in transcriptional regulators of cortical parvalbumin neurons in schizophrenia.	The American journal of psychiatry	2012	58
24448211	2571	Zhubi A	Increased binding of MeCP2 to the GAD1 and RELN promoters may be mediated by an enrichment of 5-hmC in autism spectrum disorder (ASD) cerebellum.	Translational psychiatry	2014	41
24993056	2571	Glausier JR	Lower glutamic acid decarboxylase 65-kDa isoform messenger RNA and protein levels in the prefrontal cortex in schizoaffective disorder but not schizophrenia.	Biological psychiatry	2015	15
8493557	2668	Lin LF	GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons.	Science	1993	373
12669033	2668	Gill SS	Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease.	Nature medicine	2003	186
15739547	2668	Slevin JT	Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor.	Journal of neurosurgery	2005	75
16429411	2668	Lang AE	Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease.	Annals of neurology	2006	162
19395124	2668	Marksteiner J	Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease.	Neurobiology of aging	2011	37
22328536	2668	Doi D	Prolonged maturation culture favors a reduction in the tumorigenicity and the dopaminergic function of human ESC-derived neural cells in a primate model of Parkinson's disease.	Stem cells	2012	38
9425002	2670	Wolswijk G	Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells.	The Journal of neuroscience 	1998	105
11668683	2670	Zhuo L	hGFAP-cre transgenic mice for manipulation of glial and neuronal function in vivo.	Genesis	2001	208
12853570	2670	Curtis MA	Increased cell proliferation and neurogenesis in the adult human Huntington's disease brain.	Proceedings of the National Academy of Sciences of the United States of America	2003	116
15280535	2670	Kelly S	Transplanted human fetal neural stem cells survive, migrate, and differentiate in ischemic rat cerebral cortex.	Proceedings of the National Academy of Sciences of the United States of America	2004	155
15495269	2670	Pekny M	Astrocyte intermediate filaments in CNS pathologies and regeneration.	The Journal of pathology	2004	77
16320258	2670	Quiñones-Hinojosa A	Cellular composition and cytoarchitecture of the adult human subventricular zone: a niche of neural stem cells.	The Journal of comparative neurology	2006	122
17405762	2670	Misu T	Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis.	Brain 	2007	115
17491094	2670	Thannickal TC	Hypocretin (orexin) cell loss in Parkinson's disease.	Brain 	2007	75
18240313	2670	Lee Y	GFAP promoter elements required for region-specific and astrocyte-specific expression.	Glia	2008	62
18927145	2670	Gouw AA	Heterogeneity of white matter hyperintensities in Alzheimer's disease: post-mortem quantitative MRI and neuropathology.	Brain 	2008	68
19153578	2670	Chojnacki AK	Identity crisis for adult periventricular neural stem cells: subventricular zone astrocytes, ependymal cells or both?	Nature reviews. Neuroscience	2009	45
19279265	2670	Oberheim NA	Uniquely hominid features of adult human astrocytes.	The Journal of neuroscience 	2009	183
19638961	2670	Lawlor PA	Efficient gene delivery and selective transduction of glial cells in the mammalian brain by AAV serotypes isolated from nonhuman primates.	Molecular therapy 	2009	53
19816235	2670	Ballabh P	Intraventricular hemorrhage in premature infants: mechanism of disease.	Pediatric research	2010	77
20140958	2670	Olabarria M	Concomitant astroglial atrophy and astrogliosis in a triple transgenic animal model of Alzheimer's disease.	Glia	2010	53
21079180	2670	Vos PE	GFAP and S100B are biomarkers of traumatic brain injury: an observational cohort study.	Neurology	2010	62
21219963	2670	Middeldorp J	GFAP in health and disease.	Progress in neurobiology	2011	140
21280078	2670	Gunnarsson M	Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab.	Annals of neurology	2011	41
21702960	2670	Mondello S	Neuronal and glial markers are differently associated with computed tomography findings and outcome in patients with severe traumatic brain injury: a case control study.	Critical care	2011	52
21930157	2670	Kane MJ	A mouse model of human repetitive mild traumatic brain injury.	Journal of neuroscience methods	2012	42
22517109	2670	Metting Z	GFAP and S100B in the acute phase of mild traumatic brain injury.	Neurology	2012	38
23431204	2670	Ponti G	Cell cycle and lineage progression of neural progenitors in the ventricular-subventricular zones of adult mice.	Proceedings of the National Academy of Sciences of the United States of America	2013	47
23469922	2670	Rajkowska G	Astrocyte pathology in major depressive disorder: insights from human postmortem brain tissue.	Current drug targets	2013	55
23489259	2670	Okonkwo DO	GFAP-BDP as an acute diagnostic marker in traumatic brain injury: results from the prospective transforming research and clinical knowledge in traumatic brain injury study.	Journal of neurotrauma	2013	30
23579868	2670	Misu T	Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica.	Acta neuropathologica	2013	42
23769173	2670	Yuan T	Human induced pluripotent stem cell-derived neural stem cells survive, migrate, differentiate, and improve neurologic function in a rat model of middle cerebral artery occlusion.	Stem cell research and therapy	2013	25
23865516	2670	Diaz-Arrastia R	Acute biomarkers of traumatic brain injury: relationship between plasma levels of ubiquitin C-terminal hydrolase-L1 and glial fibrillary acidic protein.	Journal of neurotrauma	2014	45
24269023	2670	Kamphuis W	Glial fibrillary acidic protein isoform expression in plaque related astrogliosis in Alzheimer's disease.	Neurobiology of aging	2014	20
24332821	2670	Chalak LF	Biomarkers for severity of neonatal hypoxic-ischemic encephalopathy and outcomes in newborns receiving hypothermia therapy.	The Journal of pediatrics	2014	22
24501367	2670	Sosunov AA	Phenotypic heterogeneity and plasticity of isocortical and hippocampal astrocytes in the human brain.	The Journal of neuroscience 	2014	23
24667434	2670	Zhang Z	Human traumatic brain injury induces autoantibody response against glial fibrillary acidic protein and its breakdown products.	PloS one	2014	24
24903744	2670	Papa L	GFAP out-performs S100β in detecting traumatic intracranial lesions on computed tomography in trauma patients with mild traumatic brain injury and those with extracranial lesions.	Journal of neurotrauma	2014	24
27018834	2670	Papa L	Time Course and Diagnostic Accuracy of Glial and Neuronal Blood Biomarkers GFAP and UCH-L1 in a Large Cohort of Trauma Patients With and Without Mild Traumatic Brain Injury.	JAMA neurology	2016	20
11801260	2688	Black PH	Stress, inflammation and cardiovascular disease.	Journal of psychosomatic research	2002	118
12119665	2688	Björntorp P	Do stress reactions cause abdominal obesity and comorbidities?	Obesity reviews 	2001	179
12764120	2688	Benedetti F	Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo/nocebo responses.	The Journal of neuroscience 	2003	93
16616726	2688	Munro CA	Sex differences in striatal dopamine release in healthy adults.	Biological psychiatry	2006	81
18279846	2688	Webster Marketon JI	Stress hormones and immune function.	Cellular immunology	2008	60
19581535	2688	Merchant TE	Late effects of conformal radiation therapy for pediatric patients with low-grade glioma: prospective evaluation of cognitive, endocrine, and hearing deficits.	Journal of clinical oncology 	2009	53
20398008	2688	Lange T	Effects of sleep and circadian rhythm on the human immune system.	Annals of the New York Academy of Sciences	2010	67
21464293	2688	Chou SH	Leptin is an effective treatment for hypothalamic amenorrhea.	Proceedings of the National Academy of Sciences of the United States of America	2011	44
21791620	2688	Mantzoros CS	Leptin in human physiology and pathophysiology.	American journal of physiology. Endocrinology and metabolism	2011	88
16373418	2796	Dungan HM	Minireview: kisspeptin neurons as central processors in the regulation of gonadotropin-releasing hormone secretion.	Endocrinology	2006	73
20501670	2796	Lehman MN	Minireview: kisspeptin/neurokinin B/dynorphin (KNDy) cells of the arcuate nucleus: a central node in the control of gonadotropin-releasing hormone secretion.	Endocrinology	2010	130
20529119	2796	Hrabovszky E	The kisspeptin system of the human hypothalamus: sexual dimorphism and relationship with gonadotropin-releasing hormone and neurokinin B neurons.	The European journal of neuroscience	2010	51
20650288	2796	Wierman ME	Gonadotropin-releasing hormone (GnRH) neuron migration: initiation, maintenance and cessation as critical steps to ensure normal reproductive function.	Frontiers in neuroendocrinology	2011	40
24881463	2796	Pagani O	Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.	The New England journal of medicine	2014	75
17643398	2890	Maeng S	Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.	Biological psychiatry	2008	248
19338055	2890	Lai M	AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location.	Annals of neurology	2009	129
21148011	2890	Schwarz LA	Activity-dependent ubiquitination of GluA1 mediates a distinct AMPA receptor endocytosis and sorting pathway.	The Journal of neuroscience 	2010	57
21338354	2890	Lin A	Nedd4-mediated AMPA receptor ubiquitination regulates receptor turnover and trafficking.	Journal of neurochemistry	2011	47
21782286	2890	Walter S	A genome-wide association study of aging.	Neurobiology of aging	2011	52
25369168	2890	Peng X	Cellular plasticity induced by anti-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor encephalitis antibodies.	Annals of neurology	2015	22
16862115	2896	Cruts M	Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21.	Nature	2006	346
16862116	2896	Baker M	Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17.	Nature	2006	454
16950801	2896	Gass J	Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration.	Human molecular genetics	2006	160
17071926	2896	Mackenzie IR	The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene.	Brain 	2006	67
18234697	2896	Beck J	A distinct clinical, neuropsychological and radiological phenotype is associated with progranulin gene mutations in a large UK series.	Brain 	2008	57
18245784	2896	Le Ber I	Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging and genetic study.	Brain 	2008	54
19158106	2896	Finch N	Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members.	Brain 	2009	86
19288468	2896	Sleegers K	Serum biomarker for progranulin-associated frontotemporal lobar degeneration.	Annals of neurology	2009	49
19679189	2896	Rohrer JD	Progressive logopenic/phonological aphasia: erosion of the language network.	NeuroImage	2010	54
20045477	2896	Rohrer JD	Distinct profiles of brain atrophy in frontotemporal lobar degeneration caused by progranulin and tau mutations.	NeuroImage	2010	43
20489155	2896	Wang WX	miR-107 regulates granulin/progranulin with implications for traumatic brain injury and neurodegenerative disease.	The American journal of pathology	2010	60
15828859	2902	Han K	A combinatorial code for splicing silencing: UAGG and GGGG motifs.	PLoS biology	2005	82
16427029	2902	Rujescu D	A pharmacological model for psychosis based on N-methyl-D-aspartate receptor hypofunction: molecular, cellular, functional and behavioral abnormalities.	Biological psychiatry	2006	63
17898324	2902	Iizuka T	Anti-NMDA receptor encephalitis in Japan: long-term outcome without tumor removal.	Neurology	2008	71
18851928	2902	Dalmau J	Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies.	The Lancet. Neurology	2008	361
19020013	2902	Li W	NMDA receptor activation by HIV-Tat protein is clade dependent.	The Journal of neuroscience 	2008	60
22875940	2902	Gleichman AJ	Anti-NMDA receptor encephalitis antibody binding is dependent on amino acid identity of a small region within the GluN1 amino terminal domain.	The Journal of neuroscience 	2012	42
23070074	2902	Weickert CS	Molecular evidence of N-methyl-D-aspartate receptor hypofunction in schizophrenia.	Molecular psychiatry	2013	52
23877059	2902	Kayser MS	Frequency and characteristics of isolated psychiatric episodes in anti–N-methyl-d-aspartate receptor encephalitis.	JAMA neurology	2013	42
24360484	2902	Gresa-Arribas N	Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study.	The Lancet. Neurology	2014	71
28095420	2902	Ogden KK	Molecular Mechanism of Disease-Associated Mutations in the Pre-M1 Helix of NMDA Receptors and Potential Rescue Pharmacology.	PLoS genetics	2017	6
11168837	2908	Welberg LA	Prenatal stress, glucocorticoids and the programming of the brain.	Journal of neuroendocrinology	2001	154
11274650	2908	Pariante CM	Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment.	Biological psychiatry	2001	176
12399952	2908	Webster MJ	Regional specificity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders.	Molecular psychiatry	2002	80
16214171	2908	de Kloet CS	Assessment of HPA-axis function in posttraumatic stress disorder: pharmacological and non-pharmacological challenge tests, a review.	Journal of psychiatric research	2006	80
17515892	2908	Seckl JR	Mechanisms of disease: glucocorticoids, their placental metabolism and fetal 'programming' of adult pathophysiology.	Nature clinical practice. Endocrinology and metabolism	2007	116
18536531	2908	Oberlander TF	Prenatal exposure to maternal depression, neonatal methylation of human glucocorticoid receptor gene (NR3C1) and infant cortisol stress responses.	Epigenetics	2008	301
19234457	2908	McGowan PO	Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse.	Nature neuroscience	2009	629
19782477	2908	Alt SR	Differential expression of glucocorticoid receptor transcripts in major depressive disorder is not epigenetically programmed.	Psychoneuroendocrinology	2010	45
20399565	2908	Anacker C	The glucocorticoid receptor: pivot of depression and of antidepressant treatment?	Psychoneuroendocrinology	2011	67
20591431	2908	Harris A	Glucocorticoids, prenatal stress and the programming of disease.	Hormones and behavior	2011	147
20854893	2908	Bower JE	Fatigue and gene expression in human leukocytes: increased NF-κB and decreased glucocorticoid signaling in breast cancer survivors with persistent fatigue.	Brain, behavior, and immunity	2011	50
21980503	2908	Charmandari E	Peripheral CLOCK regulates target-tissue glucocorticoid receptor transcriptional activity in a circadian fashion in man.	PloS one	2011	38
22088795	2908	Antoni MH	Cognitive-behavioral stress management reverses anxiety-related leukocyte transcriptional dynamics.	Biological psychiatry	2012	51
22423117	2908	Krishnadas R	Depression: an inflammatory illness?	Journal of neurology, neurosurgery, and psychiatry	2012	53
22444201	2908	Labonte B	Differential glucocorticoid receptor exon 1(B), 1(C), and 1(H) expression and methylation in suicide completers with a history of childhood abuse.	Biological psychiatry	2012	70
24465557	2908	Na KS	Association between glucocorticoid receptor methylation and hippocampal subfields in major depressive disorder.	PloS one	2014	20
24661442	2908	Yehuda R	Lower methylation of glucocorticoid receptor gene promoter 1F in peripheral blood of veterans with posttraumatic stress disorder.	Biological psychiatry	2015	41
25687413	2908	Turecki G	Effects of the Social Environment and Stress on Glucocorticoid Receptor Gene Methylation: A Systematic Review.	Biological psychiatry	2016	37
25875334	2908	Braithwaite EC	Maternal prenatal depressive symptoms predict infant NR3C1 1F and BDNF IV DNA methylation.	Epigenetics	2015	25
26067718	2908	Pivonello R	The Treatment of Cushing's Disease.	Endocrine reviews	2015	18
10973318	3060	Peyron C	A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains.	Nature medicine	2000	320
11055430	3060	Thannickal TC	Reduced number of hypocretin neurons in human narcolepsy.	Neuron	2000	317
16247044	3060	Crocker A	Concomitant loss of dynorphin, NARP, and orexin in narcolepsy.	Neurology	2005	70
17468046	3060	McCarley RW	Neurobiology of REM and NREM sleep.	Sleep medicine	2007	103
17712350	3060	Minzenberg MJ	Modafinil: a review of neurochemical actions and effects on cognition.	Neuropsychopharmacology 	2008	133
21034217	3060	Scammell TE	Orexin receptors: pharmacology and therapeutic opportunities.	Annual review of pharmacology and toxicology	2011	56
23135822	3060	Chapman CD	Intranasal treatment of central nervous system dysfunction in humans.	Pharmaceutical research	2013	28
23616752	3060	Tsujino N	Role of orexin in modulating arousal, feeding, and motivation.	Frontiers in behavioral neuroscience	2013	31
24277819	3060	Sears RM	Orexin/hypocretin system modulates amygdala-dependent threat learning through the locus coeruleus.	Proceedings of the National Academy of Sciences of the United States of America	2013	29
24382351	3060	Hasegawa E	Orexin neurons suppress narcolepsy via 2 distinct efferent pathways.	The Journal of clinical investigation	2014	25
7748555	3064	DiFiglia M	Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons.	Neuron	1995	133
9267033	3064	Davies SW	Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation.	Cell	1997	452
9302293	3064	DiFiglia M	Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain.	Science	1997	565
10087066	3064	Gutekunst CA	Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology.	The Journal of neuroscience 	1999	184
11988536	3064	Dunah AW	Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease.	Science	2002	173
12873381	3064	Tang TS	Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1.	Neuron	2003	118
12881722	3064	Zuccato C	Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes.	Nature genetics	2003	216
15340079	3064	Trushina E	Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro.	Molecular and cellular biology	2004	138
16043692	3064	Borovecki F	Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease.	Proceedings of the National Academy of Sciences of the United States of America	2005	108
16452635	3064	Benchoua A	Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin.	Molecular biology of the cell	2006	66
16522639	3064	Shibata M	Regulation of intracellular accumulation of mutant Huntingtin by Beclin 1.	The Journal of biological chemistry	2006	133
17687326	3064	Bennett EJ	Global changes to the ubiquitin system in Huntington's disease.	Nature	2007	175
18488016	3064	Yang SH	Towards a transgenic model of Huntington's disease in a non-human primate.	Nature	2008	108
18550760	3064	Gray M	Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice.	The Journal of neuroscience 	2008	183
18625748	3064	Björkqvist M	A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease.	The Journal of experimental medicine	2008	126
19289118	3064	Lombardi MS	A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference.	Experimental neurology	2009	48
19460373	3064	Sassone J	Huntington's disease: the current state of research with peripheral tissues.	Experimental neurology	2009	45
19487684	3064	Nekooki-Machida Y	Distinct conformations of in vitro and in vivo amyloids of huntingtin-exon1 show different cytotoxicity.	Proceedings of the National Academy of Sciences of the United States of America	2009	78
19646924	3064	Tabrizi SJ	Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data.	The Lancet. Neurology	2009	156
19710014	3064	Aiken CT	Phosphorylation of threonine 3: implications for Huntingtin aggregation and neurotoxicity.	The Journal of biological chemistry	2009	46
20923788	3064	Nopoulos PC	Smaller intracranial volume in prodromal Huntington's disease: evidence for abnormal neurodevelopment.	Brain 	2011	38
21130037	3064	Tabrizi SJ	Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis.	The Lancet. Neurology	2011	121
21257639	3064	Shirendeb U	Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage.	Human molecular genetics	2011	78
21395858	3064	Winner B	Neurodegenerative disease and adult neurogenesis.	The European journal of neuroscience	2011	114
21571086	3064	Moreno-Gonzalez I	Misfolded protein aggregates: mechanisms, structures and potential for disease transmission.	Seminars in cell and developmental biology	2011	42
21971427	3064	Carroll JB	Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin.	Molecular therapy 	2011	69
22031240	3064	McBride JL	Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease.	Molecular therapy 	2011	57
22137354	3064	Tabrizi SJ	Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data.	The Lancet. Neurology	2012	78
22446390	3064	Costa V	Shaping the role of mitochondria in the pathogenesis of Huntington's disease.	The EMBO journal	2012	35
22613578	3064	Juopperi TA	Astrocytes generated from patient induced pluripotent stem cells recapitulate features of Huntington's disease patient cells.	Molecular brain	2012	62
22709585	3064	Siddiqui A	Mitochondrial DNA damage is associated with reduced mitochondrial bioenergetics in Huntington's disease.	Free radical biology and medicine	2012	32
23160193	3064	Kwan W	Mutant huntingtin impairs immune cell migration in Huntington disease.	The Journal of clinical investigation	2012	33
23664844	3064	Tabrizi SJ	Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data.	The Lancet. Neurology	2013	98
23963702	3064	Østergaard ME	Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS.	Nucleic acids research	2013	31
24459107	3064	Träger U	HTT-lowering reverses Huntington's disease immune dysfunction caused by NFκB pathway dysregulation.	Brain 	2014	32
24586208	3064	Hoss AG	MicroRNAs located in the Hox gene clusters are implicated in huntington's disease pathogenesis.	PLoS genetics	2014	22
25017010	3064	Pecho-Vrieseling E	Transneuronal propagation of mutant huntingtin contributes to non-cell autonomous pathology in neurons.	Nature neuroscience	2014	26
25437566	3064	Brehme M	A chaperome subnetwork safeguards proteostasis in aging and neurodegenerative disease.	Cell reports	2014	50
27479945	3064	Horvath S	Huntington's disease accelerates epigenetic aging of human brain and disrupts DNA methylation levels.	Aging	2016	16
10582706	3091	Zhong H	Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases.	Cancer research	1999	499
11927290	3091	Semenza GL	HIF-1 and tumor progression: pathophysiology and therapeutics.	Trends in molecular medicine	2002	171
17015745	3091	Argaw AT	IL-1beta regulates blood-brain barrier permeability via reactivation of the hypoxia-angiogenesis program.	Journal of immunology	2006	62
17075581	3091	Zagzag D	Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion.	Laboratory investigation; a journal of technical methods and pathology	2006	83
17118889	3091	Tatum JL	Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy.	International journal of radiation biology	2006	165
17502379	3091	Land SC	Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif.	The Journal of biological chemistry	2007	113
19359588	3091	Zhao S	Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha.	Science	2009	284
19718046	3091	Soeda A	Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha.	Oncogene	2009	157
20463368	3091	Michelakis ED	Metabolic modulation of glioblastoma with dichloroacetate.	Science translational medicine	2010	188
20515450	3091	Méndez O	Knock down of HIF-1alpha in glioma cells reduces migration in vitro and invasion in vivo and impairs their ability to form tumor spheres.	Molecular cancer	2010	46
21321221	3091	Keunen O	Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma.	Proceedings of the National Academy of Sciences of the United States of America	2011	167
21616142	3091	Batinic-Haberle I	Diverse functions of cationic Mn(III) N-substituted pyridylporphyrins, recognized as SOD mimics.	Free radical biology and medicine	2011	47
21712410	3091	Mathieu J	HIF induces human embryonic stem cell markers in cancer cells.	Cancer research	2011	139
23842546	3091	Chae YC	Landscape of the mitochondrial Hsp90 metabolome in tumours.	Nature communications	2013	33
24366912	3091	Chesnelong C	Lactate dehydrogenase A silencing in IDH mutant gliomas.	Neuro-oncology	2014	23
17964252	3176	Wandell BA	Visual field maps in human cortex.	Neuron	2007	231
18614670	3176	Boyke J	Training-induced brain structure changes in the elderly.	The Journal of neuroscience 	2008	139
18648501	3176	Driemeyer J	Changes in gray matter induced by learning--revisited.	PloS one	2008	94
20457261	3176	Weiner KS	Sparsely-distributed organization of face and limb activations in human ventral temporal cortex.	NeuroImage	2010	65
10665620	3350	Sargent PA	Brain serotonin1A receptor binding measured by positron emission tomography with 11CWAY-100635: effects of depression and antidepressant treatment.	Archives of general psychiatry	2000	101
12559651	3350	Blier P	Is there a role for 5-HT1A agonists in the treatment of depression?	Biological psychiatry	2003	78
14507979	3350	Lemonde S	Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide.	The Journal of neuroscience 	2003	154
14736842	3350	Neumeister A	Reduced serotonin type 1A receptor binding in panic disorder.	The Journal of neuroscience 	2004	71
15758168	3350	David SP	A functional genetic variation of the serotonin (5-HT) transporter affects 5-HT1A receptor binding in humans.	The Journal of neuroscience 	2005	74
17077377	3350	Paterson DS	Multiple serotonergic brainstem abnormalities in sudden infant death syndrome.	JAMA	2006	129
19124686	3350	Fakra E	Effects of HTR1A C(-1019)G on amygdala reactivity and trait anxiety.	Archives of general psychiatry	2009	61
20592420	3350	Politis M	Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants.	Science translational medicine	2010	55
20614802	3350	Nikolaus S	Cortical GABA, striatal dopamine and midbrain serotonin as the key players in compulsive and anxiety disorders--results from in vivo imaging studies.	Reviews in the neurosciences	2010	49
24854329	3350	Devinsky O	Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.	Epilepsia	2014	53
25016186	3350	Sanchez C	Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data.	Pharmacology and therapeutics	2015	22
18772040	3356	Bubar MJ	Prospects for serotonin 5-HT2R pharmacotherapy in psychostimulant abuse.	Progress in brain research	2008	52
19373443	3356	Capela JP	Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview.	Molecular neurobiology	2009	46
21550210	3356	Abdolmaleky HM	Epigenetic dysregulation of HTR2A in the brain of patients with schizophrenia and bipolar disorder.	Schizophrenia research	2011	38
25036425	3356	Halberstadt AL	Recent advances in the neuropsychopharmacology of serotonergic hallucinogens.	Behavioural brain research	2015	25
25505168	3356	Howell LL	Serotonin 5-HT2 receptor interactions with dopamine function: implications for therapeutics in cocaine use disorder.	Pharmacological reviews	2015	25
18772396	3417	Parsons DW	An integrated genomic analysis of human glioblastoma multiforme.	Science	2008	1466
19228619	3417	Yan H	IDH1 and IDH2 mutations in gliomas.	The New England journal of medicine	2009	972
19246647	3417	Watanabe T	IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.	The American journal of pathology	2009	185
19378339	3417	Kang MR	Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers.	International journal of cancer	2009	86
19554337	3417	Hartmann C	Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.	Acta neuropathologica	2009	219
19636000	3417	Sanson M	Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.	Journal of clinical oncology 	2009	178
19737147	3417	Ohgaki H	Genetic alterations and signaling pathways in the evolution of gliomas.	Cancer science	2009	99
19805672	3417	Weller M	Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.	Journal of clinical oncology 	2009	135
19935646	3417	Dang L	Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.	Nature	2009	672
20160062	3417	van den Bent MJ	IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.	Clinical cancer research 	2010	88
20399149	3417	Noushmehr H	Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.	Cancer cell	2010	587
20427748	3417	Labussière M	All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2.	Neurology	2010	56
20513808	3417	Reitman ZJ	Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism.	Journal of the National Cancer Institute	2010	101
20975057	3417	Houillier C	IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.	Neurology	2010	84
21075857	3417	Kim YH	Molecular classification of low-grade diffuse gliomas.	The American journal of pathology	2010	43
21088844	3417	Hartmann C	Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.	Acta neuropathologica	2010	98
21129061	3417	von Deimling A	The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations.	Brain pathology	2011	41
21163902	3417	Christensen BC	DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma.	Journal of the National Cancer Institute	2011	89
21289278	3417	Reitman ZJ	Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome.	Proceedings of the National Academy of Sciences of the United States of America	2011	143
21326614	3417	Jin G	2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.	PloS one	2011	47
22015945	3417	Pope WB	Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy.	Journal of neuro-oncology	2012	57
22052461	3417	Jin SG	5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations.	Cancer research	2011	110
22238332	3417	Andronesi OC	Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy.	Science translational medicine	2012	78
22238333	3417	Elkhaled A	Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas.	Science translational medicine	2012	50
22270850	3417	Bleeker FE	Recent advances in the molecular understanding of glioblastoma.	Journal of neuro-oncology	2012	36
22281806	3417	Choi C	2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas.	Nature medicine	2012	130
22415316	3417	Gorovets D	IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma.	Clinical cancer research 	2012	40
22829908	3417	Orr BA	Decreased 5-hydroxymethylcytosine is associated with neural progenitor phenotype in normal brain and shorter survival in malignant glioma.	PloS one	2012	39
22899282	3417	Duncan CG	A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation.	Genome research	2012	48
23071237	3417	van den Bent MJ	Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.	Journal of clinical oncology 	2013	134
23090983	3417	Yan W	Molecular classification of gliomas based on whole genome gene expression: a systematic report of 225 samples from the Chinese Glioma Cooperative Group.	Neuro-oncology	2012	46
23095825	3417	Weller M	Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.	Neuro-oncology	2012	31
23115158	3417	Li S	Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.	Neuro-oncology	2013	30
23209033	3417	Ohgaki H	The definition of primary and secondary glioblastoma.	Clinical cancer research 	2013	107
23793099	3417	Tönjes M	BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1.	Nature medicine	2013	63
23896276	3417	Weller M	Molecular neuro-oncology in clinical practice: a new horizon.	The Lancet. Oncology	2013	30
24077805	3417	Borodovsky A	5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft.	Oncotarget	2013	31
24333121	3417	Emadi A	Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations.	Experimental hematology	2014	32
24516018	3417	Cairncross JG	Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.	Journal of clinical oncology 	2014	50
24722048	3417	Killela PJ	Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas.	Oncotarget	2014	45
24810474	3417	Cai J	ATRX mRNA expression combined with IDH1/2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome sequencing of 169 samples samples.	Oncotarget	2014	22
25043048	3417	Schumacher T	A vaccine targeting mutant IDH1 induces antitumour immunity.	Nature	2014	73
25143301	3417	Sahm F	Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma.	Acta neuropathologica	2014	32
25701198	3417	Olar A	IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas.	Acta neuropathologica	2015	17
25783747	3417	Weller M	Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups.	Acta neuropathologica	2015	26
26124478	3417	Sandmann T	Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial.	Journal of clinical oncology 	2015	38
26373279	3417	Kim J	Spatiotemporal Evolution of the Primary Glioblastoma Genome.	Cancer cell	2015	24
26534967	3417	Andronesi OC	Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate.	Clinical cancer research 	2016	11
26669865	3417	Emir UE	Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas with IDH1 and IDH2 Mutations.	Cancer research	2016	14
26691210	3417	de la Fuente MI	Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma.	Neuro-oncology	2016	18
27157931	3417	Louis DN	The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.	Acta neuropathologica	2016	233
27270107	3417	Wang J	Clonal evolution of glioblastoma under therapy.	Nature genetics	2016	15
8602746	3456	Jacobs LD	Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)	Annals of neurology	1996	255
11006365	3456	Jacobs LD	Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.	The New England journal of medicine	2000	140
11377645	3456	Comi G	Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.	Lancet	2001	96
15833864	3456	Nakamizo A	Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas.	Cancer research	2005	277
16510745	3456	Rudick RA	Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.	The New England journal of medicine	2006	188
18369324	3456	Aboody KS	Stem and progenitor cell-mediated tumor selective gene therapy.	Gene therapy	2008	83
19364933	3456	Bielekova B	Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.	Archives of neurology	2009	60
19475668	3456	Durelli L	T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta.	Annals of neurology	2009	73
20163990	3456	Wynn D	Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.	The Lancet. Neurology	2010	67
22362918	3456	Soilu-Hänninen M	A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon β-1b in patients with multiple sclerosis.	Journal of neurology, neurosurgery, and psychiatry	2012	37
22797642	3456	Shirani A	Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.	JAMA	2012	40
24485135	3456	Wingerchuk DM	Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.	Mayo Clinic proceedings	2014	54
24610329	3456	Jokubaitis VG	Fingolimod after natalizumab and the risk of short-term relapse.	Neurology	2014	25
9240577	3553	Yoon BH	Amniotic fluid inflammatory cytokines (interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha), neonatal brain white matter lesions, and cerebral palsy.	American journal of obstetrics and gynecology	1997	116
10358063	3553	Nath A	Transient exposure to HIV-1 Tat protein results in cytokine production in macrophages and astrocytes. A hit and run phenomenon.	The Journal of biological chemistry	1999	105
11306611	3553	Tikka T	Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia.	The Journal of neuroscience 	2001	192
15777250	3553	Nagatsu T	Inflammatory process in Parkinson's disease: role for cytokines.	Current pharmaceutical design	2005	70
16006665	3553	Fiala M	Ineffective phagocytosis of amyloid-beta by macrophages of Alzheimer's disease patients.	Journal of Alzheimer's disease 	2005	70
17178209	3553	Schubert C	The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review.	Brain, behavior, and immunity	2007	103
17475444	3553	Steptoe A	The effects of acute psychological stress on circulating inflammatory factors in humans: a review and meta-analysis.	Brain, behavior, and immunity	2007	228
19125209	3553	Anisman H	Cascading effects of stressors and inflammatory immune system activation: implications for major depressive disorder.	Journal of psychiatry and neuroscience 	2009	75
19166877	3553	Ren K	Role of interleukin-1beta during pain and inflammation.	Brain research reviews	2009	60
20127816	3553	Chakraborty S	Inflammasome signaling at the heart of central nervous system pathology.	Journal of neuroscience research	2010	45
20398920	3553	Hastie AT	Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes.	The Journal of allergy and clinical immunology	2010	88
20690185	3553	Lee JM	Interleukin-1β induces angiogenesis and innervation in human intervertebral disc degeneration.	Journal of orthopaedic research 	2011	35
20705131	3553	Ashwood P	Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome.	Brain, behavior, and immunity	2011	120
21599903	3553	Brochu ME	Developmental regulation of the neuroinflammatory responses to LPS and/or hypoxia-ischemia between preterm and term neonates: An experimental study.	Journal of neuroinflammation	2011	36
21796103	3553	Hannestad J	The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis.	Neuropsychopharmacology 	2011	100
21864400	3553	Levesque S	Air pollution &amp;amp; the brain: Subchronic diesel exhaust exposure causes neuroinflammation and elevates early markers of neurodegenerative disease.	Journal of neuroinflammation	2011	45
21906753	3553	Pandey GN	Proinflammatory cytokines in the prefrontal cortex of teenage suicide victims.	Journal of psychiatric research	2012	46
22071871	3553	Zunszain PA	Interleukin-1β: a new regulator of the kynurenine pathway affecting human hippocampal neurogenesis.	Neuropsychopharmacology 	2012	55
22138609	3553	Lukiw WJ	NF-кB-regulated micro RNAs (miRNAs) in primary human brain cells.	Experimental neurology	2012	35
22412385	3553	Eizirik DL	The human pancreatic islet transcriptome: expression of candidate genes for type 1 diabetes and the impact of pro-inflammatory cytokines.	PLoS genetics	2012	82
22764097	3553	Denes A	Caspase-1: is IL-1 just the tip of the ICEberg?	Cell death and disease	2012	53
22770526	3553	Yang EJ	Inflammasome formation and IL-1β release by human blood monocytes in response to silver nanoparticles.	Biomaterials	2012	34
22829270	3553	Librizzi L	Seizure-induced brain-borne inflammation sustains seizure recurrence and blood-brain barrier damage.	Annals of neurology	2012	37
23935251	3553	More SV	Cellular and molecular mediators of neuroinflammation in the pathogenesis of Parkinson's disease.	Mediators of inflammation	2013	38
24446952	3553	Rojas A	Cyclooxygenase-2 in epilepsy.	Epilepsia	2014	21
24901329	3553	Kumar RG	Chronic Inflammation After Severe Traumatic Brain Injury: Characterization and Associations With Outcome at 6 and 12 Months Postinjury.	The Journal of head trauma rehabilitation	2015	27
24920309	3553	Jansson D	A role for human brain pericytes in neuroinflammation.	Journal of neuroinflammation	2014	20
24948485	3553	Najjar S	Neuroinflammation and white matter pathology in schizophrenia: systematic review.	Schizophrenia research	2015	33
25541493	3553	Black C	Meta-Analysis of Cytokines and Chemokines in Suicidality: Distinguishing Suicidal Versus Nonsuicidal Patients.	Biological psychiatry	2015	23
26194183	3553	Fillman SG	Elevated peripheral cytokines characterize a subgroup of people with schizophrenia displaying poor verbal fluency and reduced Broca's area volume.	Molecular psychiatry	2016	18
11022058	3569	Vila N	Proinflammatory cytokines and early neurological worsening in ischemic stroke.	Stroke	2000	103
11831551	3569	Lenzlinger PM	The duality of the inflammatory response to traumatic brain injury.	Molecular neurobiology	2001	91
12177370	3569	Weaver JD	Interleukin-6 and risk of cognitive decline: MacArthur studies of successful aging.	Neurology	2002	114
15630704	3569	El-Hage N	Synergistic increases in intracellular Ca2+, and the release of MCP-1, RANTES, and IL-6 by astrocytes treated with opiates and HIV-1 Tat.	Glia	2005	96
18156155	3569	Lee ST	Anti-inflammatory mechanism of intravascular neural stem cell transplantation in haemorrhagic stroke.	Brain 	2008	108
18242584	3569	Brydon L	Peripheral inflammation is associated with altered substantia nigra activity and psychomotor slowing in humans.	Biological psychiatry	2008	81
18771602	3569	Kauer-Sant'Anna M	Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder.	The international journal of neuropsychopharmacology	2009	49
19018268	3569	Suzuki S	Ambivalent aspects of interleukin-6 in cerebral ischemia: inflammatory versus neurotrophic aspects.	Journal of cerebral blood flow and metabolism 	2009	53
19111922	3569	O'Donovan A	Pessimism correlates with leukocyte telomere shortness and elevated interleukin-6 in post-menopausal women.	Brain, behavior, and immunity	2009	46
19139294	3569	Sonnen JA	Different patterns of cerebral injury in dementia with or without diabetes.	Archives of neurology	2009	60
19268915	3569	Lindqvist D	Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity.	Biological psychiatry	2009	93
19321461	3569	Correale J	Immunomodulatory effects of Vitamin D in multiple sclerosis.	Brain 	2009	108
19376240	3569	Eisenberger NI	An fMRI study of cytokine-induced depressed mood and social pain: the role of sex differences.	NeuroImage	2009	61
19409533	3569	Harrison NA	Neural origins of human sickness in interoceptive responses to inflammation.	Biological psychiatry	2009	69
19423079	3569	Harrison NA	Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity.	Biological psychiatry	2009	130
19658188	3569	Wang H	Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth.	Stem cells	2009	86
19738918	3569	Bilbo SD	Early-life programming of later-life brain and behavior: a critical role for the immune system.	Frontiers in behavioral neuroscience	2009	123
19781428	3569	Förhécz Z	Red cell distribution width in heart failure: prediction of clinical events and relationship with markers of ineffective erythropoiesis, inflammation, renal function, and nutritional state.	American heart journal	2009	76
20043983	3569	Eisenberger NI	Inflammation and social experience: an inflammatory challenge induces feelings of social disconnection in addition to depressed mood.	Brain, behavior, and immunity	2010	78
20227485	3569	O'Donovan A	Clinical anxiety, cortisol and interleukin-6: evidence for specificity in emotion-biology relationships.	Brain, behavior, and immunity	2010	46
20230889	3569	Boksa P	Effects of prenatal infection on brain development and behavior: a review of findings from animal models.	Brain, behavior, and immunity	2010	114
20353817	3569	Wang XS	Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy.	Brain, behavior, and immunity	2010	49
20679216	3569	Slavich GM	Neural sensitivity to social rejection is associated with inflammatory responses to social stress.	Proceedings of the National Academy of Sciences of the United States of America	2010	78
20836906	3569	Uddin M	Epigenetic and inflammatory marker profiles associated with depression in a community-based epidemiologic sample.	Psychological medicine	2011	53
21185346	3569	Maes M	The new '5-HT' hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression.	Progress in neuro-psychopharmacology and biological psychiatry	2011	62
21784145	3569	Kiecolt-Glaser JK	Omega-3 supplementation lowers inflammation and anxiety in medical students: a randomized controlled trial.	Brain, behavior, and immunity	2011	41
21801830	3569	Pace TW	Increased peripheral NF-κB pathway activity in women with childhood abuse-related posttraumatic stress disorder.	Brain, behavior, and immunity	2012	42
21946257	3569	Baryawno N	Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target.	The Journal of clinical investigation	2011	59
22146091	3569	Pervanidou P	Metabolic consequences of stress during childhood and adolescence.	Metabolism	2012	45
22187279	3569	Boomer JS	Immunosuppression in patients who die of sepsis and multiple organ failure.	JAMA	2011	264
22426431	3569	Coussons-Read ME	The occurrence of preterm delivery is linked to pregnancy-specific distress and elevated inflammatory markers across gestation.	Brain, behavior, and immunity	2012	40
22687336	3569	Hiles SA	A meta-analysis of differences in IL-6 and IL-10 between people with and without depression: exploring the causes of heterogeneity.	Brain, behavior, and immunity	2012	35
22698992	3569	Kesler S	Reduced hippocampal volume and verbal memory performance associated with interleukin-6 and tumor necrosis factor-alpha levels in chemotherapy-treated breast cancer survivors.	Brain, behavior, and immunity	2013	54
23201587	3569	Rawdin BJ	Dysregulated relationship of inflammation and oxidative stress in major depression.	Brain, behavior, and immunity	2013	42
23486877	3569	Desplats P	Molecular and pathologic insights from latent HIV-1 infection in the human brain.	Neurology	2013	53
24033321	3569	Patel AR	Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease.	American journal of respiratory and critical care medicine	2013	30
25124710	3569	Bay-Richter C	A role for inflammatory metabolites as modulators of the glutamate N-methyl-D-aspartate receptor in depression and suicidality.	Brain, behavior, and immunity	2015	33
25455350	3569	Schwieler L	Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia--significance for activation of the kynurenine pathway.	Journal of psychiatry and neuroscience 	2015	22
25582579	3569	Loggia ML	Evidence for brain glial activation in chronic pain patients.	Brain 	2015	42
25802036	3569	de Vrij J	Glioblastoma-derived extracellular vesicles modify the phenotype of monocytic cells.	International journal of cancer	2015	18
27070405	3569	Coughlin JM	In vivo markers of inflammatory response in recent-onset schizophrenia: a combined study using (11)CDPA-713 PET and analysis of CSF and plasma.	Translational psychiatry	2016	14
8616722	3952	Schwartz MW	Cerebrospinal fluid leptin levels: relationship to plasma levels and to adiposity in humans.	Nature medicine	1996	117
8684156	3952	Caro JF	Decreased cerebrospinal-fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance.	Lancet	1996	126
14749508	3952	Bjørbaek C	Leptin signaling in the central nervous system and the periphery.	Recent progress in hormone research	2004	94
16445991	3952	Uher R	Cerebral processing of food-related stimuli: effects of fasting and gender.	Behavioural brain research	2006	64
17690262	3952	Farooqi IS	Leptin regulates striatal regions and human eating behavior.	Science	2007	137
17986612	3952	Baicy K	Leptin replacement alters brain response to food cues in genetically leptin-deficient adults.	Proceedings of the National Academy of Sciences of the United States of America	2007	66
20009056	3952	Lieb W	Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging.	JAMA	2009	93
21494606	3952	Mueller K	Sex-dependent influences of obesity on cerebral white matter investigated by diffusion-tensor imaging.	PloS one	2011	41
21902800	3952	Carnell S	Neuroimaging and obesity: current knowledge and future directions.	Obesity reviews 	2012	102
23883674	3952	Mark AL	Selective leptin resistance revisited.	American journal of physiology. Regulatory, integrative and comparative physiology	2013	35
24673196	3952	Fonken LK	The effects of light at night on circadian clocks and metabolism.	Endocrine reviews	2014	29
25232148	3952	Farooqi IS	20 years of leptin: human disorders of leptin action.	The Journal of endocrinology	2014	21
16569698	4128	Meyer-Lindenberg A	Neural mechanisms of genetic risk for impulsivity and violence in humans.	Proceedings of the National Academy of Sciences of the United States of America	2006	163
17088501	4128	Meyer JH	Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression.	Archives of general psychiatry	2006	76
17519928	4128	Buckholtz JW	Genetic variation in MAOA modulates ventromedial prefrontal circuitry mediating individual differences in human personality.	Molecular psychiatry	2008	54
18185497	4128	Yang RJ	Variation in mouse basolateral amygdala volume is associated with differences in stress reactivity and fear learning.	Neuropsychopharmacology 	2008	50
18258310	4128	Buckholtz JW	MAOA and the neurogenetic architecture of human aggression.	Trends in neurosciences	2008	60
18463263	4128	Alia-Klein N	Brain monoamine oxidase A activity predicts trait aggression.	The Journal of neuroscience 	2008	52
19255579	4128	Wakschlag LS	Interaction of prenatal exposure to cigarettes and MAOA genotype in pathways to youth antisocial behavior.	Molecular psychiatry	2010	44
1530909	4137	Goedert M	Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms.	Neuron	1992	152
2498079	4137	Goedert M	Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain.	The EMBO journal	1989	178
3088567	4137	Grundke-Iqbal I	Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology.	Proceedings of the National Academy of Sciences of the United States of America	1986	528
3131773	4137	Goedert M	Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau.	Proceedings of the National Academy of Sciences of the United States of America	1988	165
9836646	4137	Hong M	Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17.	Science	1998	200
10214737	4137	Delacourte A	The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease.	Neurology	1999	117
10391244	4137	Lu PJ	The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein.	Nature	1999	160
10595524	4137	Ishihara T	Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform.	Neuron	1999	137
12417659	4137	Allen B	Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein.	The Journal of neuroscience 	2002	124
15249677	4137	Liu F	O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease.	Proceedings of the National Academy of Sciences of the United States of America	2004	118
15615642	4137	Goedert M	Mutations causing neurodegenerative tauopathies.	Biochimica et biophysica acta	2005	107
15831501	4137	David DC	Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice.	The Journal of biological chemistry	2005	79
16443603	4137	Cripps D	Alzheimer disease-specific conformation of hyperphosphorylated paired helical filament-Tau is polyubiquitinated through Lys-48, Lys-11, and Lys-6 ubiquitin conjugation.	The Journal of biological chemistry	2006	67
16807328	4137	Dickey CA	Deletion of the ubiquitin ligase CHIP leads to the accumulation, but not the aggregation, of both endogenous phospho- and caspase-3-cleaved tau species.	The Journal of neuroscience 	2006	78
17159101	4137	Arvanitakis Z	Diabetes is related to cerebral infarction but not to AD pathology in older persons.	Neurology	2006	88
17409229	4137	Berger Z	Accumulation of pathological tau species and memory loss in a conditional model of tauopathy.	The Journal of neuroscience 	2007	131
21304998	4137	Whittington RA	Propofol directly increases tau phosphorylation.	PloS one	2011	42
21427723	4137	Cohen TJ	The acetylation of tau inhibits its function and promotes pathological tau aggregation.	Nature communications	2011	96
22608668	4137	Grossman M	The non-fluent/agrammatic variant of primary progressive aphasia.	The Lancet. Neurology	2012	31
22683529	4137	Zhang W	A highly selective and specific PET tracer for imaging of tau pathologies.	Journal of Alzheimer's disease 	2012	32
22723018	4137	Trabzuni D	MAPT expression and splicing is differentially regulated by brain region: relation to genotype and implication for tauopathies.	Human molecular genetics	2012	46
23109154	4137	Bennett DA	Relation of neuropathology to cognition in persons without cognitive impairment.	Annals of neurology	2012	54
23234879	4137	Chien DT	Early clinical PET imaging results with the novel PHF-tau radioligand F-18-T807.	Journal of Alzheimer's disease 	2013	123
23411393	4137	Xia CF	(18)FT807, a novel tau positron emission tomography imaging agent for Alzheimer's disease.	Alzheimer's and dementia 	2013	89
23684085	4137	Spillantini MG	Tau pathology and neurodegeneration.	The Lancet. Neurology	2013	121
23781007	4137	Williams-Gray CH	The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort.	Journal of neurology, neurosurgery, and psychiatry	2013	54
23948934	4137	Chien DT	Early clinical PET imaging results with the novel PHF-tau radioligand F18-T808.	Journal of Alzheimer's disease 	2014	45
25393609	4137	Sokolow S	Pre-synaptic C-terminal truncated tau is released from cortical synapses in Alzheimer's disease.	Journal of neurochemistry	2015	19
25921538	4137	Moore S	APP metabolism regulates tau proteostasis in human cerebral cortex neurons.	Cell reports	2015	23
27357347	4137	Smith R	18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers.	Brain 	2016	15
10049950	4155	Kerschensteiner M	Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation?	The Journal of experimental medicine	1999	133
11160401	4155	Back SA	Late oligodendrocyte progenitors coincide with the developmental window of vulnerability for human perinatal white matter injury.	The Journal of neuroscience 	2001	169
12853586	4155	Berger T	Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event.	The New England journal of medicine	2003	76
17000961	4155	Wegner C	Neocortical neuronal, synaptic, and glial loss in multiple sclerosis.	Neurology	2006	66
19557869	4155	Owens GP	Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid.	Annals of neurology	2009	54
20625086	4155	Pitt D	Imaging cortical lesions in multiple sclerosis with ultra-high-field magnetic resonance imaging.	Archives of neurology	2010	52
23378219	4155	Philips T	Oligodendrocyte dysfunction in the pathogenesis of amyotrophic lateral sclerosis.	Brain 	2013	38
23740901	4155	Lutterotti A	Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis.	Science translational medicine	2013	63
15121991	4204	Muhle R	The genetics of autism.	Pediatrics	2004	205
16225830	4204	Armstrong DD	Neuropathology of Rett syndrome.	Journal of child neurology	2005	76
19442733	4204	Chapleau CA	Dendritic spine pathologies in hippocampal pyramidal neurons from Rett syndrome brain and after expression of Rett-associated MECP2 mutations.	Neurobiology of disease	2009	71
19717458	4204	Joyner AH	A common MECP2 haplotype associates with reduced cortical surface area in humans in two independent populations.	Proceedings of the National Academy of Sciences of the United States of America	2009	47
20425298	4204	Gonzales ML	The role of MeCP2 in brain development and neurodevelopmental disorders.	Current psychiatry reports	2010	48
21085180	4204	Muotri AR	L1 retrotransposition in neurons is modulated by MeCP2.	Nature	2010	178
21372149	4204	Cheung AY	Isolation of MECP2-null Rett Syndrome patient hiPS cells and isogenic controls through X-chromosome inactivation.	Human molecular genetics	2011	94
22037496	4204	Szulwach KE	5-hmC-mediated epigenetic dynamics during postnatal neurodevelopment and aging.	Nature neuroscience	2011	225
23431031	4204	Han K	Human-specific regulation of MeCP2 levels in fetal brains by microRNA miR-483-5p.	Genes and development	2013	31
25650246	4204	Spiers H	Methylomic trajectories across human fetal brain development.	Genome research	2015	43
25739960	4204	Kinde B	Reading the unique DNA methylation landscape of the brain: Non-CpG methylation, hydroxymethylation, and MeCP2.	Proceedings of the National Academy of Sciences of the United States of America	2015	37
26733678	4204	Tang X	KCC2 rescues functional deficits in human neurons derived from patients with Rett syndrome.	Proceedings of the National Academy of Sciences of the United States of America	2016	10
11070098	4255	Esteller M	Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.	The New England journal of medicine	2000	348
15041700	4255	Hegi ME	Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.	Clinical cancer research 	2004	135
15758010	4255	Hegi ME	MGMT gene silencing and benefit from temozolomide in glioblastoma.	The New England journal of medicine	2005	1079
16405512	4255	Hermisson M	O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells.	Journal of neurochemistry	2006	65
17591937	4255	Mikeska T	Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis.	The Journal of molecular diagnostics 	2007	55
18445844	4255	Brandes AA	MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.	Journal of clinical oncology 	2008	137
18632623	4255	Beier D	Temozolomide preferentially depletes cancer stem cells in glioblastoma.	Cancer research	2008	81
18757334	4255	Hegi ME	Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity.	Journal of clinical oncology 	2008	161
19088037	4255	Pallini R	Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme.	Clinical cancer research 	2008	89
19107440	4255	Ohgaki H	Epidemiology of brain tumors.	Methods in molecular biology	2009	79
19188675	4255	Brandes AA	Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status.	Journal of clinical oncology 	2009	46
19269895	4255	Stupp R	Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.	The Lancet. Oncology	2009	1189
20150378	4255	Rivera AL	MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma.	Neuro-oncology	2010	53
20439646	4255	Stupp R	Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.	Journal of clinical oncology 	2010	95
21135282	4255	Lai A	Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme.	Journal of clinical oncology 	2011	132
21330401	4255	Pope WB	Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma.	AJNR. American journal of neuroradiology	2011	41
21339192	4255	Cohen KJ	Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group.	Neuro-oncology	2011	49
21709196	4255	Gállego Pérez-Larraya J	Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial.	Journal of clinical oncology 	2011	38
21988793	4255	Beier D	Chemoresistance of glioblastoma cancer stem cells--much more complex than expected.	Molecular cancer	2011	70
22139906	4255	Reifenberger G	Predictive impact of MGMT promoter methylation in glioblastoma of the elderly.	International journal of cancer	2012	45
22294349	4255	Quillien V	Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients.	Cancer	2012	39
22527250	4255	Ardon H	Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial.	Cancer immunology, immunotherapy 	2012	42
22810491	4255	Bady P	MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status.	Acta neuropathologica	2012	44
22877848	4255	Malmström A	Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.	The Lancet. Oncology	2012	126
23726844	4255	Zhang XQ	A long non-coding RNA signature in glioblastoma multiforme predicts survival.	Neurobiology of disease	2013	44
23850491	4255	Westphal M	Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial.	The Lancet. Oncology	2013	31
24912512	4255	Wick W	MGMT testing--the challenges for biomarker-based glioma treatment.	Nature reviews. Neurology	2014	47
25163906	4255	Stupp R	Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.	The Lancet. Oncology	2014	104
25411133	4255	Galldiks N	Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-18Ffluoroethyl)-L-tyrosine PET.	European journal of nuclear medicine and molecular imaging	2015	23
25762461	4255	Nabors LB	Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.	Neuro-oncology	2015	24
25959588	4255	Shao H	Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma.	Nature communications	2015	28
16330947	4763	Miettinen M	Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases.	The American journal of surgical pathology	2006	69
17283119	4763	Sharma MK	Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin.	Cancer research	2007	59
19111880	4763	Alcantara Llaguno S	Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model.	Cancer cell	2009	197
20027112	4763	Jett K	Clinical and genetic aspects of neurofibromatosis 1.	Genetics in medicine 	2010	59
20821343	4763	Wiemels J	Epidemiology and etiology of meningioma.	Journal of neuro-oncology	2010	83
10097000	4803	Berkley KJ	Sex differences in pain.	The Behavioral and brain sciences	1997	115
11040419	4803	Murer MG	Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease.	Progress in neurobiology	2001	144
15852017	4803	Tuszynski MH	A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease.	Nature medicine	2005	179
16336965	4803	Crigler L	Human mesenchymal stem cell subpopulations express a variety of neuro-regulatory molecules and promote neuronal cell survival and neuritogenesis.	Experimental neurology	2006	118
16776595	4803	Pezet S	Neurotrophins: mediators and modulators of pain.	Annual review of neuroscience	2006	189
20373268	4803	Mandel RJ	CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer's disease.	Current opinion in molecular therapeutics	2010	41
23190582	4803	Aloe L	Nerve growth factor: from the early discoveries to the potential clinical use.	Journal of translational medicine	2012	53
26302439	4803	Tuszynski MH	Nerve Growth Factor Gene Therapy: Activation of Neuronal Responses in Alzheimer Disease.	JAMA neurology	2015	23
19455354	4854	de Vries B	Molecular genetics of migraine.	Human genetics	2009	61
19539236	4854	Chabriat H	Cadasil.	The Lancet. Neurology	2009	131
10791374	4879	Troughton RW	Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations.	Lancet	2000	128
12135939	4879	McCullough PA	B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study.	Circulation	2002	88
12225726	4879	Redfield MM	Plasma brain natriuretic peptide concentration: impact of age and gender.	Journal of the American College of Cardiology	2002	105
12628948	4879	Anand IS	Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT).	Circulation	2003	83
12892964	4879	de Lemos JA	B-type natriuretic peptide in cardiovascular disease.	Lancet	2003	103
14769680	4879	Wang TJ	Impact of obesity on plasma natriuretic peptide levels.	Circulation	2004	124
15716560	4879	Kragelund C	N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease.	The New England journal of medicine	2005	73
15774989	4879	Doust JA	How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review.	BMJ	2005	89
17090767	4879	Bursi F	Systolic and diastolic heart failure in the community.	JAMA	2006	174
17448376	4879	Jourdain P	Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study.	Journal of the American College of Cardiology	2007	67
18154959	4879	Daniels LB	Natriuretic peptides.	Journal of the American College of Cardiology	2007	127
18598886	4879	Anderson PA	Contemporary outcomes after the Fontan procedure: a Pediatric Heart Network multicenter study.	Journal of the American College of Cardiology	2008	61
18760965	4879	Maisel A	State of the art: using natriuretic peptide levels in clinical practice.	European journal of heart failure	2008	87
19089336	4879	Potter LR	Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications.	Handbook of experimental pharmacology	2009	79
19176440	4879	Pfisterer M	BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial.	JAMA	2009	61
19329178	4879	Teerlink JR	Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study.	Lancet	2009	70
19917883	4879	Di Angelantonio E	B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies.	Circulation	2009	69
22356799	4879	Seto E	Mobile phone-based telemonitoring for heart failure management: a randomized controlled trial.	Journal of medical Internet research	2012	43
22634740	4879	Flett AS	Diffuse myocardial fibrosis in severe aortic stenosis: an equilibrium contrast cardiovascular magnetic resonance study.	European heart journal cardiovascular Imaging	2012	35
23500300	4879	van Veldhuisen DJ	B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction.	Journal of the American College of Cardiology	2013	49
23821090	4879	Ledwidge M	Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial.	JAMA	2013	39
24275629	4879	Matsuzawa Y	Peripheral endothelial function and cardiovascular events in high-risk patients.	Journal of the American Heart Association	2013	31
25424852	4879	Rodon J	First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma.	Clinical cancer research 	2015	31
25881932	4879	Cheng ML	Metabolic disturbances identified in plasma are associated with outcomes in patients with heart failure: diagnostic and prognostic value of metabolomics.	Journal of the American College of Cardiology	2015	19
26056125	4879	Chung ES	Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial.	European heart journal	2015	17
12787574	4908	Lessmann V	Neurotrophin secretion: current facts and future prospects.	Progress in neurobiology	2003	100
16444268	4908	Pyle AD	Neurotrophins mediate human embryonic stem cell survival.	Nature biotechnology	2006	67
19521110	4908	Deslandes A	Exercise and mental health: many reasons to move.	Neuropsychobiology	2009	46
21147038	4908	Kapogiannis D	Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer's disease.	The Lancet. Neurology	2011	83
21768599	4908	Ahlskog JE	Does vigorous exercise have a neuroprotective effect in Parkinson disease?	Neurology	2011	45
22826346	4908	Duman RS	A neurotrophic hypothesis of depression: role of synaptogenesis in the actions of NMDA receptor antagonists.	Philosophical transactions of the Royal Society of London. Series B, Biological sciences	2012	32
23254191	4908	Park H	Neurotrophin regulation of neural circuit development and function.	Nature reviews. Neuroscience	2013	227
15329723	4915	Douma S	Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB.	Nature	2004	148
15494731	4915	Yeo GS	A de novo mutation affecting human TrkB associated with severe obesity and developmental delay.	Nature neuroscience	2004	108
19124685	4915	Ernst C	Alternative splicing, methylation state, and expression profile of tropomyosin-related kinase B in the frontal cortex of suicide completers.	Archives of general psychiatry	2009	51
20655510	4915	Ginsberg SD	Microarray analysis of hippocampal CA1 neurons implicates early endosomal dysfunction during Alzheimer's disease progression.	Biological psychiatry	2010	68
21798604	4915	Mahan AL	Fear conditioning, synaptic plasticity and the amygdala: implications for posttraumatic stress disorder.	Trends in neurosciences	2012	119
22159096	4915	Zeng Y	Epigenetic enhancement of BDNF signaling rescues synaptic plasticity in aging.	The Journal of neuroscience 	2011	41
23790754	4915	Liu G	Transient inhibition of TrkB kinase after status epilepticus prevents development of temporal lobe epilepsy.	Neuron	2013	31
24802307	4915	Ray MT	Decreased BDNF and TrkB mRNA expression in multiple cortical areas of patients with schizophrenia and mood disorders.	Translational psychiatry	2014	20
26786147	4915	Zhang JC	Brain-derived Neurotrophic Factor (BDNF)-TrkB Signaling in Inflammation-related Depression and Potential Therapeutic Targets.	Current neuropharmacology	2016	12
16890230	5020	Lim MM	Neuropeptidergic regulation of affiliative behavior and social bonding in animals.	Hormones and behavior	2006	133
17137561	5020	Domes G	Oxytocin improves "mind-reading" in humans.	Biological psychiatry	2007	218
17958710	5020	Feldman R	Evidence for a neuroendocrinological foundation of human affiliation: plasma oxytocin levels across pregnancy and the postpartum period predict mother-infant bonding.	Psychological science	2007	115
18343353	5020	Guastella AJ	Oxytocin enhances the encoding of positive social memories in humans.	Biological psychiatry	2008	72
18498743	5020	Baumgartner T	Oxytocin shapes the neural circuitry of trust and trust adaptation in humans.	Neuron	2008	219
18579733	5020	Petrovic P	Oxytocin attenuates affective evaluations of conditioned faces and amygdala activity.	The Journal of neuroscience 	2008	111
18655894	5020	Heinrichs M	Neuropeptides and social behaviour: effects of oxytocin and vasopressin in humans.	Progress in brain research	2008	76
18988842	5020	Donaldson ZR	Oxytocin, vasopressin, and the neurogenetics of sociality.	Science	2008	295
19482229	5020	Lee HJ	Oxytocin: the great facilitator of life.	Progress in neurobiology	2009	159
19632787	5020	Domes G	Effects of intranasal oxytocin on emotional face processing in women.	Psychoneuroendocrinology	2010	120
19710635	5020	Strathearn L	Adult attachment predicts maternal brain and oxytocin response to infant cues.	Neuropsychopharmacology 	2009	126
19934046	5020	Rodrigues SM	Oxytocin receptor genetic variation relates to empathy and stress reactivity in humans.	Proceedings of the National Academy of Sciences of the United States of America	2009	148
20047458	5020	Macdonald K	The peptide that binds: a systematic review of oxytocin and its prosocial effects in humans.	Harvard review of psychiatry	2010	78
20371820	5020	Hurlemann R	Oxytocin enhances amygdala-dependent, socially reinforced learning and emotional empathy in humans.	The Journal of neuroscience 	2010	120
20421469	5020	Gamer M	Different amygdala subregions mediate valence-related and attentional effects of oxytocin in humans.	Proceedings of the National Academy of Sciences of the United States of America	2010	105
20538951	5020	De Dreu CK	The neuropeptide oxytocin regulates parochial altruism in intergroup conflict among humans.	Science	2010	146
20557568	5020	Baskerville TA	Dopamine and oxytocin interactions underlying behaviors: potential contributions to behavioral disorders.	CNS neuroscience and therapeutics	2010	48
20720535	5020	Labuschagne I	Oxytocin attenuates amygdala reactivity to fear in generalized social anxiety disorder.	Neuropsychopharmacology 	2010	106
21220339	5020	De Dreu CK	Oxytocin promotes human ethnocentrism.	Proceedings of the National Academy of Sciences of the United States of America	2011	81
21470595	5020	Riem MM	Oxytocin modulates amygdala, insula, and inferior frontal gyrus responses to infant crying: a randomized controlled trial.	Biological psychiatry	2011	80
21676095	5020	Feldman R	Maternal and paternal plasma, salivary, and urinary oxytocin and parent-infant synchrony: considering stress and affiliation components of human bonding.	Developmental science	2011	62
21696997	5020	Bartz JA	Social effects of oxytocin in humans: context and person matter.	Trends in cognitive sciences	2011	252
21852800	5020	Meyer-Lindenberg A	Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine.	Nature reviews. Neuroscience	2011	278
21881566	5020	Atzil S	Specifying the neurobiological basis of human attachment: brain, hormones, and behavior in synchronous and intrusive mothers.	Neuropsychopharmacology 	2011	50
22100184	5020	Bosch OJ	Both oxytocin and vasopressin are mediators of maternal care and aggression in rodents: from central release to sites of action.	Hormones and behavior	2012	62
22189289	5020	Riem MM	No laughing matter: intranasal oxytocin administration changes functional brain connectivity during exposure to infant laughter.	Neuropsychopharmacology 	2012	39
22197271	5020	Churchland PS	Modulating social behavior with oxytocin: how does it work? What does it mean?	Hormones and behavior	2012	89
22215593	5020	Chang SW	Inhaled oxytocin amplifies both vicarious reinforcement and self reinforcement in rhesus macaques (Macaca mulatta).	Proceedings of the National Academy of Sciences of the United States of America	2012	65
22245314	5020	Ebstein RP	The contributions of oxytocin and vasopressin pathway genes to human behavior.	Hormones and behavior	2012	58
22265852	5020	Guastella AJ	A critical review of the influence of oxytocin nasal spray on social cognition in humans: evidence and future directions.	Hormones and behavior	2012	76
22285934	5020	Feldman R	Oxytocin and social affiliation in humans.	Hormones and behavior	2012	79
22336563	5020	Feldman R	Sensitive parenting is associated with plasma oxytocin and polymorphisms in the OXTR and CD38 genes.	Biological psychiatry	2012	70
22365820	5020	Lischke A	Oxytocin increases amygdala reactivity to threatening scenes in females.	Psychoneuroendocrinology	2012	43
22795645	5020	Weisman O	Oxytocin administration to parent enhances infant physiological and behavioral readiness for social engagement.	Biological psychiatry	2012	39
22981649	5020	Lukas M	Oxytocin and vasopressin in rodent behaviors related to social dysfunctions in autism spectrum disorders.	Behavioural brain research	2013	26
22999263	5020	Weisman O	Plasma oxytocin distributions in a large cohort of women and men and their gender-specific associations with anxiety.	Psychoneuroendocrinology	2013	25
23025690	5020	Pedersen CA	Intranasal oxytocin blocks alcohol withdrawal in human subjects.	Alcoholism, clinical and experimental research	2013	27
23055480	5020	Yamasue H	Integrative approaches utilizing oxytocin to enhance prosocial behavior: from animal and human social behavior to autistic social dysfunction.	The Journal of neuroscience 	2012	33
23159011	5020	Bethlehem RA	Oxytocin, brain physiology, and functional connectivity: a review of intranasal oxytocin fMRI studies.	Psychoneuroendocrinology	2013	46
23325323	5020	Feldman R	Parental oxytocin and early caregiving jointly shape children's oxytocin response and social reciprocity.	Neuropsychopharmacology 	2013	34
23419544	5020	Groppe SE	Oxytocin influences processing of socially relevant cues in the ventral tegmental area of the human brain.	Biological psychiatry	2013	36
23510581	5020	Domes G	Effects of intranasal oxytocin on the neural basis of face processing in autism spectrum disorder.	Biological psychiatry	2013	43
23575742	5020	Shahrestani S	The impact of a single administration of intranasal oxytocin on the recognition of basic emotions in humans: a meta-analysis.	Neuropsychopharmacology 	2013	30
24050183	5020	Carter CS	Oxytocin pathways and the evolution of human behavior.	Annual review of psychology	2014	60
24277856	5020	Scheele D	Oxytocin enhances brain reward system responses in men viewing the face of their female partner.	Proceedings of the National Academy of Sciences of the United States of America	2013	38
24297883	5020	Gordon I	Oxytocin enhances brain function in children with autism.	Proceedings of the National Academy of Sciences of the United States of America	2013	63
24594871	5020	Dodhia S	Modulation of resting-state amygdala-frontal functional connectivity by oxytocin in generalized social anxiety disorder.	Neuropsychopharmacology 	2014	27
24694924	5020	Scheele D	An oxytocin-induced facilitation of neural and emotional responses to social touch correlates inversely with autism traits.	Neuropsychopharmacology 	2014	27
25542304	5020	Eckstein M	Oxytocin facilitates the extinction of conditioned fear in humans.	Biological psychiatry	2015	20
25908497	5020	De Dreu CK	Oxytocin Conditions Intergroup Relations Through Upregulated In-Group Empathy, Cooperation, Conformity, and Defense.	Biological psychiatry	2016	14
26001309	5020	Grinevich V	Assembling the Puzzle: Pathways of Oxytocin Signaling in the Brain.	Biological psychiatry	2016	13
26208744	5020	Neumann ID	Oxytocin in General Anxiety and Social Fear: A Translational Approach.	Biological psychiatry	2016	20
26210057	5020	Walum H	Statistical and Methodological Considerations for the Interpretation of Intranasal Oxytocin Studies.	Biological psychiatry	2016	25
26392129	5020	Feldman R	Oxytocin Pathway Genes: Evolutionary Ancient System Impacting on Human Affiliation, Sociality, and Psychopathology.	Biological psychiatry	2016	30
26503762	5020	Yatawara CJ	The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: a randomized clinical crossover trial.	Molecular psychiatry	2016	34
2563168	5243	Cordon-Cardo C	Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites.	Proceedings of the National Academy of Sciences of the United States of America	1989	193
14576852	5243	Ambudkar SV	P-glycoprotein: from genomics to mechanism.	Oncogene	2003	159
14749689	5243	Marzolini C	Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance.	Clinical pharmacology and therapeutics	2004	109
15668963	5243	Kortekaas R	Blood-brain barrier dysfunction in parkinsonian midbrain in vivo.	Annals of neurology	2005	104
21967057	5243	Sharom FJ	The P-glycoprotein multidrug transporter.	Essays in biochemistry	2011	64
22120145	5243	van Assema DM	Blood-brain barrier P-glycoprotein function in Alzheimer's disease.	Brain 	2012	42
9368550	5327	-	Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group.	Stroke	1997	115
10591382	5327	Furlan A	Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism.	JAMA	1999	274
10591384	5327	Clark WM	Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.	JAMA	1999	98
15548777	5327	Alexandrov AV	Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke.	The New England journal of medicine	2004	138
17521716	5327	Durukan A	Acute ischemic stroke: overview of major experimental rodent models, pathophysiology, and therapy of focal cerebral ischemia.	Pharmacology, biochemistry, and behavior	2007	147
18963068	5327	Yepes M	Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic.	Trends in neurosciences	2009	67
21311083	5327	Fonarow GC	Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes.	Circulation	2011	90
21885841	5327	Fonarow GC	Improving door-to-needle times in acute ischemic stroke: the design and rationale for the American Heart Association/American Stroke Association's Target: Stroke initiative.	Stroke	2011	43
23387822	5327	Ciccone A	Endovascular treatment for acute ischemic stroke.	The New England journal of medicine	2013	175
23391763	5327	Mould WA	Minimally invasive surgery plus recombinant tissue-type plasminogen activator for intracerebral hemorrhage evacuation decreases perihematomal edema.	Stroke	2013	29
23780461	5327	Saver JL	Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke.	JAMA	2013	79
24046398	5327	Schwamm LH	Temporal trends in patient characteristics and treatment with intravenous thrombolysis among acute ischemic stroke patients at Get With The Guidelines-Stroke hospitals.	Circulation. Cardiovascular quality and outcomes	2013	33
24335227	5327	Hill MD	Alberta Stroke Program early computed tomography score to select patients for endovascular treatment: Interventional Management of Stroke (IMS)-III Trial.	Stroke	2014	21
25882376	5327	Saver JL	Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke.	The New England journal of medicine	2015	234
9620771	5443	Krude H	Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans.	Nature genetics	1998	211
11502812	5443	Vgontzas AN	Chronic insomnia is associated with nyctohemeral activation of the hypothalamic-pituitary-adrenal axis: clinical implications.	The Journal of clinical endocrinology and metabolism	2001	108
12764219	5443	Schommer NC	Dissociation between reactivity of the hypothalamus-pituitary-adrenal axis and the sympathetic-adrenal-medullary system to repeated psychosocial stress.	Psychosomatic medicine	2003	76
15039002	5443	Barr CS	Rearing condition and rh5-HTTLPR interact to influence limbic-hypothalamic-pituitary-adrenal axis response to stress in infant macaques.	Biological psychiatry	2004	111
15159175	5443	Oswald LM	Opioids and alcoholism.	Physiology and behavior	2004	76
17408865	5443	Wilhelm I	Is the cortisol awakening rise a response to awakening?	Psychoneuroendocrinology	2007	64
20026350	5443	Clow A	The cortisol awakening response: more than a measure of HPA axis function.	Neuroscience and biobehavioral reviews	2010	68
21955155	5443	Bazov I	The endogenous opioid system in human alcoholics: molecular adaptations in brain areas involved in cognitive control of addiction.	Addiction biology	2013	30
23426689	5443	Zhan C	Acute and long-term suppression of feeding behavior by POMC neurons in the brainstem and hypothalamus, respectively.	The Journal of neuroscience 	2013	61
26004339	5443	Lacroix A	Cushing's syndrome.	Lancet	2015	32
7642585	5621	Chen SG	Truncated forms of the human prion protein in normal brain and in prion diseases.	The Journal of biological chemistry	1995	124
8598754	5621	Will RG	A new variant of Creutzfeldt-Jakob disease in the UK.	Lancet	1996	314
8651649	5621	Parchi P	Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease.	Annals of neurology	1996	136
10443888	5621	Parchi P	Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects.	Annals of neurology	1999	211
11476832	5621	Wadsworth JD	Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay.	Lancet	2001	158
11504948	5621	Korth C	Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease.	Proceedings of the National Academy of Sciences of the United States of America	2001	111
14522861	5621	Gambetti P	Sporadic and familial CJD: classification and characterisation.	British medical bulletin	2003	118
15302196	5621	Peden AH	Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient.	Lancet	2004	139
15741275	5621	Safar JG	Diagnosis of human prion disease.	Proceedings of the National Academy of Sciences of the United States of America	2005	81
16135751	5621	Kong Q	Chronic wasting disease of elk: transmissibility to humans examined by transgenic mouse models.	The Journal of neuroscience 	2005	78
16297838	5621	Polymenidou M	Coexistence of multiple PrPSc types in individuals with Creutzfeldt-Jakob disease.	The Lancet. Neurology	2005	69
16391566	5621	Mead S	Prion disease genetics.	European journal of human genetics 	2006	63
16518470	5621	Nonno R	Efficient transmission and characterization of Creutzfeldt-Jakob disease strains in bank voles.	PLoS pathogens	2006	62
17161728	5621	Wroe SJ	Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report.	Lancet	2006	86
17585315	5621	Aguzzi A	Insights into prion strains and neurotoxicity.	Nature reviews. Molecular cell biology	2007	98
17923484	5621	Barron RM	High titers of transmissible spongiform encephalopathy infectivity associated with extremely low levels of PrPSc in vivo.	The Journal of biological chemistry	2007	69
18096717	5621	Colby DW	Prion detection by an amyloid seeding assay.	Proceedings of the National Academy of Sciences of the United States of America	2007	67
18519020	5621	Béringue V	Prion agent diversity and species barrier.	Veterinary research	2008	51
18558863	5621	Aguzzi A	The prion's elusive reason for being.	Annual review of neuroscience	2008	132
18571782	5621	Gambetti P	A novel human disease with abnormal prion protein sensitive to protease.	Annals of neurology	2008	76
19231987	5621	Caughey B	Getting a grip on prions: oligomers, amyloids, and pathological membrane interactions.	Annual review of biochemistry	2009	119
19436715	5621	Barria MA	De novo generation of infectious prions in vitro produces a new disease phenotype.	PLoS pathogens	2009	50
19789378	5621	Aguzzi A	Prions: protein aggregation and infectious diseases.	Physiological reviews	2009	118
20070383	5621	Peden A	Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia.	Haemophilia 	2010	41
20547859	5621	Bishop MT	Defining sporadic Creutzfeldt-Jakob disease strains and their transmission properties.	Proceedings of the National Academy of Sciences of the United States of America	2010	51
21278748	5621	Atarashi R	Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion.	Nature medicine	2011	93
21350487	5621	Sandberg MK	Prion propagation and toxicity in vivo occur in two distinct mechanistic phases.	Nature	2011	94
21558432	5621	Orrú CD	Prion disease blood test using immunoprecipitation and improved quaking-induced conversion.	mBio	2011	51
21654636	5621	Freir DB	Interaction between prion protein and toxic amyloid β assemblies can be therapeutically targeted at multiple sites.	Nature communications	2011	87
22282814	5621	Béringue V	Facilitated cross-species transmission of prions in extraneural tissue.	Science	2012	40
22307640	5621	You H	Aβ neurotoxicity depends on interactions between copper ions, prion protein, and N-methyl-D-aspartate receptors.	Proceedings of the National Academy of Sciences of the United States of America	2012	53
25099576	5621	Orrú CD	A test for Creutzfeldt-Jakob disease using nasal brushings.	The New England journal of medicine	2014	39
26324905	5621	Prusiner SB	Evidence for α-synuclein prions causing multiple system atrophy in humans with parkinsonism.	Proceedings of the National Academy of Sciences of the United States of America	2015	63
8755489	5663	Thinakaran G	Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo.	Neuron	1996	206
10206645	5663	De Strooper B	A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain.	Nature	1999	466
16203860	5663	Yu WH	Macroautophagy--a novel Beta-amyloid peptide-generating pathway activated in Alzheimer's disease.	The Journal of cell biology	2005	226
16752394	5663	Kumar-Singh S	Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40.	Human mutation	2006	89
17079810	5663	Mosconi L	Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease.	Journal of nuclear medicine 	2006	72
17553989	5663	Klunk WE	Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees.	The Journal of neuroscience 	2007	111
17962197	5663	Page RM	Generation of Abeta38 and Abeta42 is independently and differentially affected by familial Alzheimer disease-associated presenilin mutations and gamma-secretase modulation.	The Journal of biological chemistry	2008	53
18300294	5663	Tomiyama T	A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia.	Annals of neurology	2008	104
20616000	5663	Miller JA	Divergence of human and mouse brain transcriptome highlights Alzheimer disease pathways.	Proceedings of the National Academy of Sciences of the United States of America	2010	124
23137948	5663	Reiman EM	Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study.	The Lancet. Neurology	2012	98
23137949	5663	Fleisher AS	Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study.	The Lancet. Neurology	2012	53
23884042	5663	Chhatwal JP	Impaired default network functional connectivity in autosomal dominant Alzheimer disease.	Neurology	2013	32
25307057	5663	Choi SH	A three-dimensional human neural cell culture model of Alzheimer's disease.	Nature	2014	111
25580592	5663	Fleisher AS	Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study.	JAMA neurology	2015	20
26481686	5663	Szaruga M	Qualitative changes in human γ-secretase underlie familial Alzheimer's disease.	The Journal of experimental medicine	2015	16
26813969	5663	Rodriguez-Vieitez E	Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease.	Brain 	2016	14
10639397	5775	Halgren E	Cognitive response profile of the human fusiform face area as determined by MEG.	Cerebral cortex	2000	94
11209067	5775	Gross J	Dynamic imaging of coherent sources: Studying neural interactions in the human brain.	Proceedings of the National Academy of Sciences of the United States of America	2001	245
15979027	5775	Apkarian AV	Human brain mechanisms of pain perception and regulation in health and disease.	European journal of pain	2005	484
16814448	5775	Pulvermüller F	Language outside the focus of attention: the mismatch negativity as a tool for studying higher cognitive processes.	Progress in neurobiology	2006	71
16859985	5775	Bartolomei F	Disturbed functional connectivity in brain tumour patients: evaluation by graph analysis of synchronization matrices.	Clinical neurophysiology 	2006	61
16950225	5775	Wilson TW	Children and adolescents with autism exhibit reduced MEG steady-state gamma responses.	Biological psychiatry	2007	97
17234696	5775	Birbaumer N	Brain-computer interfaces: communication and restoration of movement in paralysis.	The Journal of physiology	2007	94
17266107	5775	Stam CJ	Phase lag index: assessment of functional connectivity from multi channel EEG and MEG with diminished bias from common sources.	Human brain mapping	2007	185
17274021	5775	Lachaux JP	Relationship between task-related gamma oscillations and BOLD signal: new insights from combined fMRI and intracranial EEG.	Human brain mapping	2007	86
17698205	5775	Srinivasan R	EEG and MEG coherence: measures of functional connectivity at distinct spatial scales of neocortical dynamics.	Journal of neuroscience methods	2007	75
17908336	5775	Stam CJ	Graph theoretical analysis of complex networks in the brain.	Nonlinear biomedical physics	2007	155
19098986	5775	Osipova D	Gamma power is phase-locked to posterior alpha activity.	PloS one	2008	87
19343801	5775	Jerbi K	Task-related gamma-band dynamics from an intracerebral perspective: review and implications for surface EEG and MEG.	Human brain mapping	2009	65
19664815	5775	Pulvermüller F	Understanding in an instant: neurophysiological evidence for mechanistic language circuits in the brain.	Brain and language	2009	48
19931310	5775	Lu CM	Use of fNIRS to assess resting state functional connectivity.	Journal of neuroscience methods	2010	46
19932756	5775	Palva S	Graph properties of synchronized cortical networks during visual working memory maintenance.	NeuroImage	2010	54
20607220	5775	Iannetti GD	From the neuromatrix to the pain matrix (and back).	Experimental brain research	2010	77
21215806	5775	Gaetz W	Relating MEG measured motor cortical oscillations to resting γ-aminobutyric acid (GABA) concentration.	NeuroImage	2011	52
21697363	5775	Todorovic A	Prior expectation mediates neural adaptation to repeated sounds in the auditory cortex: an MEG study.	The Journal of neuroscience 	2011	62
21723129	5775	Thut G	Rhythmic TMS causes local entrainment of natural oscillatory signatures.	Current biology 	2011	77
22723684	5775	Sohoglu E	Predictive top-down integration of prior knowledge during speech perception.	The Journal of neuroscience 	2012	57
22750156	5775	Lachaux JP	High-frequency neural activity and human cognition: past, present and possible future of intracranial EEG research.	Progress in neurobiology	2012	65
22815496	5775	Poil SS	Critical-state dynamics of avalanches and oscillations jointly emerge from balanced excitation/inhibition in neuronal networks.	The Journal of neuroscience 	2012	41
23380166	5775	Charles L	Distinct brain mechanisms for conscious versus subliminal error detection.	NeuroImage	2013	32
23536086	5775	Ding N	Adaptive temporal encoding leads to a background-insensitive cortical representation of speech.	The Journal of neuroscience 	2013	32
24198372	5775	Roux F	The phase of thalamic alpha activity modulates cortical gamma-band activity: evidence from resting-state MEG recordings.	The Journal of neuroscience 	2013	26
25646516	5775	Merchant H	Finding the beat: a neural perspective across humans and non-human primates.	Philosophical transactions of the Royal Society of London. Series B, Biological sciences	2015	33
25727740	5775	Tsvetanov KA	The effect of ageing on fMRI: Correction for the confounding effects of vascular reactivity evaluated by joint fMRI and MEG in 335 adults.	Human brain mapping	2015	24
25869863	5775	Gorgolewski KJ	NeuroVault.org: A repository for sharing unthresholded statistical maps, parcellations, and atlases of the human brain.	NeuroImage	2016	12
27009409	5775	Coffey EB	Cortical contributions to the auditory frequency-following response revealed by MEG.	Nature communications	2016	17
19941350	5816	Kataoka Y	Decreased number of parvalbumin and cholinergic interneurons in the striatum of individuals with Tourette syndrome.	The Journal of comparative neurology	2010	99
21041246	5816	Fung SJ	Expression of interneuron markers in the dorsolateral prefrontal cortex of the developing human and in schizophrenia.	The American journal of psychiatry	2010	123
24217255	5816	Glausier JR	Altered parvalbumin basket cell inputs in the dorsolateral prefrontal cortex of schizophrenia subjects.	Molecular psychiatry	2014	35
24650500	5816	Lewis DA	Inhibitory neurons in human cortical circuits: substrate for cognitive dysfunction in schizophrenia.	Current opinion in neurobiology	2014	36
25043046	5816	Xue M	Equalizing excitation-inhibition ratios across visual cortical neurons.	Nature	2014	78
25561540	5816	Xu M	Targeted ablation of cholinergic interneurons in the dorsolateral striatum produces behavioral manifestations of Tourette syndrome.	Proceedings of the National Academy of Sciences of the United States of America	2015	26
25863358	5816	Gonzalez-Burgos G	Alterations in cortical network oscillations and parvalbumin neurons in schizophrenia.	Biological psychiatry	2015	41
26830140	5816	Canetta S	Maternal immune activation leads to selective functional deficits in offspring parvalbumin interneurons.	Molecular psychiatry	2016	12
12645009	6285	Rothermundt M	S100B in brain damage and neurodegeneration.	Microscopy research and technique	2003	79
17319915	6285	Marchi N	Seizure-promoting effect of blood-brain barrier disruption.	Epilepsia	2007	115
19705461	6285	Mori T	Overexpression of human S100B exacerbates cerebral amyloidosis and gliosis in the Tg2576 mouse model of Alzheimer's disease.	Glia	2010	50
1734300	6531	Jack CR Jr	MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease.	Neurology	1992	132
3399080	6531	McGeer PL	Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains.	Neurology	1988	417
9126740	6531	Volkow ND	Relationship between subjective effects of cocaine and dopamine transporter occupancy.	Nature	1997	130
9417971	6531	Gunn RN	Parametric imaging of ligand-receptor binding in PET using a simplified reference region model.	NeuroImage	1997	167
9537821	6531	Tatsumi M	Pharmacological profile of antidepressants and related compounds at human monoamine transporters.	European journal of pharmacology	1997	121
9763484	6531	McCann UD	Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with 11CWIN-35,428.	The Journal of neuroscience 	1998	123
9766762	6531	Volkow ND	Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate.	The American journal of psychiatry	1998	112
10649826	6531	Heinz A	Genotype influences in vivo dopamine transporter availability in human striatum.	Neuropsychopharmacology 	2000	116
11160455	6531	Volkow ND	Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain.	The Journal of neuroscience 	2001	104
14608034	6531	Lustig C	Functional deactivations: change with age and dementia of the Alzheimer type.	Proceedings of the National Academy of Sciences of the United States of America	2003	235
15293269	6531	Ponsen MM	Idiopathic hyposmia as a preclinical sign of Parkinson's disease.	Annals of neurology	2004	90
15590952	6531	Fahn S	Levodopa and the progression of Parkinson's disease.	The New England journal of medicine	2004	180
15872345	6531	van Dyck CH	Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene.	Journal of nuclear medicine 	2005	80
16192352	6531	Rueda MR	Training, maturation, and genetic influences on the development of executive attention.	Proceedings of the National Academy of Sciences of the United States of America	2005	154
16518646	6531	Johanson CE	Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers.	Psychopharmacology	2006	65
17470495	6531	Huang C	Changes in network activity with the progression of Parkinson's disease.	Brain 	2007	87
17493050	6531	Chang L	Structural and metabolic brain changes in the striatum associated with methamphetamine abuse.	Addiction	2007	132
17992686	6531	McCann UD	Persistent cognitive and dopamine transporter deficits in abstinent methamphetamine users.	Synapse	2008	70
18579413	6531	Chang L	Decreased brain dopamine transporters are related to cognitive deficits in HIV patients with or without cocaine abuse.	NeuroImage	2008	55
18617632	6531	Binda F	Syntaxin 1A interaction with the dopamine transporter promotes amphetamine-induced dopamine efflux.	Molecular pharmacology	2008	53
19006193	6531	Kordower JH	Transplanted dopaminergic neurons develop PD pathologic changes: a second case report.	Movement disorders 	2008	68
19091889	6531	van de Giessen E	Striatal dopamine transporter availability associated with polymorphisms in the dopamine transporter gene SLC6A3.	Journal of nuclear medicine 	2009	48
19293415	6531	Volkow ND	Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications.	JAMA	2009	127
19738093	6531	Volkow ND	Evaluating dopamine reward pathway in ADHD: clinical implications.	JAMA	2009	129
20048223	6531	Nakamura K	Brain serotonin and dopamine transporter bindings in adults with high-functioning autism.	Archives of general psychiatry	2010	68
20846908	6531	Iranzo A	Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study corrected.	The Lancet. Neurology	2010	47
21717292	6531	Purohit V	Drugs of abuse, dopamine, and HIV-associated neurocognitive disorders/HIV-associated dementia.	Molecular neurobiology	2011	48
22315428	6531	Lundblad M	Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons.	Proceedings of the National Academy of Sciences of the United States of America	2012	59
22514303	6531	Sakrikar D	Attention deficit/hyperactivity disorder-derived coding variation in the dopamine transporter disrupts microdomain targeting and trafficking regulation.	The Journal of neuroscience 	2012	39
23065479	6531	Dale RC	Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders.	Brain 	2012	43
23562390	6531	Iranzo A	Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study.	The Lancet. Neurology	2013	52
24102293	6531	Calipari ES	Extended access of cocaine self-administration results in tolerance to the dopamine-elevating and locomotor-stimulating effects of cocaine.	Journal of neurochemistry	2014	21
24911152	6531	Hansen FH	Missense dopamine transporter mutations associate with adult parkinsonism and ADHD.	The Journal of clinical investigation	2014	21
26171719	6531	Hryhorczuk C	Dampened Mesolimbic Dopamine Function and Signaling by Saturated but not Monounsaturated Dietary Lipids.	Neuropsychopharmacology 	2016	13
8632190	6532	Heils A	Allelic variation of human serotonin transporter gene expression.	Journal of neurochemistry	1996	376
11803458	6532	Bennett AJ	Early experience and serotonin transporter gene variation interact to influence primate CNS function.	Molecular psychiatry	2002	135
12130784	6532	Hariri AR	Serotonin transporter genetic variation and the response of the human amygdala.	Science	2002	485
12973026	6532	Ichise M	Linearized reference tissue parametric imaging methods: application to 11CDASB positron emission tomography studies of the serotonin transporter in human brain.	Journal of cerebral blood flow and metabolism 	2003	143
15592465	6532	Heinz A	Amygdala-prefrontal coupling depends on a genetic variation of the serotonin transporter.	Nature neuroscience	2005	164
15699291	6532	Hariri AR	A susceptibility gene for affective disorders and the response of the human amygdala.	Archives of general psychiatry	2005	217
15880108	6532	Pezawas L	5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression.	Nature neuroscience	2005	483
16012532	6532	Maciag D	Neonatal antidepressant exposure has lasting effects on behavior and serotonin circuitry.	Neuropsychopharmacology 	2006	70
16389202	6532	Sekine Y	Brain serotonin transporter density and aggression in abstinent methamphetamine abusers.	Archives of general psychiatry	2006	76
16390888	6532	Parsey RV	Effect of a triallelic functional polymorphism of the serotonin-transporter-linked promoter region on expression of serotonin transporter in the human brain.	The American journal of psychiatry	2006	73
16442081	6532	Hariri AR	Imaging genetics: perspectives from studies of genetically driven variation in serotonin function and corticolimbic affective processing.	Biological psychiatry	2006	101
16530463	6532	Hariri AR	Genetics of emotional regulation: the role of the serotonin transporter in neural function.	Trends in cognitive sciences	2006	195
16642437	6532	Hu XZ	Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder.	American journal of human genetics	2006	307
17406646	6532	Dannlowski U	5-HTTLPR biases amygdala activity in response to masked facial expressions in major depression.	Neuropsychopharmacology 	2008	51
17956909	6532	Kish SJ	Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease.	Brain 	2008	67
18005940	6532	Gotlib IH	HPA axis reactivity: a mechanism underlying the associations among 5-HTTLPR, stress, and depression.	Biological psychiatry	2008	136
18824000	6532	Murphy DL	How the serotonin story is being rewritten by new gene-based discoveries principally related to SLC6A4, the serotonin transporter gene, which functions to influence all cellular serotonin systems.	Neuropharmacology	2008	61
19213730	6532	Andersen J	Location of the antidepressant binding site in the serotonin transporter: importance of Ser-438 in recognition of citalopram and tricyclic antidepressants.	The Journal of biological chemistry	2009	47
19439600	6532	Pacheco J	Frontal-limbic white matter pathway associations with the serotonin transporter gene promoter region (5-HTTLPR) polymorphism.	The Journal of neuroscience 	2009	51
19864286	6532	Chiao JY	Culture-gene coevolution of individualism-collectivism and the serotonin transporter gene.	Proceedings. Biological sciences	2010	65
20231323	6532	Caspi A	Genetic sensitivity to the environment: the case of the serotonin transporter gene and its implications for studying complex diseases and traits.	The American journal of psychiatry	2010	355
20398062	6532	Kinnally EL	Epigenetic regulation of serotonin transporter expression and behavior in infant rhesus macaques.	Genes, brain, and behavior	2010	54
21047622	6532	Homberg JR	Looking on the bright side of serotonin transporter gene variation.	Biological psychiatry	2011	93
22745770	6532	Wang D	Peripheral SLC6A4 DNA methylation is associated with in vivo measures of human brain serotonin synthesis and childhood physical aggression.	PloS one	2012	33
23154100	6532	Bailer UF	Interaction between serotonin transporter and dopamine D2/D3 receptor radioligand measures is associated with harm avoidant symptoms in anorexia and bulimia nervosa.	Psychiatry research	2013	25
25086606	6532	Nikolova YS	Beyond genotype: serotonin transporter epigenetic modification predicts human brain function.	Nature neuroscience	2014	31
8901511	6622	Weinreb PH	NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded.	Biochemistry	1996	302
9331351	6622	Breiter HC	Acute effects of cocaine on human brain activity and emotion.	Neuron	1997	241
9726379	6622	Spillantini MG	Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies.	Neuroscience letters	1998	148
10678833	6622	Masliah E	Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders.	Science	2000	326
10885656	6622	Hamilton RL	Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry.	Brain pathology	2000	106
10991663	6622	Braak H	Pathoanatomy of Parkinson's disease.	Journal of neurology	2000	95
11923443	6622	Kirik D	Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.	The Journal of neuroscience 	2002	150
12042811	6622	Xu J	Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease.	Nature medicine	2002	141
12062037	6622	Giasson BI	Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein.	Neuron	2002	239
12084935	6622	Lee MK	Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --&amp;gt; Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice.	Proceedings of the National Academy of Sciences of the United States of America	2002	148
12122208	6622	Lo Bianco C	alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.	Proceedings of the National Academy of Sciences of the United States of America	2002	112
12217698	6622	Hoyer W	Dependence of alpha-synuclein aggregate morphology on solution conditions.	Journal of molecular biology	2002	91
12601150	6622	Kirik D	Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease.	Proceedings of the National Academy of Sciences of the United States of America	2003	82
12714745	6622	Giasson BI	Initiation and synergistic fibrillization of tau and alpha-synuclein.	Science	2003	162
15473992	6622	Ikonomovic MD	Alzheimer's pathology in human temporal cortex surgically excised after severe brain injury.	Experimental neurology	2004	101
15496679	6622	Fleming SM	Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein.	The Journal of neuroscience 	2004	129
15576511	6622	Lo Bianco C	Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease.	Proceedings of the National Academy of Sciences of the United States of America	2004	71
15753419	6622	Bennett DA	Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions.	Neurology	2005	171
15791003	6622	Zhang W	Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease.	FASEB journal 	2005	243
15845543	6622	Shin Y	The co-chaperone carboxyl terminus of Hsp70-interacting protein (CHIP) mediates alpha-synuclein degradation decisions between proteasomal and lysosomal pathways.	The Journal of biological chemistry	2005	81
15851731	6622	Braak H	Cognitive status correlates with neuropathologic stage in Parkinson disease.	Neurology	2005	79
16237129	6622	McKeith IG	Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium.	Neurology	2005	841
16358335	6622	Nishioka K	Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease.	Annals of neurology	2006	65
16399671	6622	Martin LJ	Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death.	The Journal of neuroscience 	2006	165
16847063	6622	Anderson JP	Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease.	The Journal of biological chemistry	2006	228
16930553	6622	Tokuda T	Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease.	Biochemical and biophysical research communications	2006	87
17055279	6622	Chu Y	Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?	Neurobiology of disease	2007	95
17254549	6622	Hoozemans JJ	Activation of the unfolded protein response in Parkinson's disease.	Biochemical and biophysical research communications	2007	87
18036154	6622	Reynolds AD	Nitrated alpha-synuclein-activated microglial profiling for Parkinson's disease.	Journal of neurochemistry	2008	59
18079166	6622	Orimo S	Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease.	Brain 	2008	72
18162487	6622	Fuchs J	Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain.	FASEB journal 	2008	65
18178617	6622	Gorbatyuk OS	The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease.	Proceedings of the National Academy of Sciences of the United States of America	2008	73
18245082	6622	Devi L	Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain.	The Journal of biological chemistry	2008	180
18451726	6622	Waxman EA	Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein.	Journal of neuropathology and experimental neurology	2008	72
18566453	6622	Vogiatzi T	Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells.	The Journal of biological chemistry	2008	145
18625222	6622	Mollenhauer B	Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration.	Experimental neurology	2008	86
18704197	6622	Lo Bianco C	Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease.	The Journal of clinical investigation	2008	60
18769444	6622	Brundin P	Research in motion: the enigma of Parkinson's disease pathology spread.	Nature reviews. Neuroscience	2008	77
18769546	6622	Tsigelny IF	Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases.	PloS one	2008	69
19018246	6622	Theodore S	Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease.	Journal of neuropathology and experimental neurology	2008	64
19074459	6622	Azeredo da Silveira S	Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease.	Human molecular genetics	2009	55
19155272	6622	Paleologou KE	Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies.	Brain 	2009	46
19230552	6622	Braak H	Neuroanatomy and pathology of sporadic Parkinson's disease.	Advances in anatomy, embryology, and cell biology	2009	49
19273758	6622	Tapiola T	Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.	Archives of neurology	2009	134
19295143	6622	Chung CY	Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy.	The Journal of neuroscience 	2009	88
19385059	6622	Cannon JR	A highly reproducible rotenone model of Parkinson's disease.	Neurobiology of disease	2009	96
19651612	6622	Desplats P	Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein.	Proceedings of the National Academy of Sciences of the United States of America	2009	403
19686384	6622	Danzer KM	Seeding induced by alpha-synuclein oligomers provides evidence for spreading of alpha-synuclein pathology.	Journal of neurochemistry	2009	71
19745811	6622	Karpinar DP	Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models.	The EMBO journal	2009	94
19855133	6622	Chen L	Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation.	The Journal of clinical investigation	2009	54
19903734	6622	Tong J	Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.	Brain 	2010	40
20106983	6622	Doxakis E	Post-transcriptional regulation of alpha-synuclein expression by mir-7 and mir-153.	The Journal of biological chemistry	2010	104
20152114	6622	Nemani VM	Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis.	Neuron	2010	247
20198645	6622	Li JY	Characterization of Lewy body pathology in 12- and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease.	Movement disorders 	2010	49
20203178	6622	Paleologou KE	Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions.	The Journal of neuroscience 	2010	68
20445061	6622	Jowaed A	Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease patients' brains.	The Journal of neuroscience 	2010	64
20534649	6622	Garcia-Reitböck P	SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease.	Brain 	2010	56
20554859	6622	Scott DA	A pathologic cascade leading to synaptic dysfunction in alpha-synuclein-induced neurodegeneration.	The Journal of neuroscience 	2010	81
20599975	6622	Wills J	Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia.	Experimental neurology	2010	45
20696318	6622	Oueslati A	Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies.	Progress in brain research	2010	67
20962290	6622	Tokuda T	Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease.	Neurology	2010	91
21488084	6622	Lam HA	Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human α-synuclein.	Journal of neuroscience research	2011	35
21700325	6622	Mazzulli JR	Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies.	Cell	2011	216
21766334	6622	Shannon KM	Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease.	Movement disorders 	2012	52
21994367	6622	Ebrahimi-Fakhari D	Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of α-synuclein.	The Journal of neuroscience 	2011	76
22094370	6622	Jain S	Cardiovascular dysautonomia in Parkinson disease: from pathophysiology to pathogenesis.	Neurobiology of disease	2012	35
22110584	6622	Byers B	SNCA triplication Parkinson's patient's iPSC-derived DA neurons accumulate α-synuclein and are susceptible to oxidative stress.	PloS one	2011	49
22315227	6622	Fauvet B	α-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer.	The Journal of biological chemistry	2012	118
22574141	6622	Maudoux A	Auditory resting-state network connectivity in tinnitus: a functional MRI study.	PloS one	2012	41
22737239	6622	Angot E	Alpha-synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo.	PloS one	2012	46
23352769	6622	Mercado G	An ERcentric view of Parkinson's disease.	Trends in molecular medicine	2013	46
23392688	6622	Boassa D	Mapping the subcellular distribution of α-synuclein in neurons using genetically encoded probes for correlated light and electron microscopy: implications for Parkinson's disease pathogenesis.	The Journal of neuroscience 	2013	35
23526723	6622	Lesage S	G51D α-synuclein mutation causes a novel parkinsonian-pyramidal syndrome.	Annals of neurology	2013	96
23703938	6622	Ulusoy A	Caudo-rostral brain spreading of α-synuclein through vagal connections.	EMBO molecular medicine	2013	29
23739956	6622	Harms AS	MHCII is required for α-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration.	The Journal of neuroscience 	2013	45
23900411	6622	Irwin DJ	Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies.	Nature reviews. Neuroscience	2013	90
23925565	6622	Rey NL	Transfer of human α-synuclein from the olfactory bulb to interconnected brain regions in mice.	Acta neuropathologica	2013	40
24243558	6622	Recasens A	Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys.	Annals of neurology	2014	73
24381286	6622	Guardia-Laguarta C	α-Synuclein is localized to mitochondria-associated ER membranes.	The Journal of neuroscience 	2014	48
24382629	6622	Reyes JF	Alpha-synuclein transfers from neurons to oligodendrocytes.	Glia	2014	44
24590631	6622	Asi YT	Alpha-synuclein mRNA expression in oligodendrocytes in MSA.	Glia	2014	24
24788821	6622	Doppler K	Cutaneous neuropathy in Parkinson's disease: a window into brain pathology.	Acta neuropathologica	2014	20
24995389	6622	Seidel K	The brainstem pathologies of Parkinson's disease and dementia with Lewy bodies.	Brain pathology	2015	23
25676491	6622	Sengupta U	Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies.	Biological psychiatry	2015	20
25732184	6622	Roberts RF	Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson's disease brain.	Brain 	2015	21
26076669	6622	Dettmer U	Parkinson-causing α-synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation.	Nature communications	2015	27
26446103	6622	Uchihara T	Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies.	Acta neuropathologica	2016	17
8209258	6647	Gurney ME	Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation.	Science	1994	776
11331366	6647	Pramatarova A	Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment.	The Journal of neuroscience 	2001	88
15758154	6647	Vijayvergiya C	Mutant superoxide dismutase 1 forms aggregates in the brain mitochondrial matrix of amyotrophic lateral sclerosis mice.	The Journal of neuroscience 	2005	67
15768029	6647	Ralph GS	Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model.	Nature medicine	2005	111
17038899	6647	Xu L	Human neural stem cell grafts ameliorate motor neuron disease in SOD-1 transgenic rats.	Transplantation	2006	63
18469020	6647	Vucic S	Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis.	Brain 	2008	77
18945894	6647	van Zundert B	Neonatal neuronal circuitry shows hyperexcitable disturbance in a mouse model of the adult-onset neurodegenerative disease amyotrophic lateral sclerosis.	The Journal of neuroscience 	2008	53
19483195	6647	Prudencio M	Variation in aggregation propensities among ALS-associated variants of SOD1: correlation to human disease.	Human molecular genetics	2009	61
19903735	6647	Walker AK	Protein disulphide isomerase protects against protein aggregation and is S-nitrosylated in amyotrophic lateral sclerosis.	Brain 	2010	44
21908873	6647	Ferraiuolo L	Dysregulation of astrocyte-motoneuron cross-talk in mutant superoxide dismutase 1-related amyotrophic lateral sclerosis.	Brain 	2011	37
21930926	6647	Grad LI	Intermolecular transmission of superoxide dismutase 1 misfolding in living cells.	Proceedings of the National Academy of Sciences of the United States of America	2011	76
22416121	6647	Guareschi S	An over-oxidized form of superoxide dismutase found in sporadic amyotrophic lateral sclerosis with bulbar onset shares a toxic mechanism with mutant SOD1.	Proceedings of the National Academy of Sciences of the United States of America	2012	52
23026746	6647	Graffmo KS	Expression of wild-type human superoxide dismutase-1 in mice causes amyotrophic lateral sclerosis.	Human molecular genetics	2013	30
24550511	6647	Grad LI	Intercellular propagated misfolding of wild-type Cu/Zn superoxide dismutase occurs via exosome-dependent and -independent mechanisms.	Proceedings of the National Academy of Sciences of the United States of America	2014	78
26657039	6647	Kaur SJ	Mutant SOD1 mediated pathogenesis of Amyotrophic Lateral Sclerosis.	Gene	2016	15
11005565	7422	Rubenstein JL	Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption.	Neoplasia	2000	137
15351965	7422	Storkebaum E	VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection.	BioEssays 	2004	93
16912155	7422	Bao S	Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor.	Cancer research	2006	351
17167137	7422	Sandler A	Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.	The New England journal of medicine	2006	1175
17236958	7422	Gonzalez J	Effect of bevacizumab on radiation necrosis of the brain.	International journal of radiation oncology, biology, physics	2007	64
17533168	7422	Rigau V	Angiogenesis is associated with blood-brain barrier permeability in temporal lobe epilepsy.	Brain 	2007	69
17947719	7422	Vredenburgh JJ	Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.	Journal of clinical oncology 	2007	325
18316689	7422	Norden AD	Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.	Neurology	2008	230
19167838	7422	Gutin PH	Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas.	International journal of radiation oncology, biology, physics	2009	73
19332770	7422	Quant EC	Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab.	Neuro-oncology	2009	48
19333229	7422	Gerstner ER	VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer.	Nature reviews. Clinical oncology	2009	47
19349600	7422	Nghiemphu PL	Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience.	Neurology	2009	66
19357959	7422	Jensen RL	Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target.	Journal of neuro-oncology	2009	74
19549889	7422	Sorensen AG	A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.	Cancer research	2009	108
19581909	7422	Chen HX	Adverse effects of anticancer agents that target the VEGF pathway.	Nature reviews. Clinical oncology	2009	90
20406897	7422	Gerstner ER	Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib.	Neuro-oncology	2010	44
21167939	7422	Fidler IJ	The role of the organ microenvironment in brain metastasis.	Seminars in cancer biology	2011	63
21732485	7422	Horie N	Transplanted stem cell-secreted vascular endothelial growth factor effects poststroke recovery, inflammation, and vascular repair.	Stem cells	2011	61
22035272	7422	Narayana A	A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma.	Journal of neurosurgery	2012	39
22212972	7422	Stewart MW	The expanding role of vascular endothelial growth factor inhibitors in ophthalmology.	Mayo Clinic proceedings	2012	33
22495829	7422	Oki K	Human-induced pluripotent stem cells form functional neurons and improve recovery after grafting in stroke-damaged brain.	Stem cells	2012	56
23143192	7422	Plate KH	Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited.	Acta neuropathologica	2012	35
23512266	7422	Soda Y	Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme.	Journal of molecular medicine	2013	35
23940216	7422	Batchelor TT	Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.	Journal of clinical oncology 	2013	80
24552317	7422	Gilbert MR	A randomized trial of bevacizumab for newly diagnosed glioblastoma.	The New England journal of medicine	2014	316
25117977	7422	Baker GJ	Mechanisms of glioma formation: iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapy.	Neoplasia	2014	26
25713439	7422	Lu-Emerson C	Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.	Journal of clinical oncology 	2015	25
10485682	8743	Collins MW	Relationship between concussion and neuropsychological performance in college football players.	JAMA	1999	102
11479629	8743	Ichikawa K	Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity.	Nature medicine	2001	114
11524471	8743	O'Sullivan M	Evidence for cortical "disconnection" as a mechanism of age-related cognitive decline.	Neurology	2001	156
16168730	8743	Zakzanis KK	An fMRI study of the Trail Making Test.	Neuropsychologia	2005	77
19047138	8743	Kim SM	Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma.	Cancer research	2008	73
19264968	8743	Sasportas LS	Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy.	Proceedings of the National Academy of Sciences of the United States of America	2009	122
19544410	8743	Menon LG	Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy.	Stem cells	2009	54
20160006	8743	Pérez-Iglesias R	White matter integrity and cognitive impairment in first-episode psychosis.	The American journal of psychiatry	2010	43
20406573	8743	Lukowski AF	Iron deficiency in infancy and neurocognitive functioning at 19 years: evidence of long-term deficits in executive function and recognition memory.	Nutritional neuroscience	2010	46
24088092	8743	Pandharipande PP	Long-term cognitive impairment after critical illness.	The New England journal of medicine	2013	176
24568942	8743	Yuan P	Prefrontal cortex and executive functions in healthy adults: a meta-analysis of structural neuroimaging studies.	Neuroscience and biobehavioral reviews	2014	28
24711660	8743	ten Brinke LF	Aerobic exercise increases hippocampal volume in older women with probable mild cognitive impairment: a 6-month randomised controlled trial.	British journal of sports medicine	2015	21
26754644	8743	Pase MP	Association of Aortic Stiffness With Cognition and Brain Aging in Young and Middle-Aged Adults: The Framingham Third Generation Cohort Study.	Hypertension	2016	18
1486461	9463	Hodges JR	Semantic dementia. Progressive fluent aphasia with temporal lobe atrophy.	Brain 	1992	212
11708987	9463	McKhann GM	Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease.	Archives of neurology	2001	285
15349867	9463	Hodges JR	Clinicopathological correlates in frontotemporal dementia.	Annals of neurology	2004	124
16033782	9463	Kertesz A	The evolution and pathology of frontotemporal dementia.	Brain 	2005	118
17187353	9463	Seeley WW	Early frontotemporal dementia targets neurons unique to apes and humans.	Annals of neurology	2006	69
19725834	9463	Martínez A	Protein targets of oxidative damage in human neurodegenerative diseases with abnormal protein aggregates.	Brain pathology	2010	48
20110609	9463	Kim W	Interneuronal transfer of human tau between Lamprey central neurons in situ.	Journal of Alzheimer's disease 	2010	45
12848929	10215	Ross SE	Basic helix-loop-helix factors in cortical development.	Neuron	2003	147
15198128	10215	Ligon KL	The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas.	Journal of neuropathology and experimental neurology	2004	111
15303102	10215	Aston C	Transcriptional profiling reveals evidence for signaling and oligodendroglial abnormalities in the temporal cortex from patients with major depressive disorder.	Molecular psychiatry	2005	105
16652341	10215	Ligon KL	Olig gene function in CNS development and disease.	Glia	2006	69
16682644	10215	Ligon KL	Development of NG2 neural progenitor cells requires Olig gene function.	Proceedings of the National Academy of Sciences of the United States of America	2006	75
17360586	10215	Nait-Oumesmar B	Activation of the subventricular zone in multiple sclerosis: evidence for early glial progenitors.	Proceedings of the National Academy of Sciences of the United States of America	2007	77
18515322	10215	Kuhlmann T	Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis.	Brain 	2008	148
19486010	10215	Geha S	NG2+/Olig2+ cells are the major cycle-related cell population of the adult human normal brain.	Brain pathology	2010	42
22691720	10215	Picard D	Markers of survival and metastatic potential in childhood CNS primitive neuro-ectodermal brain tumours: an integrative genomic analysis.	The Lancet. Oncology	2012	33
22901811	10215	Wang Y	ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.	Cell	2012	32
23395447	10215	Wang S	Human iPSC-derived oligodendrocyte progenitor cells can myelinate and rescue a mouse model of congenital hypomyelination.	Cell stem cell	2013	118
25254339	10215	Douvaras P	Efficient generation of myelinating oligodendrocytes from primary progressive multiple sclerosis patients by induced pluripotent stem cells.	Stem cell reports	2014	34
17140455	10763	Liu G	Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma.	Molecular cancer	2006	483
19108713	10763	Zhang M	Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients.	Journal of experimental and clinical cancer research 	2008	58
20126454	10763	Knoth R	Murine features of neurogenesis in the human hippocampus across the lifespan from 0 to 100 years.	PloS one	2010	104
22253443	10763	Xia H	Loss of brain-enriched miR-124 microRNA enhances stem-like traits and invasiveness of glioma cells.	The Journal of biological chemistry	2012	52
26138445	10763	Fornara O	Cytomegalovirus infection induces a stem cell phenotype in human primary glioblastoma cells: prognostic significance and biological impact.	Cell death and differentiation	2016	11
12446870	11315	Bonifati V	Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism.	Science	2003	510
14662519	11315	Bandopadhyay R	The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease.	Brain 	2004	84
15944198	11315	Zhang L	Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis.	Human molecular genetics	2005	108
15952880	11315	Cookson MR	The biochemistry of Parkinson's disease.	Annual review of biochemistry	2005	165
16517609	11315	Choi J	Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases.	The Journal of biological chemistry	2006	109
17499497	11315	Dodson MW	Pink1, Parkin, DJ-1 and mitochondrial dysfunction in Parkinson's disease.	Current opinion in neurobiology	2007	75
18312001	11315	Dayon L	Relative quantification of proteins in human cerebrospinal fluids by MS/MS using 6-plex isobaric tags.	Analytical chemistry	2008	124
19229105	11315	Xiong H	Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation.	The Journal of clinical investigation	2009	99
20157014	11315	Hong Z	DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease.	Brain 	2010	137
20186336	11315	Krebiehl G	Reduced basal autophagy and impaired mitochondrial dynamics due to loss of Parkinson's disease-associated protein DJ-1.	PloS one	2010	81
20506312	11315	Nuytemans K	Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update.	Human mutation	2010	99
20639397	11315	Irrcher I	Loss of the Parkinson's disease-linked gene DJ-1 perturbs mitochondrial dynamics.	Human molecular genetics	2010	108
17084815	23435	Arai T	TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.	Biochemical and biophysical research communications	2006	487
17219193	23435	Davidson Y	Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein, TDP-43.	Acta neuropathologica	2007	85
17279000	23435	Neumann M	TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations.	Journal of neuropathology and experimental neurology	2007	92
17481916	23435	Strong MJ	TDP43 is a human low molecular weight neurofilament (hNFL) mRNA-binding protein.	Molecular and cellular neurosciences	2007	96
17963732	23435	Higashi S	Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies.	Brain research	2007	82
18166704	23435	Josephs KA	Progressive aphasia secondary to Alzheimer disease vs FTLD pathology.	Neurology	2008	64
18396105	23435	Van Deerlin VM	TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis.	The Lancet. Neurology	2008	203
18434538	23435	Johnson BS	A yeast TDP-43 proteinopathy model: Exploring the molecular determinants of TDP-43 aggregation and cellular toxicity.	Proceedings of the National Academy of Sciences of the United States of America	2008	148
18474740	23435	Geser F	Evidence of multisystem disorder in whole-brain map of pathological TDP-43 in amyotrophic lateral sclerosis.	Archives of neurology	2008	73
18520774	23435	Uryu K	Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies.	Journal of neuropathology and experimental neurology	2008	100
18546284	23435	Hasegawa M	Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.	Annals of neurology	2008	128
18723524	23435	Rademakers R	Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia.	Human molecular genetics	2008	97
18845250	23435	Kimonis VE	VCP disease associated with myopathy, Paget disease of bone and frontotemporal dementia: review of a unique disorder.	Biochimica et biophysica acta	2008	57
19021630	23435	Nelson PT	Modeling the association between 43 different clinical and pathological variables and the severity of cognitive impairment in a large autopsy cohort of elderly persons.	Brain pathology	2010	78
19139911	23435	Arai T	Phosphorylated TDP-43 in Alzheimer's disease and dementia with Lewy bodies.	Acta neuropathologica	2009	70
19191304	23435	Rothstein JD	Current hypotheses for the underlying biology of amyotrophic lateral sclerosis.	Annals of neurology	2009	189
19204154	23435	Geser F	Clinical and pathological continuum of multisystem TDP-43 proteinopathies.	Archives of neurology	2009	80
19383787	23435	Zhang YJ	Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity.	Proceedings of the National Academy of Sciences of the United States of America	2009	158
19515851	23435	Nonaka T	Truncation and pathogenic mutations facilitate the formation of intracellular aggregates of TDP-43.	Human molecular genetics	2009	82
19655382	23435	Borroni B	Mutation within TARDBP leads to frontotemporal dementia without motor neuron disease.	Human mutation	2009	65
19765185	23435	Colombrita C	TDP-43 is recruited to stress granules in conditions of oxidative insult.	Journal of neurochemistry	2009	125
19781077	23435	Lu Y	Frontotemporal dementia and amyotrophic lateral sclerosis-associated disease protein TDP-43 promotes dendritic branching.	Molecular brain	2009	57
19833869	23435	Wegorzewska I	TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration.	Proceedings of the National Academy of Sciences of the United States of America	2009	190
20133711	23435	Wils H	TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration.	Proceedings of the National Academy of Sciences of the United States of America	2010	154
20369906	23435	Rabinovici GD	Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management.	CNS drugs	2010	49
20423455	23435	Buratti E	Nuclear factor TDP-43 can affect selected microRNA levels.	The FEBS journal	2010	58
20971753	23435	Seelaar H	Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review.	Journal of neurology, neurosurgery, and psychiatry	2011	88
21172843	23435	Rohrer JD	TDP-43 subtypes are associated with distinct atrophy patterns in frontotemporal dementia.	Neurology	2010	41
21346515	23435	Pao WC	Hippocampal sclerosis in the elderly: genetic and pathologic findings, some mimicking Alzheimer disease clinically.	Alzheimer disease and associated disorders	2011	37
21358640	23435	Tollervey JR	Characterizing the RNA targets and position-dependent splicing regulation by TDP-43.	Nature neuroscience	2011	244
21454603	23435	Furukawa Y	A seeding reaction recapitulates intracellular formation of Sarkosyl-insoluble transactivation response element (TAR) DNA-binding protein-43 inclusions.	The Journal of biological chemistry	2011	60
21892620	23435	Nalbandian A	The multiple faces of valosin-containing protein-associated diseases: inclusion body myopathy with Paget's disease of bone, frontotemporal dementia, and amyotrophic lateral sclerosis.	Journal of molecular neuroscience 	2011	43
21908392	23435	Leyton CE	Subtypes of progressive aphasia: application of the International Consensus Criteria and validation using β-amyloid imaging.	Brain 	2011	47
22028219	23435	Jucker M	Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders.	Annals of neurology	2011	141
22029574	23435	Xu YF	Expression of mutant TDP-43 induces neuronal dysfunction in transgenic mice.	Molecular neurodegeneration	2011	44
22120149	23435	Robinson JL	Neocortical and hippocampal amyloid-β and tau measures associate with dementia in the oldest-old.	Brain 	2011	36
22445064	23435	King OD	The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease.	Brain research	2012	159
22493728	23435	Pokrishevsky E	Aberrant localization of FUS and TDP43 is associated with misfolding of SOD1 in amyotrophic lateral sclerosis.	PloS one	2012	43
22563080	23435	Bentmann E	Requirements for stress granule recruitment of fused in sarcoma (FUS) and TAR DNA-binding protein of 43 kDa (TDP-43).	The Journal of biological chemistry	2012	63
23012333	23435	Hornberger M	In vivo and post-mortem memory circuit integrity in frontotemporal dementia and Alzheimer's disease.	Brain 	2012	32
23104007	23435	Armakola M	Inhibition of RNA lariat debranching enzyme suppresses TDP-43 toxicity in ALS disease models.	Nature genetics	2012	35
23380910	23435	Irwin DJ	Evaluation of potential infectivity of Alzheimer and Parkinson disease proteins in recipients of cadaver-derived human growth hormone.	JAMA neurology	2013	43
23475817	23435	McMillan CT	White matter imaging helps dissociate tau from TDP-43 in frontotemporal lobar degeneration.	Journal of neurology, neurosurgery, and psychiatry	2013	29
23831027	23435	Nonaka T	Prion-like properties of pathological TDP-43 aggregates from diseased brains.	Cell reports	2013	62
23842566	23435	Toledo JB	Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre.	Brain 	2013	84
23864344	23435	Nelson PT	Hippocampal sclerosis of aging, a prevalent and high-morbidity brain disease.	Acta neuropathologica	2013	43
23900071	23435	Janssens J	Pathological mechanisms underlying TDP-43 driven neurodegeneration in FTLD-ALS spectrum disorders.	Human molecular genetics	2013	33
23900711	23435	Kovacs GG	Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series.	Acta neuropathologica	2013	39
24080705	23435	Wilson RS	TDP-43 pathology, cognitive decline, and dementia in old age.	JAMA neurology	2013	41
24240737	23435	Josephs KA	Staging TDP-43 pathology in Alzheimer's disease.	Acta neuropathologica	2014	35
24252435	23435	Toledo JB	Clinical and multimodal biomarker correlates of ADNI neuropathological findings.	Acta neuropathologica communications	2013	26
24507191	23435	Alami NH	Axonal transport of TDP-43 mRNA granules is impaired by ALS-causing mutations.	Neuron	2014	97
24574501	23435	Mesulam MM	Asymmetry and heterogeneity of Alzheimer's and frontotemporal pathology in primary progressive aphasia.	Brain 	2014	40
24746362	23435	Pasanen P	Novel α-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson's disease-type pathology.	Neurobiology of aging	2014	54
27495267	23435	McAleese KE	TDP-43 pathology in Alzheimer's disease, dementia with Lewy bodies and ageing.	Brain pathology	2017	5
10591213	23621	Yan R	Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity.	Nature	1999	262
10677483	23621	Lin X	Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein.	Proceedings of the National Academy of Sciences of the United States of America	2000	156
12112088	23621	Holsinger RM	Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease.	Annals of neurology	2002	151
14978286	23621	Li R	Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients.	Proceedings of the National Academy of Sciences of the United States of America	2004	134
16407166	23621	Sastre M	Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma.	Proceedings of the National Academy of Sciences of the United States of America	2006	92
16407538	23621	Spoelgen R	Interaction of the cytosolic domains of sorLA/LR11 with the amyloid precursor protein (APP) and beta-secretase beta-site APP-cleaving enzyme.	The Journal of neuroscience 	2006	65
16904810	23621	Rossner S	Transcriptional and translational regulation of BACE1 expression--implications for Alzheimer's disease.	Progress in neurobiology	2006	65
17121991	23621	Sun X	Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression.	Proceedings of the National Academy of Sciences of the United States of America	2006	117
17576410	23621	Kim DY	BACE1 regulates voltage-gated sodium channels and neuronal activity.	Nature cell biology	2007	101
17826768	23621	Uryu K	Multiple proteins implicated in neurodegenerative diseases accumulate in axons after brain trauma in humans.	Experimental neurology	2007	95
18434550	23621	Hébert SS	Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression.	Proceedings of the National Academy of Sciences of the United States of America	2008	298
19006075	23621	Xie Z	The common inhalation anesthetic isoflurane induces caspase activation and increases amyloid beta-protein level in vivo.	Annals of neurology	2008	89
19815015	23621	Hampel H	Biological markers of amyloid beta-related mechanisms in Alzheimer's disease.	Experimental neurology	2010	41
20507594	23621	Faghihi MA	Evidence for natural antisense transcript-mediated inhibition of microRNA function.	Genome biology	2010	101
21329555	23621	Chen CH	Increased NF-κB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer's disease.	The international journal of neuropsychopharmacology	2012	35
22090477	23621	May PC	Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor.	The Journal of neuroscience 	2011	79
22285895	23621	Delay C	MicroRNAs in Alzheimer's disease.	Neurobiology of disease	2012	43
24352696	23621	Long JM	MicroRNA-339-5p down-regulates protein expression of β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) in human primary brain cultures and is reduced in brain tissue specimens of Alzheimer disease subjects.	The Journal of biological chemistry	2014	21
25621019	23621	Vassar R	BACE1 inhibitor drugs in clinical trials for Alzheimer's disease.	Alzheimer's research and therapy	2014	34
16473933	26047	Inda MC	Voltage-gated ion channels in the axon initial segment of human cortical pyramidal cells and their relationship with chandelier cells.	Proceedings of the National Academy of Sciences of the United States of America	2006	66
16571880	26047	Strauss KA	Recessive symptomatic focal epilepsy and mutant contactin-associated protein-like 2.	The New England journal of medicine	2006	166
18179893	26047	Alarcón M	Linkage, association, and gene-expression analyses identify CNTNAP2 as an autism-susceptibility gene.	American journal of human genetics	2008	274
18179895	26047	Bakkaloglu B	Molecular cytogenetic analysis and resequencing of contactin associated protein-like 2 in autism spectrum disorders.	American journal of human genetics	2008	184
21048216	26047	Scott-Van Zeeland AA	Altered functional connectivity in frontal lobe circuits is associated with variation in the autism risk gene CNTNAP2.	Science translational medicine	2010	75
21310003	26047	Whitehouse AJ	CNTNAP2 variants affect early language development in the general population.	Genes, brain, and behavior	2011	52
21387375	26047	Lancaster E	Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia.	Annals of neurology	2011	81
22473710	26047	Irani SR	Morvan syndrome: clinical and serological observations in 29 cases.	Annals of neurology	2012	55
23228431	26047	Graham SA	Decoding the genetics of speech and language.	Current opinion in neurobiology	2013	41
23714751	26047	Rodenas-Cuadrado P	Shining a light on CNTNAP2: complex functions to complex disorders.	European journal of human genetics 	2014	40
16275808	27185	Cannon TD	Association of DISC1/TRAX haplotypes with schizophrenia, reduced prefrontal gray matter, and impaired short- and long-term memory.	Archives of general psychiatry	2005	98
16959794	27185	Hashimoto R	Impact of the DISC1 Ser704Cys polymorphism on risk for major depression, brain morphology and ERK signaling.	Human molecular genetics	2006	72
19716984	27185	Lodge DJ	Gestational methylazoxymethanol acetate administration: a developmental disruption model of schizophrenia.	Behavioural brain research	2009	60
19805229	27185	Nakata K	DISC1 splice variants are upregulated in schizophrenia and associated with risk polymorphisms.	Proceedings of the National Academy of Sciences of the United States of America	2009	58
20048751	27185	Ayhan Y	Differential effects of prenatal and postnatal expressions of mutant human DISC1 on neurobehavioral phenotypes in transgenic mice: evidence for neurodevelopmental origin of major psychiatric disorders.	Molecular psychiatry	2011	70
20512377	27185	Allman JM	The von Economo neurons in frontoinsular and anterior cingulate cortex in great apes and humans.	Brain structure and function	2010	67
22099458	27185	Singh KK	Common DISC1 polymorphisms disrupt Wnt/GSK3β signaling and brain development.	Neuron	2011	37
25132547	27185	Wen Z	Synaptic dysregulation in a human iPS cell model of mental disorders.	Nature	2014	89
12080485	54209	Paloneva J	Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype.	American journal of human genetics	2002	134
23150908	54209	Jonsson T	Variant of TREM2 associated with the risk of Alzheimer's disease.	The New England journal of medicine	2013	372
23150934	54209	Guerreiro R	TREM2 variants in Alzheimer's disease.	The New England journal of medicine	2013	426
23855984	54209	Forabosco P	Insights into TREM2 biology by network analysis of human brain gene expression data.	Neurobiology of aging	2013	38
24119542	54209	Cuyvers E	Investigating the role of rare heterozygous TREM2 variants in Alzheimer's disease and frontotemporal dementia.	Neurobiology of aging	2014	40
24899047	54209	Jin SC	Coding variants in TREM2 increase risk for Alzheimer's disease.	Human molecular genetics	2014	32
24990881	54209	Kleinberger G	TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis.	Science translational medicine	2014	85
25186950	54209	Lue LF	TREM2 Protein Expression Changes Correlate with Alzheimer's Disease Neurodegenerative Pathologies in Post-Mortem Temporal Cortices.	Brain pathology	2015	19
27196974	54209	Yuan P	TREM2 Haplodeficiency in Mice and Humans Impairs the Microglia Barrier Function Leading to Decreased Amyloid Compaction and Severe Axonal Dystrophy.	Neuron	2016	26
11170305	57142	Menon V	Error-related brain activation during a Go/NoGo response inhibition task.	Human brain mapping	2001	206
11201742	57142	Fournier AE	Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration.	Nature	2001	228
15950000	57142	Aron AR	The cognitive neuroscience of response inhibition: relevance for genetic research in attention-deficit/hyperactivity disorder.	Biological psychiatry	2005	134
16699079	57142	Picton TW	Effects of focal frontal lesions on response inhibition.	Cerebral cortex	2007	73
17300757	57142	Waltz JA	Selective reinforcement learning deficits in schizophrenia support predictions from computational models of striatal-cortical dysfunction.	Biological psychiatry	2007	113
18939997	57142	Swick D	Left inferior frontal gyrus is critical for response inhibition.	BMC neuroscience	2008	110
19308934	57142	Mazaheri A	Prestimulus alpha and mu activity predicts failure to inhibit motor responses.	Human brain mapping	2009	49
20035509	57142	Ballanger B	Stimulation of the subthalamic nucleus and impulsivity: release your horses.	Annals of neurology	2009	59
20833229	57142	Dong G	Impulse inhibition in people with Internet addiction disorder: electrophysiological evidence from a Go/NoGo study.	Neuroscience letters	2010	46
21399712	57142	Tottenham N	Elevated amygdala response to faces following early deprivation.	Developmental science	2011	97
21415172	57142	Cajochen C	Evening exposure to a light-emitting diodes (LED)-backlit computer screen affects circadian physiology and cognitive performance.	Journal of applied physiology	2011	38
21876169	57142	Casey BJ	Behavioral and neural correlates of delay of gratification 40 years later.	Proceedings of the National Academy of Sciences of the United States of America	2011	90
23020899	57142	Jovanovic T	Reduced neural activation during an inhibition task is associated with impaired fear inhibition in a traumatized civilian sample.	Cortex; a journal devoted to the study of the nervous system and behavior	2013	30
23498139	57142	Silveri MM	Frontal lobe γ-aminobutyric acid levels during adolescence: associations with impulsivity and response inhibition.	Biological psychiatry	2013	27
25891220	57142	Gyurak A	Frontoparietal Activation During Response Inhibition Predicts Remission to Antidepressants in Patients With Major Depression.	Biological psychiatry	2016	12
12595101	78996	Bammer R	Basic principles of diffusion-weighted imaging.	European journal of radiology	2003	80
17598166	78996	Horovitz SG	Low frequency BOLD fluctuations during resting wakefulness and light sleep: a simultaneous EEG-fMRI study.	Human brain mapping	2008	162
17686438	78996	Nir Y	Coupling between neuronal firing rate, gamma LFP, and BOLD fMRI is related to interneuronal correlations.	Current biology 	2007	142
18439825	78996	Goense JB	Neurophysiology of the BOLD fMRI signal in awake monkeys.	Current biology 	2008	153
18927326	78996	Hofmann M	MRI-based attenuation correction for PET/MRI: a novel approach combining pattern recognition and atlas registration.	Journal of nuclear medicine 	2008	56
20057496	78996	Zhang D	Disease and the brain's dark energy.	Nature reviews. Neurology	2010	229
20372169	78996	Chen JJ	Global cerebral oxidative metabolism during hypercapnia and hypocapnia in humans: implications for BOLD fMRI.	Journal of cerebral blood flow and metabolism 	2010	52
21931738	78996	Zotev V	Self-regulation of amygdala activation using real-time FMRI neurofeedback.	PloS one	2011	52
23623973	78996	Griffa A	Structural connectomics in brain diseases.	NeuroImage	2013	52
15680457	120892	Gilks WP	A common LRRK2 mutation in idiopathic Parkinson's disease.	Lancet	2005	151
16269541	120892	West AB	Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity.	Proceedings of the National Academy of Sciences of the United States of America	2005	305
16272164	120892	Khan NL	Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data.	Brain 	2005	73
16437559	120892	Ross OA	Lrrk2 and Lewy body disease.	Annals of neurology	2006	64
16437584	120892	Giasson BI	Biochemical and pathological characterization of Lrrk2.	Annals of neurology	2006	67
16750377	120892	Greggio E	Kinase activity is required for the toxic effects of mutant LRRK2/dardarin.	Neurobiology of disease	2006	227
17120249	120892	Biskup S	Localization of LRRK2 to membranous and vesicular structures in mammalian brain.	Annals of neurology	2006	178
17341485	120892	Hatano T	Leucine-rich repeat kinase 2 associates with lipid rafts.	Human molecular genetics	2007	59
18539534	120892	Healy DG	Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study.	The Lancet. Neurology	2008	251
19545277	120892	Gillardon F	Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability--a point of convergence in parkinsonian neurodegeneration?	Journal of neurochemistry	2009	76
19640926	120892	Alegre-Abarrategui J	LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model.	Human molecular genetics	2009	138
20642453	120892	Nichols RJ	14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization.	The Biochemical journal	2010	89
20659558	120892	Melrose HL	Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice.	Neurobiology of disease	2010	81
20876399	120892	Meixner A	A QUICK screen for Lrrk2 interaction partners--leucine-rich repeat kinase 2 is involved in actin cytoskeleton dynamics.	Molecular and cellular proteomics 	2011	36
21168496	120892	Winner B	Adult neurogenesis and neurite outgrowth are impaired in LRRK2 G2019S mice.	Neurobiology of disease	2011	50
21248115	120892	Dusonchet J	A rat model of progressive nigral neurodegeneration induced by the Parkinson's disease-associated G2019S mutation in LRRK2.	The Journal of neuroscience 	2011	44
21362567	120892	Nguyen HN	LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress.	Cell stem cell	2011	178
21494637	120892	Ramonet D	Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2.	PloS one	2011	96
22363216	120892	Stafa K	GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1.	PLoS genetics	2012	40
22764206	120892	Cooper O	Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease.	Science translational medicine	2012	100
23075850	120892	Liu GH	Progressive degeneration of human neural stem cells caused by pathogenic LRRK2.	Nature	2012	72
23125283	120892	Cho HJ	MicroRNA-205 regulates the expression of Parkinson's disease-related leucine-rich repeat kinase 2 protein.	Human molecular genetics	2013	30
23455607	120892	Orenstein SJ	Interplay of LRRK2 with chaperone-mediated autophagy.	Nature neuroscience	2013	100
23916833	120892	Manzoni C	Inhibition of LRRK2 kinase activity stimulates macroautophagy.	Biochimica et biophysica acta	2013	27
25080504	120892	Gómez-Suaga P	LRRK2 delays degradative receptor trafficking by impeding late endosomal budding through decreasing Rab7 activity.	Human molecular genetics	2014	21
25653221	120892	Fuji RN	Effect of selective LRRK2 kinase inhibition on nonhuman primate lung.	Science translational medicine	2015	19
26117366	120892	Alcalay RN	Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.	Brain 	2015	18
15629698	121278	Zhang X	Loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression.	Neuron	2005	82
17241888	121278	Gershon MD	The serotonin signaling system: from basic understanding to drug development for functional GI disorders.	Gastroenterology	2007	226
19120094	121278	Lowry CA	Serotonergic systems, anxiety, and affective disorder: focus on the dorsomedial part of the dorsal raphe nucleus.	Annals of the New York Academy of Sciences	2008	66
20124538	121278	Duncan JR	Brainstem serotonergic deficiency in sudden infant death syndrome.	JAMA	2010	84
9809557	146713	Eriksson PS	Neurogenesis in the adult human hippocampus.	Nature medicine	1998	976
10915564	146713	Sanchez-Ramos J	Adult bone marrow stromal cells differentiate into neural cells in vitro.	Experimental neurology	2000	221
11220740	146713	Kordower JH	Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment.	Annals of neurology	2001	95
18442397	146713	Jiang Y	Isolation of neuronal chromatin from brain tissue.	BMC neuroscience	2008	68
19226510	146713	Azevedo FA	Equal numbers of neuronal and nonneuronal cells make the human brain an isometrically scaled-up primate brain.	The Journal of comparative neurology	2009	231
19606083	146713	Boldrini M	Antidepressants increase neural progenitor cells in the human hippocampus.	Neuropsychopharmacology 	2009	157
21646517	146713	Kohler SJ	Maturation time of new granule cells in the dentate gyrus of adult macaque monkeys exceeds six months.	Proceedings of the National Academy of Sciences of the United States of America	2011	38
22338017	146713	Christie LA	Impaired cognitive function and hippocampal neurogenesis following cancer chemotherapy.	Clinical cancer research 	2012	36
21777828	161882	Nutt JG	Freezing of gait: moving forward on a mysterious clinical phenomenon.	The Lancet. Neurology	2011	89
24937008	161882	Fling BW	Functional reorganization of the locomotor network in Parkinson patients with freezing of gait.	PloS one	2014	26
25640958	161882	Vercruysse S	Microstructural changes in white matter associated with freezing of gait in Parkinson's disease.	Movement disorders 	2015	15
22083254	203228	Murray ME	Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72.	Acta neuropathologica	2011	97
22101323	203228	Al-Sarraj S	p62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTLD and MND/ALS.	Acta neuropathologica	2011	132
22105541	203228	Ince PG	Molecular pathology and genetic advances in amyotrophic lateral sclerosis: an emerging molecular pathway and the significance of glial pathology.	Acta neuropathologica	2011	45
22154785	203228	Gijselinck I	A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study.	The Lancet. Neurology	2012	149
22181065	203228	Troakes C	An MND/ALS phenotype associated with C9orf72 repeat expansion: abundant p62-positive, TDP-43-negative inclusions in cerebral cortex, hippocampus and cerebellum but without associated cognitive decline.	Neuropathology 	2012	40
22228244	203228	Stewart H	Clinical and pathological features of amyotrophic lateral sclerosis caused by mutation in the C9ORF72 gene on chromosome 9p.	Acta neuropathologica	2012	46
22300873	203228	Snowden JS	Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations.	Brain 	2012	112
22300876	203228	Simón-Sánchez J	The clinical and pathological phenotype of C9ORF72 hexanucleotide repeat expansions.	Brain 	2012	73
22305801	203228	Byrne S	Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study.	The Lancet. Neurology	2012	89
22366792	203228	Cooper-Knock J	Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72.	Brain 	2012	71
22366793	203228	Boeve BF	Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72.	Brain 	2012	82
22366794	203228	Chiò A	Clinical characteristics of patients with familial amyotrophic lateral sclerosis carrying the pathogenic GGGGCC hexanucleotide repeat expansion of C9ORF72.	Brain 	2012	47
22366795	203228	Whitwell JL	Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics.	Brain 	2012	95
22420316	203228	Van Langenhove T	The molecular basis of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum.	Annals of medicine	2012	52
22875087	203228	Sha SJ	Frontotemporal dementia due to C9ORF72 mutations: clinical and imaging features.	Neurology	2012	36
23117491	203228	Irwin DJ	Cognitive decline and reduced survival in C9orf72 expansion frontotemporal degeneration and amyotrophic lateral sclerosis.	Journal of neurology, neurosurgery, and psychiatry	2013	29
23381195	203228	Mori K	hnRNP A3 binds to GGGGCC repeats and is a constituent of p62-positive/TDP43-negative inclusions in the hippocampus of patients with C9orf72 mutations.	Acta neuropathologica	2013	91
23393093	203228	Mori K	The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS.	Science	2013	233
23413259	203228	Lesage S	C9orf72 repeat expansions are a rare genetic cause of parkinsonism.	Brain 	2013	28
23720273	203228	Ciura S	Loss of function of C9orf72 causes motor deficits in a zebrafish model of amyotrophic lateral sclerosis.	Annals of neurology	2013	71
23818065	203228	Fratta P	Homozygosity for the C9orf72 GGGGCC repeat expansion in frontotemporal dementia.	Acta neuropathologica	2013	34
24011653	203228	van Blitterswijk M	Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study.	The Lancet. Neurology	2013	51
24166615	203228	Belzil VV	Reduced C9orf72 gene expression in c9FTD/ALS is caused by histone trimethylation, an epigenetic event detectable in blood.	Acta neuropathologica	2013	59
24248382	203228	Zu T	RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia.	Proceedings of the National Academy of Sciences of the United States of America	2013	116
24252525	203228	Mann DM	Dipeptide repeat proteins are present in the p62 positive inclusions in patients with frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72.	Acta neuropathologica communications	2013	40
24394885	203228	Gendron TF	Mechanisms of toxicity in C9FTLD/ALS.	Acta neuropathologica	2014	32
24493408	203228	Cooper-Knock J	The widening spectrum of C9ORF72-related disease; genotype/phenotype correlations and potential modifiers of clinical phenotype.	Acta neuropathologica	2014	27
24559645	203228	Waite AJ	Reduced C9orf72 protein levels in frontal cortex of amyotrophic lateral sclerosis and frontotemporal degeneration brain with the C9ORF72 hexanucleotide repeat expansion.	Neurobiology of aging	2014	38
24598541	203228	Haeusler AR	C9orf72 nucleotide repeat structures initiate molecular cascades of disease.	Nature	2014	155
24806409	203228	Liu EY	C9orf72 hypermethylation protects against repeat expansion-associated pathology in ALS/FTD.	Acta neuropathologica	2014	39
25120191	203228	May S	C9orf72 FTLD/ALS-associated Gly-Ala dipeptide repeat proteins cause neuronal toxicity and Unc119 sequestration.	Acta neuropathologica	2014	51
25132468	203228	Su Z	Discovery of a biomarker and lead small molecules to target r(GGGGCC)-associated defects in c9FTD/ALS.	Neuron	2014	53
25173361	203228	Zhang YJ	Aggregation-prone c9FTD/ALS poly(GA) RAN-translated proteins cause neurotoxicity by inducing ER stress.	Acta neuropathologica	2014	54
25398948	203228	Yamakawa M	Characterization of the dipeptide repeat protein in the molecular pathogenesis of c9FTD/ALS.	Human molecular genetics	2015	25
25575510	203228	Tao Z	Nucleolar stress and impaired stress granule formation contribute to C9orf72 RAN translation-induced cytotoxicity.	Human molecular genetics	2015	29
25638642	203228	Rohrer JD	C9orf72 expansions in frontotemporal dementia and amyotrophic lateral sclerosis.	The Lancet. Neurology	2015	32
25662776	203228	Rohrer JD	Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis.	The Lancet. Neurology	2015	30
25716178	203228	Xi Z	The C9orf72 repeat expansion itself is methylated in ALS and FTLD patients.	Acta neuropathologica	2015	19
26085200	203228	Schludi MH	Distribution of dipeptide repeat proteins in cellular models and C9orf72 mutation cases suggests link to transcriptional silencing.	Acta neuropathologica	2015	29
26308891	203228	Zhang K	The C9orf72 repeat expansion disrupts nucleocytoplasmic transport.	Nature	2015	105
26481318	203228	Gijselinck I	The C9orf72 repeat size correlates with onset age of disease, DNA methylation and transcriptional downregulation of the promoter.	Molecular psychiatry	2016	16
26637797	203228	Peters OM	Human C9ORF72 Hexanucleotide Expansion Reproduces RNA Foci and Dipeptide Repeat Proteins but Not Neurodegeneration in BAC Transgenic Mice.	Neuron	2015	27
21294650	100506658	Carrano A	Amyloid Beta induces oxidative stress-mediated blood-brain barrier changes in capillary amyloid angiopathy.	Antioxidants and redox signaling	2011	45
21909359	100506658	Biron KE	Amyloid triggers extensive cerebral angiogenesis causing blood brain barrier permeability and hypervascularity in Alzheimer's disease.	PloS one	2011	49
22197032	100506658	Xu R	HIV-1 Tat protein increases the permeability of brain endothelial cells by both inhibiting occludin expression and cleaving occludin via matrix metalloproteinase-9.	Brain research	2012	37
25794137	100506658	Shan R	A New Panel of Blood Biomarkers for the Diagnosis of Mild Traumatic Brain Injury/Concussion in Adults.	Journal of neurotrauma	2016	12
